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Abstract 
 
Background 
Prostate cancer is a common disease, and external beam radiotherapy is a 
treatment often offered to men.  The delivery of radiotherapy for prostate cancer 
needs to continue to evolve and assured to be of high quality.  Simultaneously, 
better biomarkers are required both to help define the prognosis of a newly 
diagnosed man, but also to help predict who is more likely to suffer significant 
treatment related toxicity.   
 
Methods 
The optimisation of the management of prostate cancer is addressed in two major 
sections.  The initial section focusses on the harnessing of newer radiotherapy 
technologies into the routine management of prostate cancer.  One approach 
explores the use of a mathematical decision tool to target radiotherapy to areas at 
risk of subclinical disease involvement.  Treatment is then delivered using a 
compressed 28 day schedule using larger radiotherapy doses each day than are 
used in a conventional 39 day regimen.  The other approach uses external oversight 
to ensure that complex radiotherapy treatments are being planned in a safe manner.  
The subsequent section explores two different types of biomarker; one using serial 
magnetic resonance imaging (MRI) to predict for significant longer term toxicity from 
treatment, and the other using a blood test for circulating tumour cells (CTCs) as a 
potential prognostic test.   
 
Results 
Regarding treatment adaptation, the use of a mathematical decision aid was not only 
feasible in 27 men, but the often significantly larger radiotherapy volumes commonly 
targeting the pelvic lymph nodes treated on the 28 day schedule were well tolerated 
by patients.  Furthermore, the monitoring of radiotherapy treatment for 147 men with 
prostate cancer treated at 12 different hospitals showed a very low rate of major 
protocol violations of <1%.  The raises the possibility of less stringent monitoring 
being necessary in future studies.  
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As an imaging biomarker of later treatment toxicity, MRI can be used to quantify 
marrow structure and changes over time in a manner which has some correlation 
with later measured changes in bone mineral density on DEXA scanning in a cohort 
of 17 men (r= -0.44, p=0.076).  CTCs occur relatively infrequently in men with high 
risk non-metastatic prostate cancer (5/36 men, 14%; 95% CI 5-30%).  
Counterintuitively, some men with very high risk disease such as being lymph node 
positive were CTC negative, whilst others with lower grade and earlier stage disease 
could be CTC positive.   
 
Conclusion 
The results of the publications presented in this thesis have made a contribution to 
improving our understanding of both how to harness new radiotherapy technologies 
and treatments into the management of prostate cancers as well as the emerging 
role of imaging and serum biomarkers in toxicity and outcome prediction.  Some 
future directions building on these rapidly evolving fields are presented. 
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Preface 
 
I am currently a Staff Specialist in Radiation Oncology working at the Calvary Mater 
Newcastle and Genesis Cancer Care, both in Australia. 
 
I obtained my undergraduate Bachelor degrees in Medicine and Surgery after 
completion of a six year full time course through the University of Otago in Dunedin, 
New Zealand.  Following broad experience in New Zealand, England and Australia, I 
commenced my specialist training in Radiation Oncology at the Peter MacCallum 
Cancer Centre in Melbourne.  After the completion of my training, I did a clinical 
research fellowship at the Princess Margaret Hospital in Toronto, Canada.  Following 
a 9 month locum consultant position at the Royal Brisbane and Women’s Hospital, I 
helped set up a new radiotherapy centre in the regional Queensland centre of 
Toowoomba prior to relocating to metropolitan Newcastle in 2012. 
 
My main sub-speciality interest is genitourinary oncology.  I am the national Principal 
Investigator in an international randomised trial in prostate cancer which has accrued 
over 200 men in Australia over a 3 year period, and is likely to have an impact on 
patient management by demonstrating it is safe and effective to halve the duration of 
treatment from eight weeks down to four.  I established a clinical trials centre in 
Toowoomba which accrued more patients to national studies in its first 3 years than 
any other radiotherapy centre in Queensland.  I set up Queensland’s only regional 
multidisciplinary meeting for clinicians to discuss complex genitourinary oncology 
cases.  I am currently Director of Research at the Calvary Mater Newcastle, and 
have overseen an expansion of research productivity including a doubling in the 
number of peer-reviewed publications to fifty per annum over the last three years.  I 
also have a visiting position with Genesis Cancer Care which is Australia’s largest 
private Radiation Oncology provider, and with whom I am helping introduce a clinical 
trial culture. 
 
Motivation for this Thesis 
As a junior specialist, my management of prostate cancer mimicked and was 
reassured by the approaches I learnt from my professional mentors.  With greater 
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professional maturity, I began to appreciate both the limitations of some aspects of 
these approaches as well as the opportunities afforded by more recent findings and 
newer technologies.  Conversations with mentors and peers demonstrated that I was 
far from alone in these realizations.  Some form of research was clearly warranted to 
try to progress our collectively understanding. 
 
I was then confronted with a range of clinically relevant issues, and a decision about 
which would be best to invest effort into trying to advance our knowledge.  Improving 
tumour control, and minimizing toxicity are both key goals for any Oncologist.  Each 
of these has multiple variations.  For example, treatment often involves multiple 
components such as radiotherapy and androgen deprivation therapy, both of which 
can be monitored and modulated in ways that can impact efficacy and side effects.  
A key choice was whether to launch a definitive randomized study which would 
potentially answer one question, or a broader single armed study with multiple 
exploratory aspects.  As is often the case, I ended up with a hybrid approach, using 
a subgroup from a randomized study for one part of the thesis, and a phase two 
cohort for the remainder. 
 
Any Research Higher Degree is a mentoring exercise at many levels, but as a mid-
career clinician who has already accumulated a reasonable research track record it 
is necessary to be clear as to what skills are likely to be beneficial.  Modern imaging 
has become a cornerstone of radiation oncology, and I felt that immersion in this 
rapidly changing and expanding field would be valuable.  Over the years of my 
apprenticeship in imaging I have transformed from a clinician with minimal acumen in 
this area to someone who has made contributions to the radiography literature, and 
can act with confidence as a reviewer for imaging journals as well as speak with 
some authority in various forums with experts in the field.  Overall I would suggest 
that this will prove to be the greatest dividend achieved through this research 
journey. 
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Section 1 - Prostate Cancer: Clinical Challenges and Research Opportunities 
 
Chapter 1 – The State of the Art 
 
The management of a man with a newly diagnosed Prostate Cancer is hugely 
challenging.  Multiple disease, patient and treatment factors interplay with changing 
technologies and clinician biases.  Every patient who presents for treatment needs to 
have consideration of treatment options as well as how best to administer them, the 
quality of the treatment to be delivered, their likelihood of treatment induced toxicity 
as well as an estimation of their likely outcomes.  This thesis explores all of these 
issues sequentially, which, in their entirety, aims to improve the care of men with this 
disease. 
 
Prostate – Anatomy, Function and Pathology 
 
The male prostate is a pelvic organ located immediately below the bladder, in front of 
the rectum, and behind the pubic symphysis (see Figure 1.1, below).  The urethra 
traverses the length of the prostate, and allows the flow of urine from the bladder 
towards the penis.  There are also bundles of nerves and blood vessels in close 
proximity The prostate is largely made up of a smooth muscular central zone and a 
glandular peripheral 
zone.  This glandular 
component produces a 
component of seminal 
fluid which supports the 
survival and function of 
sperm and is expelled 
at the time of 
ejaculation by the 
central smooth muscle 
component.  These 
anatomical relations, 
especially the rectum, 
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urethra, neurovascular bundles and bladder, as well as the contribution to ejaculation 
explain many of the toxicities associated with prostate cancer treatment.  With aging, 
under the influence of testosterone exposure, the central zone often grows in a 
process called benign prostatic hypertrophy (BPH).  BPH is an extremely common 
condition in older men of European extraction, and manifests with obstructive urinary 
symptoms such as poor flow, hesitancy and terminal dribbling.   
 
Prostate Cancer - Background 
 
Prostate cancer is the most commonly diagnosed malignancy in men in developed 
countries, and is also a leading cause of cancer death.  Like all malignancies, 
prostate cancer consists of mutated cells which have escaped the body’s control 
mechanisms and have gained the ability to travel to other parts of the body.  
Problematically, both BPH and prostate cancer often coexist in the same gland, and 
both can lead to an increase in the serum Prostate Specific Antigen (PSA), 
necessitating further invasive investigations such as biopsy to confirm the diagnosis.  
Some prostate cancers have a very indolent natural history which are unlikely to 
cause problems in a population which is generally elderly at the time of diagnosis.  
Conversely, others can pursue a much more rapid clinical trajectory, necessitating 
more aggressive management.  Since the widespread use of PSA screening in the 
community, it is now very common for men to present in the asymptomatic state, 
hence making prostate cancer treatment an exercise in later risk management.  A 
key challenge for clinicians is therefore to use knowledge of the tumour’s likely 
behaviour at presentation based largely on the PSA level, degree of structural 
organization on microscopic examination (Gleason Grading) and tumour extent, or 
stage, to predict later behaviour.   
 
A wide variety of management strategies are available to treat prostate cancer.  For 
very low risk tumours, most international guidelines recommend a policy of Active 
Surveillance, where men are monitored closely to select those with a less indolent 
natural history who are therefore more likely to benefit from consideration of local 
therapy.1  At the other end of the spectrum, metastatic disease has several systemic 
therapy options beginning with Androgen Deprivation Therapy (ADT).  ADT acts 
indirectly by lowering serum testosterone levels, which leads to less activation of the 
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Androgen Receptor (AR) and subsequently less signalling for cell growth.  In the era 
of guidelines advocating PSA screening of men in the community, the majority of PC 
is diagnosed at the earlier parts of this spectrum. 
 
For PC localized to the pelvis, the two main treatment modalities are surgery and 
radiotherapy.  Other ablative approaches such as High Intensity Focussed 
Ultrasound, Cryotherapy and Electroporation are also available, but as they lack high 
level evidence of efficacy, are not recommended as a primary treatment approach 
outside of a clinical trial.  In many instances, both radiotherapy and surgery can be 
considered as first line management strategies with approximately equal long term 
rates of disease control.  They have very different toxicity profiles.  Surgery has a 
high probability of erectile dysfunction and a lower chance of long term urinary 
leakage.  Radiotherapy can cause chronic bowel and bladder symptoms, and in the 
longer term can affect sexual function.  The two treatments are sometimes given 
together, or with other therapies such as ADT, which increases the potential 
toxicities.  Psychologically, some men are better suited to the concept of surgical 
removal of the prostate and a rapid lowering of the PSA.  Others prefer the fact that 
daily radiotherapy can be performed as an outpatient procedure with only a modest 
impact of their usual routines.  Clinical trials investigating promising new treatment 
approaches may be available for a man to consider.  Furthermore, not all men have 
ready access to a radiotherapy facility.  In short, multiple factors come into play in 
the decision making process for a man newly diagnosed with prostate cancer, and 
their final decision is ideally arrived at after multiple consultations with various 
clinicians and patient advocates as well as review of tailored information. 
 
For patients managed with radiotherapy, there are a variety of means this can be 
delivered.  One demarcation is between external beam radiotherapy (EBRT) and 
brachytherapy.  For brachytherapy, a radioactive source is inserted either 
permanently or temporarily into the prostate.  Although this technique achieves 
excellent efficacy results in expert hands, the technical requirements and potential 
for severe toxicity such as urethral strictures have limited the widespread uptake of 
the various brachytherapy approaches.2,3  In the case of EBRT, high energy photons 
are directed towards the prostate from outside the patient in a manner to concentrate 
energy on areas either involved with PC or at high risk of involvement.  Recent 
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developments in EBRT include the routine use of intensity modulated RT (IMRT) to 
reduce unwanted dose to neighbouring critical structures such as the rectum, and 
image guided RT (IGRT) where soft tissue localization occurs prior to each treatment 
to ensure accurate treatment delivery to a mobile organ.4,5 
 
EBRT Quality Assurance 
 
Modern EBRT, encompassing IGRT and IMRT, as a complex, multistep process.  
There are many steps where errors can occur.  There is therefore potential for flaws 
in treatment delivery to expose patients to risks of both increased toxicity and 
reduced efficacy from misdirected treatment.  Compared with surgery, the indirect 
manner in which EBRT is given, frequent lack of pathological correlation, and 
delayed timeframe for both late toxicity and treatment failure to manifest present 
challenges in the quality assurance (QA) of EBRT.  One key advantage of EBRT is 
that many aspects of treatment preparation and delivery can be archived for future 
forensic examination, in contradistinction to surgery. 
 
Many studies have used EBRT clinical trial populations to assess the impact of 
suboptimal EBRT treatment delivery on disease control outcomes.6,7  A common 
finding is that incorrect adherence to the trial protocol in identifying target volumes 
can lead to worse patient outcomes.  The most famous data in this regard was from 
the TROG 02-02 trial in patients with head and neck cancer.8  An attempt was made 
before treatment commenced to provide feedback to centres on every case, 
including recommendations to change target volumes if they deviated from protocol 
recommendations.  The final plan was then reassessed, and outcomes in terms of 
local disease control and overall survival were presented depending on plan quality.  
The key finding was that comparing the plans with no major issues verses those with 
persisting major issues at the final review, 2-year local disease control and overall 
survival decrements of 24% and 20% respectively were observed.  The trial was 
initially designed to assess the efficacy of the drug Tirapazamine, but the large effect 
exerted by EBRT plan quality overwhelmed the ability of the study to detect any 
difference.  This was a sobering point of reflection regarding the importance of 
ensuring the baseline care delivered on clinical trials. 
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Extrapolating from the TROG 02-02 findings, the majority of EBRT clinical trials now 
undergo extensive QA.9  This extends from site visits, use of phantoms to verify dose 
delivery, facility questionnaires, credentialing cases and this use of real time review 
(RTR).10  The latter initiative seeks for external review of EBRT plans prior to 
treatment commencing, and for any major deviations to be corrected and verified via 
resubmission.  Extensive infrastructure and staffing is required to manage such QA 
programs, which has driven up the cost of conducting a clinical trial involving EBRT.  
A key conversation now is how best to verify the benefits to be gained from each 
element of a QA program and how best to subsequently risk adapt the QA program 
for a particular clinical trial.11   
 
The evidence base for EBRT QA program benefits in a prostate clinical trial 
population is poor.  Where it exists, it can contradict conventional thinking, with one 
report showing the only benefit from submitting credentialing cases was that centres 
gained expertise in submitting good credentialing cases rather than any 
improvement in their performance with patients on study.12  The most expensive 
element of a EBRT QA protocol is the use of RTR due to the extensive software and 
hardware infrastructure required as well as the need for expert involvement at 
several steps including plan submission, integrity checks, dose review, plan review 
and report generation, all under the pressure of a patient being due to commence 
treatment within days, if not hours.  For this reason, one chapter of my thesis is an 
attempt to measure the impact of a RTR element of a comprehensive QA 
program in a prostate EBRT clinical trial.13 
 
Optimising EBRT - Hypofractionation 
 
One method being explored in optimising the delivery of EBRT is altering the daily 
dose of radiotherapy delivered – so called hypofractionation.  Observational data 
suggested that a larger dose of RT each day may lead to greater PC cell kill than 
rectal mucosal effects.14  This is quantified by the alpha-beta ratio, which appears to 
be lower for PC than most other invasive tumours.15  Many phase 2 series have 
explored this concept of increasing the daily RT dose beyond the standard 2 Gy, and 
subsequently decreasing the total number of RT sessions far below the usual 37-40 
visits.16  A number of randomized clinical trials have compared such conventional 
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fractionation with hypofractionation, with the experimental arm given in 19-28 
fractions, with all to date suggesting approximately equivalent efficacy and toxicity.17-
19  The approach with the most mature data in the era of IGRT and IMRT is to give 
the treatment over 28 fractions, and thus this regimen was selected as a component 
of this study.20  
 
Optimising EBRT – Target Individualisation 
 
There are several different regions which can be targeted in the management of 
prostate cancer with EBRT.  However, beyond treating the whole of the gland to a 
minimum dose of radiation, there is little consensus on how best to direct treatment.  
Gross disease detected on MRI may receive a more intense dose of treatment than 
the remainder of the gland which harbours a >70% risk of multifocal disease.  Other 
areas of gross disease involvement such as the seminal vesicles also justify a higher 
dose of radiation.4  The question of elective volumes is even more vexing.  Here a 
prediction is made as to where subclinical disease may reside, and efforts made to 
address this by targeting them with an intermediate dose of radiation.  Such 
approaches are standard in the management of rectal, cutaneous and head and 
neck cancers,21 but have attracted varying support in the treatment of prostate 
cancer.  This is largely due to two RCTs randomizing between whole pelvic 
radiotherapy (WPRT) and prostate only treatment not finding any definitive evidence 
of a disease control benefit from the use of WPRT.22,23  These trials have been 
criticized on several grounds,24-26 but their findings have served largely to continue 
the controversy about electively targeting areas at high risk of disease involvement.4 
 
One approach would be to improve our ability to select which patients might benefit 
from the use of elective EBRT treatment volumes.  Nomograms hold some promise 
in this regard.27  Nomograms are multivariate decision aids which take into account 
all known prognostic factors and their interactions in a non-linear fashion to generate 
predictions on some desired endpoint.  There is evidence of greater accuracy with 
the use of nomograms than other more coarse decision aids such as the use of 
single prognostic variable or risk stratification as with the D’Amico approach.  
Endpoints can also be allowed to vary between disease control and disease 
distribution.  Furthermore, a nomogram can be externally validated, where it is tested 
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in a group separate to that used in its generation to ensure its performance can be 
generalized to the broader population. 
 
The Memorial Sloan Kettering Cancer Centre Prostate Cancer Nomogram uses a 
database of thousands of men managed surgically for their prostate cancer, and has 
been externally validated.27  It correlates baseline factors such as PSA level, stage 
and Gleason score on core biopsies with the risk of microscopic disease beyond the 
prostatic capsule, in the seminal vesicles and/or in pelvic lymph nodes.  This 
captures some of the spatial heterogeneity of a particular patient’s prostate cancer, 
and allows some attempt to customize the EBRT treatment volumes accordingly.  It 
does, however, require a decision regarding a threshold of risk of disease 
involvement.  Mirroring some past experience, a risk threshold of 15% was set in this 
study, although it could be argued this leads to overtreatment of approximately 85% 
of men.  The use of a nomogram is not standard, and is complex, so there is a 
need to explore whether such an approach is feasible as well as collecting 
acute toxicity data in a prospective manner to determine whether the generally 
larger treatment volumes can be targeted in a way tolerable to patients. 
 
Optimising EBRT - ADT 
 
Several large randomized trials have explored various combinations of ADT and 
EBRT, with several showing an improvement in overall survival for men managed 
with both approaches verses either ADT or EBRT alone.28-31  The main controversies 
in this area are now appropriate patient selection, the duration of ADT and 
management of ADT related toxicities.  There is some evidence that longer durations 
(18-36 months) of ADT lead to improved survival compared with shorter durations (4-
6 months), but there continues to be uncertainty as to which subgroups of patients 
are destined to benefit given the certainty of greater toxicity with prolonged ADT.32-34 
 
Regarding ADT toxicity, strategies are available to address issues such as 
vasomotor symptoms, loss of bone mineral density, weight gain, dyslipidaemia, 
hypertension and loss of muscle strength.  Guidelines exist for management of ADT 
toxicity, but much of their evidence is derived from populations not managed with 
ADT.35,36   
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There are indications of poor levels of adherence to such guidelines, especially in 
the area of bone health.  Level one data has shown both increased loss of bone 
mineral density (BMD) and fracture risk for hypogonadal men, as well as successful 
strategies to prevent this including the use of RANK Ligand inhibitors such as 
Denosumab or Osteoclast inhibiting Bisphophanates like Zolendronate.37-40  There is 
also compelling population data showing reduced survival for men who have an 
osteoporotic fracture whilst being managed with ADT.41,42   
 
Despite such an iatrogenic toxicity with proven therapeutic solutions, management of 
bone health is poor.  A gold standard is to perform a DEXA scan at baseline, and 
manage anyone with low BMD with anti-resorptive agents.  Population based data 
linking ADT prescriptions with requests for DEXA imaging show that only 
approximately 15-20% of men who commence ADT have a DEXA performed within 
12 months of treatment initiation.43,44  There are several potential ways to explain this 
gap between evidence and practice.  There is the delayed manifestation between 
ADT administration and an osteoporotic fracture.  On a related point, there is the 
issue that osteoporotic fractures become increasing common with age, making it 
easy to ascribe any such events to the population background rate rather than the 
use of ADT.  A more subtle point may be that Radiation Oncologists and Urologists 
have traditionally focussed on disease eradication rather than late toxicity 
management.  Compare this culture with the analogous situation in breast cancer 
where women managed with an Aromatase Inhibitor will routinely have a bone 
management plan instigated.45  The main difference here is that physician trained 
Medical Oncologists manage the bone health of such patients. 
 
Potential Biomarkers of BMD Changes on ADT 
 
A biomarker (or biological marker) is a measurable characteristic which can identify 
associated disease or physiological processes.  They are commonly used to either 
predict outcomes to particular approaches and hence adapt management, or 
prognostic, in where outcomes can be estimated independent of treatment.  
Promising biomarkers are initially explored to determine if there are potential 
associations between its level and an outcome of interest.  This is the main approach 
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with biomarkers in this thesis.  Subsequently, once a biomarker appears to have 
utility through this initial step, validation needs to occur, where the same biomarker is 
tested in an independent cohort. 
 
One approach which could assist with bone health management would be improved 
identification of a high risk population.  Currently, this is largely dictated by the 
baseline BMD, although clinical factors such as smoking status and use of 
concurrent medications such as glucocorticoids are also incorporated into predictive 
models.35  All of this is static data from a single point in time, and doesn’t look at the 
effects of ADT on a particular individual’s BMD.  Indeed, there is a wide variation in 
rates of loss of BMD on ADT, with averages in different studies ranging from 2-8% 
per annum, depending on the imaging modality used (DEXA verses quantitative CT 
– see figure 1.2).37,46  Even with such variation across studies, there are extremes 
within studies, with some men losing >10% of their BMD within one year, and others 
paradoxically experiencing improvements in their BMD measurements.  There is 
therefore merit in exploring whether any data available within the first 6 months of 
treatment with ADT predicts which men are likely to experience more rapid loss in 
BMD.  If such a subgroup can be identified early, there may be an argument in 
exploring more aggressive management of these selected patients. 
 
Figure 1.2: Data estimating 
loss of BMD using quantitative 
CT in a cohort of men with 
prostate cancer managed with 
ADT (Leuprolide) either with 
placebo (left) or an oral 
bisphosphonate (pamidronate).  
Note the 8% loss of trabecular 
BMD of the Lumbar spine for 
men managed with ADT after 
48 weeks.  (from Smith MR, 
McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-
deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55.) 
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Given the large number of randomized controlled trials exploring therapeutics for 
men on ADT with low baseline BMD, here is relatively little work in exploring 
predictive biomarkers of accelerated loss of BMD on ADT.  One approach is to do 
serial DEXA scanning,47 and only deploy anti-resorptive interventions for men 
experiencing more significant reductions in BMD.  A similar approach has been 
explored in a RCT comparing either continuous use of a bisphosphonate verses a 
six month course of treatment either at baseline or commencing six months after 
starting ADT, finding the continuous approach to be superior in maintaining BMD.48  
A potential criticism of this approach is that rather than assessing timing of the 
intervention, it ended up primarily assessing the duration of exposure to the 
intervention, and hence is relatively uninformative regarding the primary question of 
risk adaptation.  An alternative approach is to use serum and urine markers of bone 
turnover.  There is evidence from a small study that changes in levels of P1NP can 
predict eventual changes in BMD, but this was the result of multiple analyses of 
several potential markers with varying thresholds and these findings are yet to be 
replicated (see Figure 1.3).49 
 
Figure 1.3: Tertiles of 
P1NP six months after 
starting ADT compared 
with changes in BMD at 
12 months showing 
patients in the highest 
tertile of bone turnover 
according to this 
biomarker have a larger 
degree of later bone loss.  
(from Greenspan SL, 
Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM. Bone loss after initiation 
of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol 
Metab 2005;90:6410-7.) 
 
A completely different strategy would be to use novel imaging approaches to assess 
bone health over time.  Both ultrasound and CT have some data in this regard, but 
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suffer from issues of interobserver reproduction for the former, and radiation dose for 
the latter.50  MRI has the advantage of no radiation dose and the acquisition of 3-
dimensional information, unlike DEXA, which suffers from artifacts given the 2-
dimensional nature of the modality.47  Furthermore, various MRI sequences can be 
selected tailored to the underlying biological processes being examined.  For 
example, either MR Spectroscopy (MRS) or In-Out Phase imaging are able to 
quantify the proportion of marrow make up of adipose tissue, the Fat Fraction (FF).51  
Osteoporosis has been termed ‘Obesity of the Bones’, as due to redirected cellular 
differentiation within a confined region, increased fat should conversely mean 
reduced Osteoblasts and haematopoietic progenitors (see figure 1.4).52  
Furthermore, consistent correlations have been observed between MRI assessed FF 
and DEXA measured BMD (figure 1.5, 1.6).51,53-55 
 
Figure 1.4: Schematic showing crosstalk between mesenchymal and 
haematopoietic stem cells.  This mechanism underpins the observed inverse 
correlation between MRI Fat Fraction from increased differentiation into the 
adipocyte lineage, and corresponding reduced bone formation through lower rates of 
osteoblast activation and hence bone formation.  One hypothesis is that reduced 
levels of testosterone and oestrogens increases differentiation from preosteoblasts 
into preadipocytes (from Rosen CJ, Bouxsein ML. Mechanisms of disease: is 
osteoporosis the obesity of bone? Nature clinical practice Rheumatology 2006;2:35-
43.) 
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Figure 1.5: A 210 person 
cohort of men and women of 
either African American (AA) or 
Caucasian (C) ethnicity 
comparing lumbar spine BMD 
with MRI computed Bone 
Marrow Adipose Tissue 
(BMAT), also referred to as the 
Fat Fraction.  Note the strong 
inverse correlation of lower 
BMD as the FF increases 
irrespective of race or gender.  
(from Shen W, Scherzer R, Gantz M, et al. Relationship between MRI-measured 
bone marrow adipose tissue and hip and spine bone mineral density in African-
American and Caucasian participants: the CARDIA study. J Clin Endocrinol Metab 
2012;97:1337-46.) 
 
Figure 1.6: Correlation 
between MRI measured Fat 
Fraction on the y-axis and 
worsening bone mineral 
density.  Note, however, the 
large degree of overlap 
despite the statistically 
significant difference in the 
median values.   
(Griffith JF, Yeung DK, 
Antonio GE, et al. Vertebral 
bone mineral density, marrow perfusion, and fat content in healthy men and men 
with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy. 
Radiology 2005;236:945-51.) 
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A key aspect of this thesis explores the question of whether MRI can be used as an 
imaging biomarker to identify which men managed with ADT experience accelerated 
BMD loss on serial DEXA scans.  In addition to MRS and In-Out Phase imaging, 
Apparent Diffusion Coefficients (ADC) have also been explored (see figure 1.7).56  
Chapter 3 is a methods paper, looking at interobserver variations in five 
patients and initial findings.57  Chapter 4 builds on this with a separate cohort 
of 28 men who while treated with ADT had two MRIs six months apart and two 
DEXA scans a year apart, and seeks correlations between the various 
sequences and scans with the aim of trying to identify an early imaging 
biomarker of later toxicity. 
 
Figure 1.7: Mid-sagittal MRI of 
the lumbosacral spine of the 
author showing (clockwise from 
upper left) Fat only, Water only, 
Diffusion and Apparent Diffusion 
Coefficient (ADC) map.  The first 
two are Dixon sequences derived 
from In and Out of phase images, 
and the ADC map is derived from 
various diffused weighted b-
values from 0 to 750 in three 
orthogonal planes. 
 
 
Efficacy Biomarkers 
 
Whilst a core component of this thesis is trying to determine which men are likely to 
experience greater toxicity, the vast majority of work with biomarkers has focussed 
on their utility in predicting tumour control outcomes.58-60  Some are well validated 
across multiple tumour types, including TNM tumour staging and tumour grade, 
which in the case of prostate cancer, uses the Gleason grading system.  Unique to 
prostate cancer is the use of Prostate Specific Antigen, or PSA.  PSA continues to 
create controversy in some settings, most notably in the screening setting where a 
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large proportion of men found with asymptomatic indolent disease are destined to 
die of other causes, and hence subjecting them to interventions only leads to 
increased morbidity and cost.61,62  However, once prostate cancer is diagnosed, the 
PSA level proves to be a very strong prognostic factor as it tends to be a good, 
although still imperfect, surrogate for the volume of disease.  Indeed, other accurate 
biomarkers of prostate cancer outcomes such as PSA velocity heavily rely on serial 
PSA measurement.63,64 
 
One promising alternative avenue of efficacy biomarker research is the direct 
measurement of circulating tumour cells (CTCs).65  These are tumour cells which 
have detached from the primary and gained access to the systemic venous 
circulation (see Figure 1.8).  They have been investigated in several tumour types, 
and found to have prognostic power in the setting of established metastatic disease 
in a range of histologies including breast, colorectal and non-small cell lung 
cancers.66  The data in prostate cancer is more emergent, but a substudy of a RCT 
looking at the efficacy of the agent Abiraterone in men with metastatic disease 
previously treated with Docetaxel chemotherapy showed an inverse correlation 
between CTC levels and overall survival.67 
 
Figure 1.8: Schematic demonstrating some of the steps of how a primary tumour 
eventually can establish a metastasis.  Note the intermediate step of circulating 
tumour cells in red, which can be directly enumerated at low volume.  (from Dotan E 
et al. Circulating Tumor Cells: Evolving Evidence and Future Challenges. The 
Oncologist 2009;14:1070-82). 
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Men with High Risk Prostate Cancer (HRPC) have unfavourable baseline 
characteristics such as a high Gleason score of 8-10, a PSA >20, or stage T3-4, 
without evidence of established metastatic disease.  The ability of any investigation 
to detect metastatic disease is subject to a threshold effect, below which a test can 
prove to be insensitive by giving a false negative result.  Moderate cellular tumour 
burdens can exist despite a normal scan.  For example, abdominopelvic CT imaging 
is still recommended as the standard scan to assess for metastatic disease to 
regional lymph nodes.68  Any lymph node with a short axis diameter of less than 10 
mm is considered negative.  Given the size of a cell of approximately 10 microns, up 
to 109 or one billion cells may be present despite the scan being called normal.  This 
is undoubtably a large part of the reason that a large proportion of men with HRPC 
are destined for metastatic relapse: the disease is already micrometastatic at the 
time of diagnosis, but at a volume too low to detect with conventional imaging.   
 
A more sensitive biomarker of low-volume metastatic disease in men with HRPC 
would have multiple uses.  It may present men from receiving morbid and ultimately 
futile treatment to the pelvis if more disseminated disease is detected.  Conversely, it 
may help identify a subgroup for whom more aggressive systemic therapy could be 
justified at the time of initial therapy delivery.  Given the use of CTCs in the 
metastatic setting, and the observation that some men with HRPC really represent a 
watershed between localized and metastatic disease, it was felt that this population 
would warrant further exploration with this promising new biomarker.69 Chapter six 
aims to quantify the incidence of CTC positivity in men with HRPC, with further 
follow-up necessary to assess the impact this may have on efficacy. 
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Section 2: Optimising treatment for High Risk Prostate Cancer 
 
The use of modern radiotherapy has opened a host of options for men with prostate 
cancer.  The increased complexity of safe treatment delivery is both a risk and an 
opportunity.  Key risks relate to the potential for suboptimal treatment, which can 
compromise the chance of tumour control, and increase the potential toxicities.  This 
is particularly important within the context of a clinical trial, where unproven regimens 
are being used.  These experimental approaches inherently carry risk due to the 
uncertainty of their efficacy and long term toxicity profiles.  Furthermore, large clinical 
trials need to accrue from many centres, some of which may not necessarily be at 
the forefront of innovation.  It is also possible for poor treatment to confound the key 
results being measured within a clinical trial.  In chapter two we present a report on 
an aspect of a strict quality assurance program which was designed to mitigate many 
of these risks.  A key finding was that we were appearing to reach a limit of useful 
risk management, and subsequent work has sought to be much more risk adaptive 
in the intensity of quality assurance required. 
 
An opportunity is to try to harness complexity to benefit prostate cancer patients.  We 
designed an innovative approach using a multivariate nomogram to help tailor the 
radiotherapy treatment based on a patient’s specific risk factors.  Such treatments 
could be safely delivered in 5 ½ weeks rather than the standard 8 week regimen, 
and were well tolerated by the men.  However, some aspects of the treatment were 
needlessly complex, without proof of any additional benefit to be gained.  Once 
again, we appeared to be approaching a limit where more processes were not 
necessarily helpful, leading to a more measured approach in subsequent work. 
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Chapter 2 – Prostate radiotherapy clinical trial Quality Assurance 
 
Modern radiotherapy is a highly technical and complex treatment.  As treatment and 
toxicity outcomes can be delayed by years, it is essential to have robust quality 
assurance processes in place to ensure radiotherapy is delivered in an optimal 
manner.  However, it is difficult to determine exactly what degree of quality 
assurance is necessary, with a temptation existing to add further processes without 
necessarily having any evidence of the additional benefit of such extra steps.  Within 
the confines of an international clinical trial, a natural experiment occurred where 
men in Canada had a moderate degree of quality assurance performed, whilst men 
in Australia had extra layers applied.  This allowed us the opportunity to assess any 
additional value derived from the extra quality assurance processes used in 
Australia.  Our results showed no discernible impact from such extra steps.  As such, 
subsequent studies have taken a more risk adaptive approach where the intensity of 
quality assurance is more risk managed and titrated against a range of factors 
including the complexity of target volumes and number of patients enrolled at a 
particular centre. 
 
Published as ‘Martin J, Frantzis J, Chung P, et al. Prostate radiotherapy clinical trial 
quality assurance: How real should real time review be? (A TROG-OCOG Intergroup 
Project). Radiother Oncol 2013; 107(3): 333-338.’ 
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Abstract 
 
Background and Purpose 
Review of plans early in treatment offers the potential to reduce the chance of sub-
optimal treatment delivery.  We compare the use of Real Time Reviews (RTR) either 
before randomization (pre-rand 3D RTR) or following randomization (post-rand 2D 
RTR). 
 
Materials and Methods 
PROFIT is an international randomized trial for men with prostate cancer which had 
credentialing via multiple dummy runs.  In Australia, but not Canada, all plans were 
submitted for pre-rand 3D RTR using 3D software, and resubmission was requested 
if significant protocol deviations (PD) were seen.  All plans from Canada and 
Australia then underwent post-rand 2D RTR using a 2D assessment.   
 
Results 
For 147 Australian patients, pre-rand 3D RTR was fast (median 1 day, 95% range 0-
4 days).  51 minor and 5 major PD were observed and 15 of the 147 cases (10%) 
required resubmission.  Of the 5 major PD, 4 were remedied on resubmission and 1 
was withdrawn from study.  For the post-rand 2D RTR, reports from 147 Australian 
cases and 193 Canadian cases were reviewed.  No major PD were reported from 
Australian cases, but 3 were seen in Canadian cases (0% v 1.5%; p=0.26).  There 
was also no difference in the rate of minor PD (14.3% v 15.3%; p=NS). 
 
Conclusions 
In a study using relatively simple treatment volumes after comprehensive 
credentialing, pre-rand 3D RTR offers only modest benefits compared with post-rand 
2D RTR. In the future the intensity of RTR may need to vary according to protocol 
and site specific factors. 
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Introduction 
 
Modern radiotherapy requires the accurate delivery of radiation dose to a defined 
tissue volume.  Dose escalated radiotherapy for prostate cancer requires complex 
planning techniques including intensity modulated radiotherapy (IMRT) to reduce 
dose to neighbouring critical structures.[1]  A suboptimal radiotherapy treatment plan 
can be responsible for under-dosing of the planning target volume (PTV) or 
overdosing of neighbouring critical structures.  These in turn can have consequences 
for both tumour control probability, as well as the incidence of normal tissue 
complications.[2]  More fundamentally, poor delineation of target volumes can cause 
errors that no amount of planning expertise can circumvent.[3]   
 
In the context of a clinical trial, it is important to monitor for such errors, as incorrect 
contouring or suboptimal planning can cause a greater effect on outcomes than the 
intervention under investigation.[2]  This has led to greater attention being paid to the 
area of quality assurance (QA), which can be applied to many stages of the patient’s 
treatment journey, although the historical trend has been to introduce interventions 
earlier in the treatment process.[4]  The ultimate aim would be to introduce a 
thorough QA process for every treatment plan prior to the patient starting 
treatment.[5]  Through the process of audit, such a real time review (RTR) process 
must be shown to provide tangible benefits to justify the effort required to establish 
and maintain it. 
 
PROFIT (PROstate Fractionated Irradiation Trial) (NCT00304759) is a randomized 
controlled trial designed to determine whether a 78 Gy in 39 fraction course of 
radiotherapy can be safely compressed into a 60 Gy in 20 fraction regimen with non-
inferior clinical-biochemical control.  Building on phase 2 data for both treatment 
arms, this Ontario Clinical Oncology Group (OCOG) trial originated in Canada, and 
subsequently opened in Australia under the auspices of the Trans-Tasman Radiation 
Oncology Group (TROG).[6,7]  All cases are submitted and reviewed in 2-
Dimensions (2D) after randomisation by OCOG.  For Australian sites, there is 
additional 3-Dimensional (3D) review which is completed prior to randomisation by 
TROG. Here we explore whether pre-randomization (pre-rand) 3D RTR have enough 
impact to justify the additional resources required to sustain such a process.[8]  This 
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is a novel question, as true RTR is a relatively recent phenomenon.  If additional 
benefit is seen compared with post-randomization (post-rand) 2D review, pre-rand 
review may be considered as a standard of care for future prostate radiotherapy 
trials.  
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Methods and Materials 
 
Hypothesis 
 
Performing 3D real time review (RTR) prior to randomization reduces the incidence 
of protocol deviations (PD). 
 
Credentialing 
 
Prior to activation for PROFIT, all centres have to submit data for 5 ‘dry-run’ cases 
with plans conforming to the protocol constraints for the 60 Gy arm of the trial (table 
1, also showing the 78 Gy constraints).  These cases were deidentified patient 
datasets previously treated at each of the submitting centres.  In Australia, 2 centres 
which were outreach clinics of a larger centre rotating the same staff were only 
required to submit 2 dry run cases each.  Being the experimental arm of the trial, the 
dose constraints for the 60 Gy regimen were more difficult to achieve than the 
standard 78 Gy arm.  Contouring instructions are outlined in table 2, similar to those 
validated in the preceding phase 2 protocols.[6,7]  The data requested included a 
Dose-Volume Histogram (DVH) and screen captures of the three orthogonal axial, 
sagittal and coronal planes through the centre of the prostate.  Centres received 
educational material and presentations on protocol requirements, including dose 
constraints. A QA helpdesk was available to facilitate rapid resolution of any protocol 
queries or technical planning issues.   Any deviations noted would result in a request 
for the case to be replanned prior to being reassessed.  In addition, TROG centres 
submitted the same 5 cases for 3D review (described subsequently), usually at the 
same time as 2D submission.  Other accreditation components such as Image 
Guided Radiotherapy credentialing and site visits for dosimetric verification of IMRT 
treatment delivery have been reported separately.[9,10] 
 
Plan Generation 
 
Any patient who consented to entering PROFIT needed to have a 60 Gy plan 
generated.  Centres were instructed to ensure that contouring and dosing conformed 
to protocol requirements prior to proceeding towards randomization (tables 1 and 2). 
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3D Real Time Review 
 
For Australian centres, all plans needed to be assessed by a Radiation Therapist 
and a Radiation Oncologist not involved in the direct care of the patient prior to 
randomization.  Plans were made anonymous and DICOM data of the radiotherapy 
plan (including DVH) remotely uploaded into the TROG Central Quality Management 
System (CQMS).  The data transfer was assessed at the TROG Central Operations 
Office prior to the assessing centre being notified of the readiness of the plan for 
review.  The SWAN software was used to review the plan in 3D including contouring 
and adherence to dose constraints.  Results were compared with protocol 
constraints and any minor deviations were recorded and a recommendation was 
made to the treating centre to address these prior to randomization.  Any major 
deviations led to personal contact with the treating centre to discuss the case directly 
and randomization was not permitted until such problems had been remedied.  
PROFIT 60 Gy arm dose constraints and protocol contouring instructions are listed 
in tables 2.1 and 2.2.  In general, a minor dosimetric deviation was defined at the 
start of the trial as being up to 102.5% of the target threshold while a major deviation 
was anything beyond that. 
 
Table 2.1: PROFIT protocol 60 Gy arm dose constraints.  All contouring 
(Prostate±Seminal Vesicles, Correct CTV-PTV expansion, Rectal Wall, Bladder Wall, 
Proximal Femurs) also had to comply with protocol for a plan to be passed. 
 
Structure and Metric Acceptable Dose Minor Deviation Major Deviation 
CTV D99 ≥60 Gy <60 Gy <59.4 Gy 
PTV D99 ≥57 Gy <57 Gy <56.4 Gy 
PTV Max Dose to 1 cc ≤63 Gy >63 Gy >64.5 Gy 
Rectal Wall D30 ≤47.15 Gy >47.15 Gy >48.3 Gy 
Rectal Wall D50 ≤37.93 Gy >37.93 Gy >38.85 Gy 
Bladder Wall D30 ≤47.15 Gy >47.15 Gy >48.3 Gy 
Bladder Wall D50 ≤37.93 Gy >37.93 Gy >38.85 Gy 
Left or Right Femur 
D5 
≤44.08 Gy >44.08 Gy >45.15Gy 
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Table 2.2: Contouring instructions for PROFIT. 
Structure Instruction 
CTV Contour Prostate.  Add proximal 10 mm of seminal 
vesicle if risk of seminal vesicle invasion >15% via 
Partin tables. 
PTV Non-uniform expansion around CTV of 10 mm in all 
directions, except for 7 mm posteriorly. 
Rectal Wall 2-3 mm thick wall extending from 8 mm inferior to the 
PTV to 8 mm superior to the PTV. 
Bladder Wall 2-3 mm thick wall extending from bladder base to 8 mm 
superior to the PTV. 
Femoral Necks All of femur superior and medial to a plane through the 
greater and lesser trochanters. 
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2D Real Time Review 
 
Following randomization, the final plan from either Australia or Canada (either 60 Gy 
or 78 Gy) was submitted via e-mail for central review by a Canadian Radiation 
Oncologist.  The submission took a similar form to the credentialing dry-runs ie 
orthogonal screen captures, a screen capture of the DVH, and the centre supplying 
data on requested DVH parameters.  Submission was encouraged to occur prior to 
the 3rd fraction of treatment having being delivered.  If any dosing or contouring 
deviations were noted, the centre was advised to address these; however no formal 
mechanism was in place to ensure this occurred.  As all patients were anonymized 
and five Australian patients were removed from the study between the two reviews, 
the outcomes of the 2D and 3D reviews can only be reported as a pooled result. 
 
Endpoints 
 
Firstly a baseline measurement of the rate of deviations from each centre was 
established from the 2D credentialing phase with the 5 dry runs.  The resubmission 
rate was defined as the total number of resubmissions divided by the total number of 
submissions separately for OCOG and TROG centres. 
 
Secondly, the incidence of minor and major deviations for the Australian and 
Canadian centres were recorded separately for the pre-rand (Australian only) and 
post-rand (both Australian and Canadian) RTRs.  As some Canadian centres had 
contributed >200 patients and were activated up to 4 years before other centres, the 
maximum number of cases from any one center was capped at 20.  This is also in 
keeping with the observation that centres which accrue heavily to a trial have 
demonstrated a lower overall rate of deviations.[2]]  The characteristics of each 
deviation were recording including the structure affected, whether  contouring or 
dosimetry was involved, and whether the deviation was major or minor.  For the pre-
rand 3D RTR, as an indicator of the feasibility of this process, the number of working 
days from submission to report was also recorded. 
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Results 
 
Baseline Measures 
 
In Australia, 54 cases were submitted from 12 sites for initial credentialing.  In total, 8 
resubmissions were required for a range of contouring and dosimetric deviations.  
The Australian resubmission rate was therefore 8/(54+8)=12.9%.  For Canada, 70 
cases were submitted from 14 sites, and 10 resubmissions were required, giving a 
Canadian resubmission rate of 10/(70+10)=12.5%.  There was no significant 
difference in the resubmission rates between the two countries (Chi-squared 
p=0.84). 
 
Pre-Randomization Real Time Reviews 
 
Pre-rand 3D RTR were achievable within the required timeframes, with a median 
time from receipt of treatment plan to completion of review 1 day, and 95% of case 
reviews being performed within 4 days.  Of the first 147 Australian cases submitted 
for pre-rand 3D RTR, a total of 3202 dosimetric, contouring, technique and 
verification parameters were assessed.  Of these, there were 51 minor and 5 major 
deviations recorded.  Of the 56 deviations the most common were minor deviations 
in the maximum dose to 1 cc of the PTV (17, or 33%), and incorrect contouring of the 
bladder or rectal walls (15, or 29%).  15 of the 147 cases (10%) required 
resubmission with the reasons for resubmission request detailed in table 2.3.  The 
five major deviations all occurred in different patients giving a major PD rate of 3.4%.  
Of the 5 major deviations, 4 were corrected prior to randomization and 1 was 
withdrawn from the study due to inability to meet dose constraints following CTV 
recontouring.  Images from one patient whose CTV was assessed to require 
correction are shown in figure 2.1, with figure 2.2 showing the changes made after 
initial reivew.  At final review 16 deviations had been reversed leaving 40 minor 
deviations for patients approved to proceed to randomization.  Centres had all 
deviations high-lighted to them, and were recommended to remedy them prior to 
randomization and submission for the post-rand 2D RTR. 
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Table 2.3:  Reasons for the 15 resubmission requests in Australian pre-
randomization real time review cases.  Impact is graded as Likely, Possible and 
Unlikely to reflect the perceived probability of an adverse clinical outcome had the 
major deviation not being addressed. 
 
Deviation Impact Outcome 
CTV was central zone of 
prostate on MRI only 
Likely Remedied, Resubmitted, Passed 
Prostate not fully 
included in CTV 
Likely Patient withdrawn from study, as 
following recontouring 60 Gy dose 
constraints could not be satisified. 
Bladder Wall D30 Major 
Deviation 
Possible Remedied, Resubmitted, Passed 
CTV D99% was 59 Gy = 
Major deviation 
Possible Remedied, Resubmitted, Passed 
Excessive CTV 
contouring including 
penile bulb 
Possible Remedied, Resubmitted, Passed 
CTV to PTV margin 7 
mm instead of 10 mm 
inferior and/or superior 
(4 cases) 
Unlikely Remedied, Resubmitted, Passed 
Bladder and/or Rectal 
Wall contouring (3 
cases) 
Unlikely Remedied, Resubmitted, Passed 
CTV should have 
included seminal 
vesicles 
Unlikely Remedied, Resubmitted, Passed 
CTV should not have 
included seminal 
vesicles 
Unlikely Remedied, Resubmitted, Passed 
CTV should not have 
included seminal 
vesicles 
Unlikely Not Remedied, Passed after 
discussion with treating clinician who 
elected to treat SV. 
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Figure 2.1: Pre-randomization 
real time review where the CTV 
was assessed to not include the 
entire prostate.  Further 
investigation showed that the 
CTV was defined using an MRI 
and that the central zone was 
mistaken for the entire gland.   
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Figure 2.2: This was remedied, 
replanned, the new contouring 
and plan reassessed then 
passed prior to randomization. 
 
 
 
 
 
 
 
 
 
 
 
Post-Randomization Real Time Reviews 
 
For the post-rand 2D RTR, reports from 147 Australian cases from 11 centres (one 
of the 12 centres credentialled did not accrue any patients) and 193 Canadian cases 
from 13 centres were reviewed.  No major deviations were reported from Australian 
cases and 3 from Canadian cases (0 v 1.5%; p>0.15 for relevant equality of 
proportions exact tests).  The nature of the major deviations in the 3 Canadian cases 
related to insufficient prostate CTV contouring, >7.5% dose inhomogeneity across 
the PTV and the Bladder Wall D30 dose constraint.  All were seen in patients 
randomized to the 60 Gy arm of the study.   
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Table 2.4: Frequencies and percentages of major and minor deviations on the post-
randomization real time review.  Note that one Canadian patient had both a major 
and a minor deviation recorded, hence the row adds up to 197 deviations for 196 
patients. 
 Total 
Cases 
No 
Deviations 
Major 
Deviations 
Minor Deviations 
 One Two ≥Three 
Australia 147 126  
(85.7%) 
0 18 
(12.2%) 
2  
(1.4%) 
1  
(0.7%) 
Canada 196 166  
(84.7%) 
3  
(1.5%) 
25 
(12.8%) 
2  
(1.0%) 
1  
(0.5%) 
 
 
Table 2.4 shows the relative frequencies of minor deviations within the two countries, 
once again showing no significant differences (exact chi-square p > 0.95).  For both 
countries the largest proportion of minor deviations noted related to maximum PTV 
dosing (Australia 48% and Canada 88% of cases exhibiting this deviation, 
sometimes in conjunction with other deviations).  Combining both minor and major 
deviations together, 14.3% of Australian cases and 15.3% of Canadian cases 
exhibited at least one deviation (exact chi-square p > 0.95).  There was also no 
difference in the frequency of 2 or more deviations being recorded in the same case, 
at 2% in both groups.   
 
A total of 26 minor deviations were noted in 21 Australian cases, compared with the 
40 minor deviations commented on in the final pre-rand 3D RTR.  This suggests that 
although approximately 35% of minor deviations were remedied as recommended, 
the remaining 65% were not.  Further analysis showed that no bladder or rectal wall 
deviations were noted for Australian patients on the post-rand 2D RTR, suggesting 
that this was the main area where rectification occurred. 
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Discussion 
 
Dose escalated radiotherapy has become a standard treatment option for men with 
prostate cancer because of proven benefits demonstrated in randomized 
trials.[11,12]  However a higher rate of rectal toxicity has generally been reported in 
these trials, emphasizing the importance of improving the accuracy and conformality 
of treatment delivery.  There are many steps where errors can occur, including CTV 
and organ at risk contouring, margin generation, treatment planning, plan transfer to 
the linear accelerator, patient positioning and treatment delivery.  This justifies the 
implementation of quality assurance processes to try to minimize the impact of such 
errors on treatment outcomes. 
 
We have shown that it is feasible to conduct 3-dimensional pre-rand RTR in a timely 
and effective manner.  Four major deviations were remedied and one managed with 
conventional fractionation off-study for Australian patients through the pre-rand 3D 
RTR process.  Although the incidence of major deviations on post-rand 2D RTR are 
low in Canada at 1.5%, they have been completely eliminated in Australia.  This may 
be the greatest value of the pre-rand 3D RTR process, as treatment can be delayed 
until remedial action has been taken to correct the most egregious radiotherapy 
planning issues.   
 
Compared with post-rand 2D RTR, the additional gains from pre-rand 3D RTR 
appear to be modest in this trial of prostate radiotherapy.  There are several potential 
explanations for this.  One is that the study was not a truly randomized comparison, 
either of RTR timing or 2D versus 3D, and that for methodological reasons 
undetected biases have prevented an existing advantage from being observed.  
Another is that prostate radiotherapy is relatively simple, and that the true advantage 
from pre-rand 3D RTR may be achieved in more complex scenarios such as head 
and neck radiotherapy.  It is also plausible that the strict credentialing process 
educated clinicians in how to avoid deviations, making subsequent deviations less 
likely to occur.  Overall, the data does not support the routine integration of pre-rand 
3D RTR into prostate radiotherapy trials with credentialing and post-rand 2D RTR 
similar to PROFIT, and that such an approach should be further investigated in more 
complex treatments.  This adds to the debate regarding the optimal QA framework, 
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as recent data from the EORTC regarding dry runs suggests that the main benefit 
from doing them is an improvement in future dry run results rather than affecting trial 
outcomes.[13] 
 
It might be argued that no minor deviations should have been observed in Australian 
cases given the potential to identify and correct these during the pre-rand 3D RTR 
process.  The relatively low incidence of PD overall may be due to the need to 
perform 5 dry runs as part of the credentialing process.  The vast majority of the 
minor deviations noted in the Australian cases were either very close to thresholds 
(eg CTV D99 of 7790 cGy rather than 7800 cGy) or in PTV dose homogeneity 
metrics, usually the maximum dose to 1 cc of the PTV (48% of cases where a 
deviation was seen).  Given the slight differences in dose calculation across different 
treatment planning systems, it is clear that some degree of latitude is needed in 
applying dose thresholds when plans are imported into 3-dimensional software for 
RT QA case reviews, particularly on the interface between ‘acceptable’ and ‘minor 
deviation’.  The deviation classifications includes a tolerance range to take this into 
account, and screen captures from the treatment centres’ planning system were also 
used to clarify and confirm ‘borderline’ deviations identified at QA case review. 
 
Pioneering work in the early 1990s on the pre-treament QA of a large Hodgkin’s 
Disease clinical trial concentrated on advising centres about appropriate fields after 
reviewing baseline pathology and imaging.[14]  Prior to electronic submission of 
radiotherapy plans the only plan review that was feasible was often performed 
following the completion of treatment.[15]  This approach clearly left no opportunity 
to intervene for the plan and patient in question and instead served mainly to 
educate clinicians in order to hopefully avoid similar errors in the future. Real time 
review has evolved to allow an opportunity for intervention and has now been around 
in progressively more technologically elaborate forms for more than 15 years.[5]   
 
Major radiotherapy PDs for patients on clinical trials have been linked to adverse 
tumour control outcomes.[16]  It has previously been reported for children with 
medulloblastoma receving craniospinal radiotherapy that RTR and intervention to 
correct diagnosed planning errors are feasible and reduces relapses associated with 
incorrect eye shield placement compared with historical controls.[17]  There is some 
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evidence in the setting of head and neck cancers that RTR can correct plans with 
significant deviations.[2]  Indeed, that study suggests local control and survival 
benefits of the order of 20% in the favour of protocol compliant plans.  There is 
clearly momentum building for RTR to be performed prior to study entry, leaving the 
actual structure of the RTR program as a key issue to be addressed. 
 
Australian investigators clearly used some discretion to which deviations were 
clinically significant.  Issues of PTV dosing were more common while deviations to 
critical structures were relatively rare.  This perhaps reflects the stronger evidence 
for negative consequences from exceeding dose constraints for the rectum.[12] 
Given the relatively generous margins in PROFIT in the IGRT era,  reduced PTV 
coverage may have been considered during the planning process and deemed 
clinically acceptable and an appropriate means of achieving the rectal constraints.  
Consensus agreement on clinically relevant dose parameters and contouring are 
helpful although problems arise when different recommendations are presented.  For 
example, although QUANTEC (“Quantitative Analysis of Normal Tissue Effects in the 
Clinic”) recommends the rectum be contoured as a solid structure, ICRU-83 presents 
an argument to contour the rectum as a walled structure.[18,19]  Both arms of the 
PROFIT study have dose constraints and contouring guidelines derived from 
published prospective series with low late toxicity rates giving some validation for 
their use.[6,7] 
 
Contouring of the prostate using planning CT datasets involves a degree of 
interobserver variation in practice.[3]]  Judging where ‘reasonable practice’ ends and 
a PD begins can be difficult to quantify in all but the extreme cases.  This 
emphasizes the importance of trying to select and callibrate the cut off points for 
deviations in a clinically meaningful manner and developing guidelines for reviewers 
on how best to apply them. 
 
Although the timing of the RTR may have some importance in selected scenarios, 
the advantage of 3D v 2D methods are less evidence based.  The former is much 
more complex and resource intensive to administer and the latter should detect all 
but the most subtle issues for prostate radiotherapy.  Although feasible in the setting 
of 1-2 patients needing review per week, upscaling of this to 1-2 patients per day 
 41 
 
would require a full time reviewer with significant cost implications.  Most of the 
issues rectified following 3D review appeared to relate to contouring of the critical 
structures, which should have been apparent on 2D review.  Overall, 2D review may 
be all that is justified in some situtations, although further effort will be required to 
clarify in what cases this may be. 
 
A limitation of this study is that a pre-selected patient population had access to the 
pre-rand 3D RTR.  The similar rates of major deviations on the credentialing dry runs 
and pre-intervention RTRs support our claim that it was the pre-rand 3D RTR which 
was likely to be responsible for the elimination of major deviations.  A further 
limitation is that the 147 Australian cases were not matched exactly between the two 
reviews due to some patients being managed off trial after the first RTR and them 
being anonymous prior to randomization.  Due to only 5 patients dropping out of the 
trial, >95% of the cohorts will have been the same patients and by selecting the 
same number of cases over the same timespan for the two reviews, we aimed to 
minimize this issue. 
 
The integration of various digital-imaging modalities into treatment planning, the 
facilities  to transfer large data files relatively quickly and QA review systems which 
support rapid analysis and reporting of RT QA results make Real Time Reviewing 
likely to become central to future clinical trials.  The leaders in integrating this into 
clinical trial RT QA processes have been the Image-Guided Therapy QA Center 
(ITC) and the Quality Assurance Review Center (QARC) in the US, and TROG and 
the SWAN software group in Australasia.[20,21]  The EORTC now also has a similar 
facility available via the VODCA platform.[18] Pre-treatment RTR is feasible, and 
intervention possible, but only with a significant investment of effort with instigation of 
an appropriate informatics platform.[22]  Now that such facilities exist, a key question 
raised in our study is whether all studies benefit from a very comprehensive QA 
approach, or whether a more flexible structure is required where the intensity of QA 
is titrated against the complexity of treatment delivered, extent of credentialing and 
number of patients accrued by a site to a particular trial. 
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Conclusion  
 
With appropriate central QA facilities including IT infrastructure, the ability to utilise 
the RTR approach to enable intervention when a major PD is identified and 
modification of a treatment plan prior to treatment commencing is feasible in modern 
clinical trials.  It is possible, and has been demonstrated within the PROFIT trial, that 
the inclusion of pre-rand 3D RTR to the QA process can eliminate major deviations.  
In this study we did not show significant superiority of the pre-rand 3D RTR approach 
compared with a post-rand 2D RTR.  It may be that a more flexible RTR is needed 
for future clinical trials, where the intensity of review is dependent on a range of trial, 
credentialing and tumour site specific factors. 
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Chapter 3 – Nomogram based prostate radiotherapy target volumes 
 
Most guidelines suggest a generally similar approach to the treatment of prostate 
cancer with radiotherapy.  This ignores some of the heterogeneity of disease 
behaviour, particularly with regarding to the varying patterns of microscopic spread.  
We explored the use of a nomogram as a decision aid to assist in defining regions at 
risk of subclinical disease involvement.  This lead to an adaptation of radiotherapy 
treatment volumes, which were delivered using varying doses per day.  Our main 
interest was in the feasibility of applying this different approach to target delineation 
and planning, as well as patient tolerability of this novel treatment regimen.  The 
main findings were that although the voluming of targets was largely protocol 
compliant, the excessive complexity of some of the organs at risk proved more 
challenging for clinicians.  An important lesson here was not to engage with needless 
complexity.  Furthermore, acute toxicity was similar to what would be expected from 
more standard treatments, suggesting that the regimen is tolerable.  Only more 
mature follow-up will reveal efficacy and any significant late toxicity of this schedule.  
 
Published as ‘Wu R, Woodford H, Capp A, Hunter P, Cowin G, Tai KH, Nguyen P, 
Chong P, Martin J. A prospective study of nomogram-based adaptation of prostate 
radiotherapy target volumes. Radiat Oncol 2015;10:243.’    
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Abstract 
 
Background: 
A prospective clinical trial was conducted to evaluate the feasibility of a novel 
approach to the treatment of patients with high risk prostate cancer (HRPC) through 
the use of a nomogram to tailor radiotherapy target volumes. 
 
Methods: 
27 subjects with HRPC were treated with a mildly hypofractionated radiotherapy 
regimen using image-guided IMRT technique between Jun/2013-Jan/2015. 
 
A set of validated prognostic factors were inputted into the Memorial-Sloan-Kettering 
Cancer Center (MSKCC) prostate cancer nomogram to estimate risk of loco-regional 
spread (LRS). The nomogram risk estimates for extra-capsular extension (ECE), 
seminal vesicles involvement (SVI), and pelvic lymph nodes involvement (LNI) were 
used to adapt radiotherapy treatment volumes based on a risk threshold of ≥15% in 
all cases. A planning guide was used to delineate target volumes and organs at risk 
(OAR).  Up to three dose levels were administered over 28 fractions; 70Gy for gross 
disease in the prostate +/- seminal vesicles (2.5Gy/fraction), 61.6Gy for subclinical 
peri-prostatic disease (2.2Gy/fraction) and 50.4Gy to pelvic nodes (1.8Gy/fraction).  
 
Data regarding protocol adherence, nomogram use, radiotherapy dose distribution, 
and acute toxicity were collected. 
 
Results: 
Nomogram use 
100% of patients were treated for ECE, 88.9% for SVI, and 70.4% for LNI. The three 
areas at risk of LRS were appropriately treated according to the study protocol in 
98.8% cases.  The MSKCC nomogram estimates for LRS differed significantly 
between the time of recruitment and analysis. 
 
  
 49 
 
Contouring protocol compliance 
Compliance with the trial contouring protocol for up to seven target volumes was 
93.0% (159/171). Compliance with protocol for small bowel contouring was poor 
(59.3%). 
 
Dose constraints compliance 
Compliance with dose constraints for target volumes was 97.4% (191/196). 
Compliance with dose constraints for OAR was 88.2% (285/323). 
 
Acute toxicity 
There were no grade 3 acute toxicities observed. 20/27 (74.1%) and 6/27 (22.2%) 
patients experienced a grade 2 genitourinary and gastrointestinal toxicity 
respectively.  
 
Conclusions: 
We have demonstrated the feasibility of this novel risk-adapted radiation treatment 
protocol for HRPC. This study has identified key learning points regarding this 
approach, including the importance of standardization and updating of risk 
quantification tools, and the utility of an observer to verify their correct use. 
 
Trial registration: 
ClincialTrials.gov identifier NCT01418040 
Hunter New England Human Research Ethics Committee (HNEHREC) reference 
number 12/08/15/4.02 
 
Keywords 
Prostatic Neoplasms, Radiotherapy, Nomograms. 
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Background 
Radiotherapy (RT) has been shown to independently improve overall survival for 
men with high risk prostate cancer (HRPC) managed with androgen deprivation 
therapy (ADT)[1, 2]. The traditional approach to radiotherapy for HRPC is to treat the 
prostate alone. However, there is extensive surgical pathological literature 
demonstrating the risk of subclinical disease infiltration of HRPC into pelvic lymph 
nodes (PLN), seminal vesicles (SV), and in an extra-prostatic distribution [3–5]. With 
the increased uptake of intensity modulated radiotherapy (IMRT), there is a potential 
opportunity to tailor treatment to such areas at significant risk of loco-regional spread 
(LRS) rather than managing all men with HRPC in an identical manner. In other sub-
sites, for example in the treatment of mucosal squamous cell carcinoma of the head 
and neck (HNSCC), this treatment approach has long been accepted as standard of 
care.  
 
Uncertainty regarding the role of whole pelvis radiotherapy (WPRT) in high risk 
prostate cancer is reflected in various clinical guidelines, in which the elective 
treatment of pelvic nodes is left up to the treating clinician’s discretion [6, 7]. Two 
randomized controlled trials (RTOG 9413 and GETUG-01) have failed to 
convincingly demonstrate improvement in progression free survival with the use of 
WPRT versus prostate-only treatment [8, 9], although later results from the RTOG 
study show improved biochemical control in a subset of patients receiving neo-
adjuvant hormonal therapy. Reasons for a lack of benefit from WPRT have been 
described, including insufficient radiation dose, inadequate coverage of at-risk 
nodes, and poorly targeted patient selection [10, 11].  Despite the lack of level I 
evidence for WPRT, this practice has been incorporated into the standard treatment 
of HRPC in multiple practice-defining randomized controlled trials (RCT) [12–14]. 
 
WPRT in this setting is not without its risks; there is mixed evidence to suggest 
increased acute and late grade 3 gastrointestinal toxicity and decreased bowel 
quality of life [8, 9, 15, 16]. Despite reductions in dose to critical structures and late 
GI adverse effects achieved through the use of IMRT over 3D-conformal RT [17, 18], 
WPRT is still likely to result in increased toxicity compared to treatment of the 
prostate alone. It is therefore important to reserve the use of WPRT, and to a lesser 
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extent irradiation of the SV and peri-prostatic regions, for those patients that are 
most likely to experience improved tumour control outcomes.  
We conducted a prospective clinical trial to assess the feasibility and tolerability of a 
hypofractionated radiotherapy treatment protocol for HRPC that employed the use of 
a widely accessible and externally validated online nomogram to estimate risk of 
LRS and accordingly adapt delineation of target volumes. 
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Methods 
 
Study design and participants 
This prospective phase two single institution study enrolled patients with high-risk 
prostate cancer for 18 months (Jan 2013-June 2014). Patients were eligible for the 
study if they met the following inclusion criteria: histologically confirmed 
adenocarcinoma of the prostate, high risk disease (defined by any one of baseline 
prostate-specific antigen (PSA) ≥ 20 µg/L, Gleason Score (GS) 8-10 and/or clinical 
stage T3-T4), and conventional staging imaging negative for distant metastases 
(technetium-99m whole body bone scan and CT of abdomen and pelvis). Exclusion 
criteria included: previous pelvic radiotherapy, history of prior malignancy within the 
last 5 years (excluding non-melanomatous skin cancers), Eastern Cooperative 
Oncology Group (ECOG) performance status ≥ 2, or any contraindication to insertion 
of intra-prostatic fiducial markers or planning MRI prior to RT simulation.  All patients 
were administered a total of 18 months of ADT in the form of Leuprorelin 22.5mg 
every 3 months. 
 
All patients gave written informed consent. The study was reviewed and approved by 
the Hunter and New England Human Research Ethics Committee (HNEHREC Ref: 
12/08/15/4.02). The trial was registered with ClincialTrials.gov (identifier 
NCT01418040).  
 
Nomogram use 
A set of parameters (age, PSA, tumour GS, clinical stage and percentage of positive 
biopsies) were inputted into the Memorial-Sloan-Kettering Cancer Center (MSKCC) 
prostate cancer nomogram [19] prior to radiotherapy and again at time of analysis to 
estimate risk of LRS. The pre-RT nomogram risk estimates for extra-capsular 
extension (ECE), seminal vesicles involvement (SVI), and pelvic lymph nodes 
involvement (LNI) were used to adapt radiotherapy treatment volumes based on a 
risk threshold of ≥15% in all cases. 
 
Simulation and planning protocol 
Radiotherapy commenced after 6 months of neo-adjuvant ADT, in keeping with the 
results from the TROG 96.01 randomised trial showing superiority of this duration 
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verses 3 months or no ADT [20].  Following insertion of three intra-prostatic gold 
fiducials, all patients underwent CT simulation (Aquilion LB TSX-201A, Toshiba 
Medical Systems Corporation) in the supine position with customized immobilization. 
Patients were instructed to have a comfortably full bladder and an empty rectum for 
simulation and treatment. A 3-tesla non-contrast planning MRI scan (MAGNETOM 
Skyra, Siemens) using 2mm slices and T2 weighting was completed on the same 
day and co-registered with the simulation CT by matching to the fiducial markers. 
 
A standardized planning guide was developed and used to direct contouring of target 
volumes and organs at risk (OAR) on the CT and MRI imaging. Target volumes were 
contoured as listed in table 1. Elective irradiation of extra-capsular disease 
extension, proximal seminal vesicles, and/or pelvic lymph nodes was completed if 
the risk of involvement of each respective region exceeded 15%, as estimated by the 
MSKCC nomogram. 
 
The rectum, bladder, neck of femur, small bowel and penile bulb were contoured as 
organs at risk (OAR). The rectum was contoured as a solid organ from the ano-rectal 
junction to the recto-sigmoid flexure. The entire bladder was also contoured as a 
solid organ. The small bowel was contoured as any visible small bowel as well as 
peritoneal contents within 8mm of the superior margin of the PTV. This volume was 
expanded 3mm in all directions to create a small bowel planning organ at risk 
volume (PRV). 
 
Radiotherapy technique 
Radiotherapy was administered over 28 daily fractions, given five fractions per week 
using an image-guided dynamic IMRT technique. Pre-treatment image guidance was 
conducted using matching of kilovoltage electronic portal imaging to the three intra-
prostatic gold fiducial markers with a 1 mm action threshold for a translational shift.  
Extrapolating from the HNSCC literature, and given the expectation of reduced 
clonogen density in imaging-negative areas, reduced radiotherapy dosing was 
administered to elective regions. Up to three dose levels were treated in 28 fractions 
using a simultaneous integrated boost:  
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 All patients received radiotherapy to the prostate +/- seminal vesicles (if 
grossly involved on clinical examination or MRI) to a dose of 70 Gy (2.5 Gy 
per fraction). 
 If the nomogram estimate for ECE ≥15%, an additional volume (formed by a 
3mm isotropic expansion from the prostate excluding overlap with the rectum) 
was treated to 61.6 Gy (2.2 Gy per fraction). 
 If the nomogram estimate for SVI ≥15%, the proximal 20mm of the seminal 
vesicles was treated to 61.6 Gy (2.2 Gy per fraction). 
 If the nomogram estimate for LNI ≥15%, the pelvic lymph nodes were treated 
to 50.4 Gy (1.8 Gy per fraction), contoured according to RTOG consensus 
guidelines [21] with a modified upper border of 10mm inferior to the sacral 
promontory. 
 
Dose constraints 
Planning objectives and field arrangement were optimized to achieve the best 
dosimetry to satisfy dose constraints for target volumes and OAR (listed in table 2).  
All planning was performed using the Eclipse Treatment Planning System v12 
(Varian Medical Systems).  In particular, dosing to the PTVs aimed to deliver 100% 
of the prescribed dose to 98% of the target volume as per ICRU 83 [22]. 
 
Data collection and analysis 
Genitourinary and gastrointestinal toxicity were assessed on a weekly basis during 
radiotherapy, at 1.5 months and 4.5 months post radiotherapy, then at 6 monthly 
intervals thereafter. Scoring of toxicity was completed using the Radiation Therapy 
Oncology Group (RTOG) acute and late radiation morbidity scoring criteria. 
 
Efficacy of treatment will be assessed by biochemical no evidence of disease 
(bNED) as defined by the ASTRO Phoenix definition (nadir + 2.0mcg/L) [23]. bNED 
was and will be assessed at each post-RT review. Treatment efficacy outcome 
results will be presented at a later date when longer follow-up has been achieved. 
 
Evaluation of compliance with the trial protocol for nomogram-directed target volume 
delineation, contouring, and dose constraints were conducted after the final patient 
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completed radiotherapy. To demonstrate feasibility, we aimed to achieve ≥90% 
protocol compliance rate with each of these parameters. 
 
Up to seven target structures (CTVP, CTVECE, CTVSVA/SVI, CTVLN, PTV70, PTV61.6, 
and PTV50.4) were generated for each patient according to the protocol outlined in 
table 3.1. At the time of analysis, each patient’s plan was reviewed to determine 
whether appropriate target structures were treated according to the threshold of 
≥15% risk of involvement as estimated by the MSKCC nomogram. Each target 
structure was assessed for strict adherence to the contouring protocol by a third 
party not involved in the original planning process (RW). This assessment was 
repeated for contouring of OAR. 
 
Table 3.1: Contouring protocol for target volumes 
Structure Contouring protocol Condition 
CTVP Prostate as defined using CT and MRI imaging + any 
extra-prostatic extension as noted on examination or 
pre-ADT imaging 
All patients 
CTVECE 3mm isotropic margin from CTVP, excluding overlap 
with rectum 
If ECE risk ≥ 
15% 
CTVSVI Entire bilateral seminal vesicles (only contoured if 
known seminal vesicle involvement) 
If SV involved 
CTVSVA Proximal 20mm of SV, measured obliquely along long 
axis of SV 
(only contoured for adjuvant treatment of seminal 
vesicles) 
If SVI risk ≥ 
15% 
CTVLN Pelvic nodes: 7mm margin around obturator, pre-
sacral, and external and internal iliac vessels 
contoured as per RTOG consensus guidelines [21], up 
to 10mm inferior to the sacral promontory) 
If LNI risk ≥ 
15% 
PTV70 If no SV involvement: 5mm margin around CTVP                                              
If SV involvement: 5mm margin around CTVP + 7mm 
margin around CTVSVI anteriorly and posteriorly and 
5mm otherwise 
All patients 
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Structure Contouring protocol Condition 
PTV61.6 If SV involvement or SVI risk <15%: 5mm margin 
around CTVECE     If no SV involvement and SVI risk 
≥15%: 5mm margin around CTVECE + 7mm margin 
around CTVSVA anteriorly and posteriorly and 5mm 
otherwise 
If CTVECE or 
CTVSVA 
contoured 
PTV50.4 5mm margin around CTVLN If CTVLN 
contoured 
 
Dose constraints for target volumes and OAR were assessed according to the 
objectives listed in table 3.2. Values exceeding the ‘mandatory’ limits were termed 
‘major variations’. Values in between the ‘mandatory’ and ‘ideal’ limits were termed 
‘minor variations’.  In all cases, descriptive statistics generated from Microsoft Excel 
are presented. 
 
Table 3.2: Dose constraints for target volumes and organs at risk 
Target volumes Mandatory Ideal 
PTV70 D98% ≥70.0 Gy - 
PTV70 D1cc ≤77.0 Gy ≤74.9 Gy 
PTV61.6 D98% ≥61.6 Gy - 
PTV50.4 D98% ≥50.4 Gy - 
CTVP  ≥70.0 Gy - 
CTVSVI D99% ≥70.0 Gy - 
CTVECE D99% ≥61.6 Gy - 
CTVLN D99% ≥50.4 Gy - 
Organs at risk Mandatory Ideal 
Rectum D15% ≤74.0 Gy ≤74.0 Gy 
Rectum D25% ≤69.0 Gy ≤60.0 Gy 
Rectum D35% ≤64.0 Gy ≤50.0 Gy 
Rectum D50% ≤59.0 Gy ≤40.0 Gy 
Bladder D15% ≤79.0 Gy ≤74.0 Gy 
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Bladder D25% ≤74.0 Gy ≤60.0 Gy 
Bladder D30% ≤69.0 Gy ≤50.0 Gy 
Bladder D50% ≤64.0 Gy ≤40.0 Gy 
Neck of femur D5% ≤44.0 Gy - 
Small bowel PRV D99% ≤52.0 Gy - 
Small bowel V45Gy ≤195 cc - 
Penile bulb mean dose - ≤51.0 Gy 
 
Sub-studies examining the use of imaging to predict risk of ADT-induced loss of 
bone mineral density, and the prognostic significance of circulating tumour cells were 
completed concurrently using the same patient cohort and are reported on 
separately [24, 25]. 
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Results 
 
Patient characteristics 
28 patients were enrolled onto the trial, of which 27 (96.4%) completed the planned 
treatment without unscheduled breaks. The remaining patient was not suitable for 
treatment due to an acute myocardial infarction prior to radiotherapy. Two patients 
were enrolled to the trial despite baseline characteristics not fulfilling the inclusion 
criteria for high risk disease. Median follow-up at the time of analysis was 11.4 
months. The patient characteristics are shown in table 3.3. 
 
Table 3.3: Baseline patient characteristics 
 Median (range) 
Age 70.6 years (54.6 – 78.9) 
PSA 12.4 ng/mL (4.0 – 52.1) 
% biopsy cores positive 50% (25 – 100) 
 
Gleason Score Number of patients (%) 
3 + 4 2 (7%) 
4 + 3 3 (11%) 
4 + 4 3 (11%) 
4 + 5 16 (59%) 
5 + 4 4 (15%) 
 
T stage Number of patients (%) 
T1b 1 (4%) 
T1c 3 (11%) 
T2a 1 (4%) 
T2b 7 (25%) 
T2c 4 (14%) 
T3a 9 (32%) 
T3b 3 (11%) 
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Nomogram use and radiotherapy treatment volumes 
The MSKCC nomogram was used to estimate risk of loco-regional spread (ECE, SVI 
and LNI) both prior to radiotherapy (to direct treatment), and later at the time of data 
analysis. There was a difference in nomogram outputs between these two time 
points (table 3.4). Student’s t-test demonstrated significant increases for ECE and 
LNI (both p<0.001), but no change for SVI (p=0.35). If current nomogram outputs 
were used instead of those obtained prior to RT, 9 of 27 patients would have 
received different treatment; 7 patients using larger volumes and 2 patients using 
smaller volumes. 
 
Table 3.4: Nomogram estimates for risk of LRS at pre-radiotherapy and at time of 
data analysis 
  Pre-RT At analysis Paired t-test 
ECE 70.7% (20.8) 87.1% (13.8) p < 0.001 
SVI 47.0% (24.1) 43.5% (24.7) p = 0.356 
LNI 32.05% (27.7) 50.4% (26.9) p < 0.001 
Data are presented as mean (standard deviation) 
Two patients with known pelvic lymph node metastases were entered as 100% risk of LNI 
 
Radiotherapy target volumes were expanded to account for risk of ECE in 27/27 
patients (100%), SVI in 24/27 (88.9%), and LNI in 19/27 (70.4%). An example of the 
volumes treated to three different dose levels is shown in figure 3.1.  Areas at risk of 
LRS were appropriately included/omitted from treatment according to the study 
protocol in 98.8% of cases. However, error in inputting post-ADT rather than pre-
ADT PSA into the nomogram for two patients resulted in falsely low estimates of 
LRS, and the incorrect omission of treatment of both SV and PLN.  
 
Contouring of target volumes and OAR 
The seven target volumes were correctly delineated according to the trial contouring 
protocol in 94.1% of cases (160/170). Compliance with protocol for contouring of 
OAR (rectum, bladder, small bowel) was 70.4% (57/81), although 22/24 variations 
were due to small bowel contouring that was incorrect or omitted. 
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Figure 3.1: Typical radiotherapy dose distribution.  Legend: PTV70 (yellow), 
PTV61.6 (cyan) and PTV50.4 (dark blue) are displayed with dose colour wash 
overlay 
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Dose constraints  
Each patient’s radiotherapy plan was assessed for adherence to 5-8 target volume 
dose constraints and up to 13 OAR dose constraints, dependent upon the volumes 
treated. Compliance with dose constraints for target volumes was 97.1% (170/175), 
with 1.7% minor variations and 1.1% major variations. Compliance with dose 
constraints for OAR was 88.2% (285/323), with 9.9% minor variations and 1.9% 
major variations. 
 
Acute toxicity 
There was no grade ≥3 genitourinary (GU) or gastrointestinal (GI) acute toxicity 
observed (table 3.5). 20/27 (74.1%) patients experienced grade 2 GU toxicity at 
some point during radiotherapy. In all cases this was either increased obstructive or 
irritative urinary symptoms managed with supportive measures such as Tamsulosin 
or urinary alkalinisation respectively.  6/27 (22.2%) patients experienced grade 2 GI 
toxicity in the form of increased bowel frequency managed with Loperamide. 
 
Table 3.5: Maximal acute toxicity (during radiotherapy) 
 Grade 0 Grade 1 Grade 2 ≥ Grade 3 
Genitourinary 2 (7.4%) 5 (18.5%) 20 (74.1%) 0 (0%) 
Gastrointestinal 12 (44.4%) 9 (33.3%) 6 (22.2%) 0 (0%) 
Data are presented as number of patients (% of total cohort)  
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Discussion 
 
We have demonstrated the feasibility of a risk-adjusted radiotherapy treatment 
protocol that adapts target volume delineation based on nomogram estimates of risk 
of LRS. This treatment was shown to be technically feasible, clinically practicable, 
and resulted in acceptable levels of acute toxicity in line with standard of care.  
 
It is important to appreciate the natural patterns of spread of disease when 
determining target volumes to be treated. A rich surgical pathological literature is 
available to inform this approach, demonstrating the frequency, and often extent of 
disease involvement. For example, the risk of SV involvement in patients with T2 
disease has been described, as has the fact that in 90% of such cases disease is 
confined to the proximal 20 mm of the SV measured along the axis of the structure 
[4]. It is perhaps noteworthy that in the HNSCC setting, such data regarding 
pathological risk of loco-regional involvement is deemed appropriate to allow clinical 
implementation without prospective clinical trial validation [26]. Yet in the prostate 
radiotherapy setting, clinical trials attempting to quantify the benefit of WPRT 
continue to be performed (e.g. RTOG 0534 and RTOG 0924). In the era of improved 
imaging, integration of new systemic agents, and highly conformal radiotherapy, it 
will be challenging for such studies to definitively answer such questions for all 
patients, which is part of the reason that most modern protocols simply mandate the 
extent of elective volume treatment [27]. 
 
The twenty-eight treatment hypofractionated radiotherapy regimen used in this study 
was first described by the Cleveland Clinic [28]. This original protocol has been 
adapted to form the experimental arm in the RTOG 0415 study, a multi-centre phase 
III randomized controlled trial examining modest hypofractionation for treatment of 
favourable risk prostate cancer. Neither of these treatment regimens included 
elective WPRT. Two separate groups in the US have published their experiences 
administering conventionally fractionated WPRT concurrently or sequentially with 
hypofractionated prostate irradiation [16, 29]. Early data regarding biochemical 
control and toxicity from these four groups have demonstrated encouraging results 
with the modestly hypofractionated treatment. 
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The frequency of grade ≥2 acute GU toxicity (74.1%) observed in this trial was 
slightly higher than that recorded by the aforementioned studies of McDonald et al. 
(52%) and Pollack et al. (approximately 56%) [16, 29]. This difference may be 
accounted for by the increased dose to the seminal vesicles (61.6 Gy vs. 56 Gy or 
50 Gy respectively) or more likely, a lower threshold for the use of interventions. The 
increase in toxicity was limited in severity to RTOG grade 2, and it remains to be 
seen whether this will translate into more meaningful differences in late toxicity. The 
absence of grade 3 acute toxicity in this study is reassuring and consistent with the 
published data using similar treatments. The incidence of grade ≥2 acute GI toxicity 
(22.2%) was in the same range as the levels seen in the University of Alabama at 
Birmingham series (37%) [16].  Their series treated all HRPC men with the same 
radiotherapy doses to the primary disease and pelvic lymph nodes as in our cohort, 
and have reported efficacy and late toxicity rates similar to conventional treatment. 
Our data adds to the literature that supports the feasibility of moderately 
hypofractionated radiotherapy treating the prostate and pelvis concurrently for men 
with HRPC. 
 
The question remains as to how best to select patients for radiotherapy volume 
adaptation.  Some guidelines such as from the EORTC recommend using the 
D’Amico risk stratification.  This would probably lead to overtreatment, as some 
patients designated as high risk actually have very favourable outcomes, illustrating 
the heterogeneity of such risk groupings [30]. Clinical tools such as the ‘Partin tables’ 
[31] have analysed historical data from large cohorts of patients undergoing radical 
prostatectomy to demonstrate the correlation between LRS and prognostic factors 
such as PSA, GS, and clinical staging. These data could provide an individualized 
estimate for risk and degree of LRS, which may then be used to adapt the extent of 
treatment.  The use of a web-based nomogram (such as the MSKCC nomogram) 
allows further refinements to this approach.  The clinical tool is widely accessible, 
simple to use, considers the additional variable of tumour volume, and considers 
relevant prognostic factors as continuous rather than discrete variables. 
Furthermore, as the calculations are not completed manually, the underlying 
algorithm can be sufficiently complex to achieve maximal accuracy. For these 
reasons, a computer-based nomogram is a powerful tool that facilitates risk-adapted 
treatment individualization. 
 64 
 
 
There are, however, a number of limitations in using a nomogram in this fashion. 
First of all, the nomogram is dependent upon historical data that may not be suitable 
for extrapolation to the current population. Changes in disease epidemiology, 
staging, and screening practices mean that the effect of prognostic factors may differ 
between contemporary and historical populations, and the estimates may therefore 
be inaccurate.  A key example of this was the upward migration of Gleason scoring 
in recent years, partly due to the altered definitions of the core biopsy grading 
system introduced in 2005 [32]. There is therefore a need to regularly review the 
applicability of historical results to current populations and update the nomogram 
algorithms accordingly (which then also prompts the need for external re-validation). 
The degree to which this affects results is illustrated in the difference in nomogram 
outputs between the time of planning and analysis (table 4).  
 
Secondly, most clinical tools used to estimate the risk of LRS in prostate cancer are 
based upon radical prostatectomy series that employed limited lymph node 
dissection. It has been demonstrated that standard/limited pelvic lymph node 
dissections may result in false negative rates for pathological involved nodes of over 
50% compared to extended dissections [33]. Nomogram algorithms that have been 
derived from these data may therefore generate estimates of LNI that are 
deceptively low. 
 
Thirdly, there is a danger that data entry errors may result in grossly inaccurate 
estimates of LRS and incorrect clinical decision-making. For example, a misplaced 
decimal point, or inputting the post-ADT PSA rather than PSA at diagnosis may alter 
the nomogram estimates considerably. The latter error occurred twice in our study 
and resulted in artificially low estimates of LRS and incorrect non-treatment of 
seminal vesicles and pelvic nodes in these patients. Simple safeguards would 
prevent such errors from occurring, for example, a second observer to verify correct 
data entry and nomogram use. 
 
Fourthly, there are small sub-groups of prostate cancer patients who are not suitable 
for nomogram-directed adaptation of treatment. Outcomes for PSA-negative tumours 
for example are not correctly predicted with current nomograms. This group however 
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represents only a very select subset of patients (1% or less of total prostate cancer 
cases) who very often present late with metastatic disease that is not suitable for 
curative treatment [34]. Neuroendocrine carcinoma of the prostate is another group 
for which standard prognostic tools are similarly unsuitable. 
 
A further lesson from our experience was appreciating the danger in over-
complicating treatment. 
The novel treatment regimen used in this study involves a number of features that 
increase its complexity compared to standard practice. These include the use of a 
nomogram to define risk of LRS and adapt target delineation, protocolised 
generation of multiple target structures to be treated using up to three different dose 
levels, and a hypofractionated regimen with many unfamiliar dose constraints. Added 
complexity is liable to increase the likelihood of errors and protocol non-compliance 
and must be justified with a benefit to clinical outcomes. We identified a number of 
examples of this, including rotation of the simulation CT images to contour the 
proximal seminal vesicles along their axes, or the use of multiple, redundant dose 
constraints for rectum and bladder.  Here, excessive and unfamiliar processes are 
unlikely to improve outcomes and should be simplified. If additional complexity is 
value-adding, it may be necessary to implement further safeguards such as peer 
review of contouring and the use of checklists to maximise protocol compliance. 
 
We have demonstrated feasibility and deliverability of a complex risk-adapted 
treatment for patients with HRPC. Many future directions are being pursued along 
similar lines. The use of more extreme hypofractionation coupled with pelvic 
radiotherapy is increasing, for example in the ‘SATURN’ trial, in which stereotactic 
radiotherapy treatment is administered over 5 fractions to both the prostate and 
pelvic lymph nodes. A similar protocol used in the earlier ‘FASTR’ trial however 
resulted in unacceptable levels of late toxicity, suggesting caution in using such an 
approach [35]. 
In contrast, emerging imaging modalities such as PSMA PET are likely to detect 
early metastatic spread with increased sensitivity, which may reduce the number of 
at-risk patients with negative staging investigations who are therefore candidates for 
elective loco-regional treatment. If this does eventuate, however, we would then face 
the question of how to treat this growing group of patients with early loco-regional or 
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oligometastatic disease, an area where there is again a paucity of evidence to guide 
management. It is likely that the management of prostate cancer will shift further 
towards a risk-adapted approach as the results of current trials and integration of 
new imaging into clinical practice continues.
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Conclusions 
We have demonstrated the feasibility of this novel risk-adapted radiation treatment 
protocol for HRPC. This study has identified key learning points regarding this 
approach, including the importance of standardization and updating of risk 
quantification tools, and the utility of an observer to verify their correct use. 
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Section 3: Biomarkers of toxicity and efficacy 
 
There is great interest in oncology in trying to predict outcomes early in the 
management of patients.  Various approaches can be taken to achieve this.  One 
touched on in the previous chapter is to use a mathematical model incorporating 
information available at the time of diagnosis.  Another avenue is to use the patient’s 
own inherent reaction to treatment.  This can be assessed in many ways, but two 
general approaches are to either use samples from the patient (either tumour, blood 
or other specimens), or non-invasive imaging.   In the next three chapters, we 
explore both methods.  Chapters 4 and 5 assess the utility of multiparametric MRI as 
an imaging biomarker of later treatment toxicity, in this case, the risk of rapid loss in 
bone mineral density with the use of androgen deprivation therapy.  Chapter 6 
assesses Circulating Tumour Cells, a serum biomarker, to determine their sensitivity 
in a high risk prostate cancer population. 
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Chapter 4 – MRI Assessed Vertebral Fat Fraction: A Pilot Study 
 
Based on prior work showing a relationship between MRI derived fat fraction in bone 
and DEXA scan measured bone mineral density, we performed a local pilot study.  
Our main aims were to assess inter- and intra-observer variability in calculating the 
fat fraction, as well as exploring a Dixon technique as an alternative to MR 
Spectroscopy to assess the fat fraction.  Although only five men were assessed, we 
found that there was minimal variability in assessing the fat fraction, and that the fat 
fraction tended to increases the more inferiorly in the spine the measurements were 
taken.  These findings allowed us to proceed with the more comprehensive study 
presenting in Chapter 5. 
 
Published as ‘Martin J, Nicholson G, Cowin G, Ilente C, Wong W, Kennedy D. Rapid 
determination of vertebral fat fraction over a large range of vertebral bodies. J Med 
Imaging Radiat Oncol 2014;58:155-63.’ 
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Abstract 
 
Introduction 
 
Vertebral body Fat Fraction (FF) has been found to vary between lumbar vertebrae 
using Magnetic Resonance Spectroscopy (MRS).  We aim to more quickly assess a 
larger number of adjacent vertebrae using a single T2-weighted iterative 
decomposition of water and fat with echo asymmetric and least squares estimation 
(IDEAL) sequence. 
 
Methods 
 
Five males had DEXA and 1.5 Tesla MR scans performed.  MRS was performed at 
L3, and a sagittal IDEAL sequence resulting in separate pure fat and pure water 
readings from T10 to S2.  For the IDEAL measurements, two independent observers 
followed a set reading protocol with five observations each per vertebra.  Intra- and 
Inter-observer variability was assessed as deviations from the mean respectively 
within and between observers. 
 
Results 
 
For FF measurements there was limited intra-observer variation, with observers 
being on average within 3.4% of the pooled mean value.  Similarly, there was good 
interobserver agreement with an average variation of 2.1%.  All men showed a 
reduced FF between L5-S1 of between 1.6–7%.  Otherwise, there was a trend for 
increasing FF moving inferiorly from T10 to S2.  This averaged 2.7%/vertebra (range 
1.1-3.8%), and may not be dependent of MRS measured FF at the L3 level.  There 
was poor correlation between MRS FF at L2-4 and BMD using DEXA (R2=0.06). 
 
Conclusion 
 
IDEAL measurements are generally reproducible between observers following a set 
protocol.  There appears to be a gradient in FF moving from T10 to S2 with S1 
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showing a consistent decrease.  This variation may better describe overall marrow 
function than a single vertebral reading. 
 
Key Words: 
 
Magnetic Resonance Imaging 
Magnetic Resonance Spectroscopy 
Bone Marrow 
Fat Fraction 
Fat Imaging 
Osteoporosis  
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Introduction 
 
Bone marrow contains hematopoietic stem cells, generating circulating blood and 
osteoclasts as well as mesenchymal stem cells which can mature into osteoblasts 
and adipocytes/fat 1 . The ratio of these respective red and yellow cells is not 
constant and changes with age, gender and anatomical location 2, 3. The fat fraction 
(FF) is ratio of fat-to-water-plus-fat and has been determined by magnetic resonance 
spectroscopy (MRS) and imaging (MRI) 3, 4.  Marrow Fraction is the inverse of FF (ie 
100% - FF), and is thought to correlate with marrow function 5.  
 
The FF is known to vary according to anatomical site. This has been indirectly 
demonstrated in work with 18F-fluoro-L-deoxythymidine Positron Emission 
Tomography (FLT-PET) imaging looking at the inverse of FF in the form of marrow 
proliferation 6. This group reported high marrow proliferation in the thoracic spine 
(19.9%), intermediate in the lumbar spine (16.6%) decreasing in the sacrum (9.2%). 
However, PET/CT studies are not suitable for repeated measures or acquiring 
normative data due to the radiation exposure. Early experience measuring FF via 
MRS at two separate lumbar vertebrae showed increasing FF for the more inferior 
vertebra 3.  This observation is consistent with a later report assessing the four 
vertebrae from L1 to L4, showing the same trend, even between neighbouring 
vertebrae 2.  It is therefore plausible that a point estimate of FF in a single vertebra 
doesn’t completely describe marrow function.  A more comprehensive measurement 
of not only FF but also change in FF according to anatomical site and time may 
provide a more complete description. 
 
Preliminary work suggests there is a correlation between the Fat Fraction (FF) 
estimated by Magnetic Resonance Spectroscopy (MRS) in Lumbar vertebrae and 
the accepted standard of Bone Mineral Density (BMD) measured by DEXA 7.  
However, there is a wide degree of overlap between subjects classified as normal, 
osteopaenic and osteoporotic on DEXA and their corresponding FF values.  Some of 
this variability would be explained by clinical factors such as age and gender 4, which 
are routinely incorporated into fracture risk nomograms such as FRAX 8.  However, 
due to the complex physiology of bone beyond what can be quantified through DEXA 
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imaging and clinical parameters, it is plausible that some of this variability may be 
due to other factors which MRI would be well placed to assess. 
 
The T2-weighted iterative decomposition of water and fat with echo asymmetric and 
least squares estimation (IDEAL) image sequences produce separate water and fat 
only images, and have previously been shown to correlate very strongly with MRS 
derived FF measurements in bone 3, 9. The advantage of imaging approaches 
applied to a sagittal section of vertebrae is that the FF can be estimated for a larger 
number of structures in a much shorter time than performing MRS in multiple 
Regions of Interest (ROI).  We aim to use the IDEAL sequence in a group of older 
male patients entering onto a clinical trial investigating the effects of androgen 
deprivation on marrow function.   
 
Evaluation of normal and pathological changes in bone marrow FF would ideally use 
non-invasive methods that do not require x-rays or radiotracers. The variation of FF 
along the vertebral column suggests the requirement of assessing a large a range of 
the spine as possible.  MRI methods including IDEAL imaging as investigated in this 
study show some promise in this regard.    
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Methods 
 
Participants 
 
Eligible patients were men with localized prostate cancer who were to receive 
androgen deprivation therapy (ADT) and prostate radiotherapy.  None had a history 
of lower back problems.  Screening thoracolumbar X-Rays were performed to 
exclude osteoporotic compression fractures, advanced degenerative changes or any 
other gross abnormalities.  A whole body 99m-Technicium bone scan was performed 
and needed to be negative for the presence of metastatic bony disease.  Signed 
informed consent was obtained from five participants aged between 70 to 75 years, 
without any destroy of bisphosphonate, corticosteroid or ADT treatment, nor any 
history of low trauma fracture or osteoporosis.  This project received ethics approval 
from the Toowoomba and Darling Downs Human Research Ethics Committee.  
 
Imaging details 
 
Protons in water and lipids have unique chemical environments, resulting in 
particular MRI characteristics such as resonance frequencies at each magnetic field 
strength. Immediately after the excitation pulse the proton spins of the water and 
lipids are in–phase, resulting is addition of the water and fat signal. As the TE 
increases the difference in frequency results in the water and lipid spins having 
different phase off-set until they are 180° out-of-phase, resulting in subtraction of the 
water and fat signals. This results in periodic changes in image intensity, dependent 
on the phase offset of the water and lipid. The change in image intensity of a series 
of images can be modelled to determine the separated water and lipid contents. 
 
All MR examinations were performed on a GE 1.5 Tesla Signa Excite system using a 
lumbar phased-array coil.  Patients were positioned using a knee rest to minimise 
lumbar lordosis.  Initial scout images were followed by axial In-phase and Out-of-
phase imaging (5 mm slice thickness, 0 mm inter-slice gap, 36 cm field of view, 22 
sec) were acquired as a breathhold from T10 – S2.  An IDEAL-Fast Spin Echo (FSE) 
sequence (TR 3000 ms, TE 60 ms, 32 cm field of view, 20 slices, 3.0 mm slice 
thickness, 0.5 mm interslice gap, 6.35 min) was performed.  The IDEAL sequence is 
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a three point Dixon technique which has been demonstrated to provide uniform and 
reliable fat suppression10, 11 Online processing of the raw data of the sagittal IDEAL 
produced water only, fat only, and recombined in-phase and out-phase images. 
Twenty sagittal images of the spine from T10 to the mid-Sacrum were obtained using 
this approach for each patient. 
 
DEXA scanning was performed on all individuals with individual readings from L2, L3 
and L4 vertebral bodies.  Z- and T-Scores were also calculated based on Australian 
data. 
 
Data Extraction 
 
Offline two independent observers (JM and WW) extracted data from the sagittal Fat 
T2 IDEAL images using proprietary software (Voyager Telerad Picture Archive and 
Communication System, Intellrad Solutions Pty Ltd, Melbourne, Australia).  A set 
protocol was followed with separately drawn ROIs on five adjacent sagittal slices per 
vertebra.  The observers were instructed to begin at the sagittal slice 5 mm from 
cortical bone and to make freehand ROIs to provide measurements of vertebral fat 
content for all vertebral bodies within the field of view.  To limit peripheral artefact, 
the most superior and inferior vertebrae were not assessed.  Observers were 
instructed to exclude bony cortex, or any anatomical abnormalities observed on the 
T2 images.  They would then proceed from right to left on serial sagittal slices 
repeating the measurements five times overall.  An example of this is illustrated in 
figure 4.1. 
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Figure 4.1: 
Sample 
sagittal view 
of a Fat T2 
IDEAL 
image with 
Regions of 
Interest 
(ROIs) on 
L1-L5 
showing the 
mean fat 
content at 
each 
vertebral 
level. 
 
 
 
 
 
 
 
 
 
 
Magnetic Resonance Spectroscopy 
 
MR spectroscopy (MRS) was performed at the L3 level on all five patients. MRS was 
acquired using the point resolved spectroscopy sequence (PRESS) (TR 2000ms, TE 
35ms, 2.20min). Non-fat suppressed spectra were obtained by setting the fat 
suppression settings to zero. A single voxel was prescribed of approximately 2.0 cm3 
in size within the trabecular bone of L3. Particular care was taken to ensure that the 
voxel did not ‘protrude’ outside the confines of the vertebral body. Presaturation 
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bands were placed posteriorly, superiorly, inferiorly and anterior to the vertebral body 
to help eliminate unwanted signal contamination from outside the voxel. The 
software package SAGE (GE Medical Systems) was used to extract the areas under 
the peaks for separate fat and water peaks (Af and Aw respectively).  Post 
processing time was approximately 15 minutes per voxel using the SAGE software 
package. Fat fraction (FF) was calculated as Af / (Aw + Af ).  As this has very high 
correlation with FF using the IDEAL approach (R2 values of 0.85-0.9 3, 9), this figure 
was used to calculate a measurement for pure fat on the IDEAL: Fat images.  This 
was done by dividing the mean measure from the IDEAL:Fat image at L3 by the FF 
figure from the MRS for the same vertebral body.  The FF for all other vertebrae 
were then calculated by dividing the Fat: IDEAL measure for that vertebra by the 
pure fat measure.  For example, if the MRS gave a FF at L3 of 0.4, and IDEAL:Fat 
ROI gave a reading of 300 for L3, pure fat was calculated as 300 / 0.4 = 750.  Then if 
the IDEAL;Fat ROI reading for another vertebra was 400, FF would be calculated as 
400 / 750 = 0.53. 
 
Data Analysis 
 
Regarding intra-observer variation, for each observation, the percentage deviation 
from the mean for that vertebra and observer was calculated.  Similarly, inter-
observer percentage deviation was calculated as the absolute value for Observer A 
– Observer B divided by the average of the two.  If minimal deviations were noted, 
then a pooled mean value using data from all ten observations would be used in the 
subsequent analyses. 
 
Descriptive plots were constructed to assess for trends in observer variation as well 
as FF across adjacent vertebral bodies.  Linear regression using a mixed model was 
used to model the changes observed in FF within each participant. This approach 
allowed investigation of any trends across vertebrae, any differences in these trends 
between patients, and any anomalous measures between vertebrae.  R version 
2.15.1 was used for this analysis.  For the comparison between MRS FF and DEXA 
bone mineral density, a Pearson correlation coefficient was calculated, with the 
square of this being R2.    
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Results 
 
Reproducibility of Marrow Fat Fraction Measures 
Figure 4.2: Colour 
enhanced Fat T2 
IDEAL sagittal image 
from a patient 
demonstrating 
vertebrae from T9 to 
S2 where green 
represents a lower 
FF than red.  Note 
how the more rostral 
vertebrae are 
generally more green 
coloured than the 
redder caudal 
vertebra suggesting 
increasing fat fraction 
moving caudally. 
 
 
 
Figure 4.2 shows an example of a false colour LINEAR Fat MRI sagittal image.  To 
ensure stability of the FF measures, tests were done of intra- and inter-observer 
variation.  Between the two observers, 94 vertebral body Fat measurements were 
obtained, with a median of 5 observations per vertebral body.  A total of 464 
measurements were recorded.  Figure 4.3 shows the percentage deviation of each 
observation from the mean for the corresponding vertebral level and observer.  The 
overall average intra-observer variation was 3.4%, and in greater than 95% of      
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Figure 4.3: Line graphs showing low intraobserver variation in Fat measurements 
across all observations for both observers and nine vertebral bodies. 
 
instances, observations were within 9% of the mean.  No one patient’s vertebra had 
two separate measurements greater than 9% from the mean, nor was any individual 
deviation greater than 18%.  It was therefore concluded that there would be little 
effect from outliers on the data, and that the mean rather than the median would be a 
robust measure of data location. 
 
Similarly, inter-observer variation was compared across 45 different vertebral levels 
(nine vertebral bodies in five patients each) between the two observers.  Of the total 
of 45 observations, the overall average inter-observer variation was 2.1%, with 21 of 
the vertebrae within 1% between the two observers, 33 within 3% and 39 within 5%.  
The maximal variation was 8.1%.  This suggests that the reading protocol lead to 
consistent results within and between observers, and justified using a pooled mean 
value in the subsequent analyses. 
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Fat Fraction 
 
Figure 4.4 shows FF at each vertebral level for each of the five patients.  Note that 
all show a gradual trend of increasing FF moving from the most rostral towards the 
most caudal vertebral body.  Table 4.1 quantifies the average differences in FF 
between adjacent vertebrae.   Note the anomaly in the trend that all patients show a 
reduced FF in S1 compared with L5.  This ‘L5-S1 Dip’ is noted in all five patients with 
figures of -4.9%, -6.1%, -2.4%, -7.0% and -1.6% respectively.  Fitting a mixed linear 
model to the data with patients as a random factor and vertebrae as a fixed factor, 
with S1 excluded there is a highly significant upward linear trend in mean FF from 
T11 to S2 (p<0.0001).  The L5-S1 change is significantly different to that observed at 
the other levels (p=0.0007). 
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Figure 4.4: Fat 
fraction from 
T11 to S2 for 
the five patients 
measured.  
Most patients 
demonstrate a 
trend of 
increasing fat 
fraction moving 
caudally. 
 
 
Table 4.1: Difference in Fat Fraction between adjacent vertebrae.  Note the steady 
increase at all levels except for L5-S1. 
 
Vertebra Fat Fraction Mean 
(Range) 
Difference 
to previous 
T11 29.4% (19.7 – 36.9)  
T12 33.9% (25.1 – 44.5) 4.6% 
L1 37.6% (29.6 – 54.4) 3.7% 
L2 38.6% (32.7 – 54.2) 1.0% 
L3 40.0% (33.8 – 55.1) 1.4% 
L4 44.3% (36.3 – 58.7) 4.3% 
L5 46.6% (37.8 – 60.8) 2.3% 
S1 42.2% (31.5 – 58.5) -4.4% 
S2 47.9% (33.3 – 66.7) 5.7% 
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Due to one patient being shorter than the others, it was possible for a larger range of 
twelve vertebral bodies to be measured, and his FF per vertebrae is shown in Figure 
4.5.  The trend of increasing FF moving inferiorly appears even more pronounced, 
with a 50.9% difference in FF seen between T10 (29.1%) and S4 (80.0%) seen.  
Even excluding the most peripheral vertebral bodies because of the possibility of 
peripheral artifact, the range of FF from T11 to S3 is greater than 43%. 
 
 
Figure 4.5: The patient who due to his smaller size was able to have FF estimated 
for 12 adjacent vertebral bodies showing a range of values of over 50% across the 
field of view. 
  
 90 
 
Table 4.2: L3 MRS FF, with linear regression slope (an indicator of gradient in FF 
across the adjacent vertebral bodies), R2 values and T-Scores.  Note that normal 
BMD corresponds to a T-score of > -1, osteopaenia is between -1 and -2.5, and <-
2.5 indicates osteoporosis.   
 
Patient 
MRS FF at 
L3 
FF Slope 
(FF%/vertebra) 
R2 T-Score 
1 35.8 2.23 0.94 0.7 
2 41.2 2.74 0.82 -2.1 
3 55.1 3.84 0.83 -0.2 
4 34.2 1.10 0.81 -0.2 
5 33.8 3.44 0.96 2.3 
 
Fat Fraction Gradient 
 
The gradient in FF between T11 to L5 was fitted to a linear regression model.  For all 
five patients, a linear regression model proved a very good fit of the data, with R2 
values of between 0.81 and 0.96 (see Table 4.2).  The slope of the regression line 
varied from 1.1%/vertebra to 3.8%/vertebra (see Table 4.2).  Note how patients with 
similar L3 MRS FF readings can have different FF gradients.  Patients 1, 4 and 5 
have L3 MRS FF of 34.8+/-1%, yet despite this similarity the FF gradient varies by a 
factor of 3.5 across the full range of observed FF gradient values for these 3 
patients.  This suggests that a FF reading at a single vertebral level does not 
completely describe the functional marrow distribution.  However, the gradients were 
not significantly different in the mixed linear model used in the previous section 
(p=0.15). 
 
DEXA versus MRS FF 
 
The T-scores for the Lumbar vertebra were -2.1, -0.2, 2.3, -0.2 and 0.65, suggesting 
that 4 of the participants had normal BMD and one was osteopaenic.  The isolated 
DEXA BMD reading at L3 was compared with the MRS FF reading at the same 
vertebral level.  Only a weak negative correlation was noted between the two 
readings (R2=0.17).  Similarly weak negative correlations were noted at L2 and L4 
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(R2=0.12 and 0.11 respectively).  Considering all 15 of the individual L2, L3 and L4 
vertebral bodies together, although there is a negative correlation overall between 
BMD and FF, the relationship is weak (R2=0.06, Figure 4.6). 
 
 
 
Figure 4.6: Scatterplot of DEXA measured BMD verses Fat Fraction which shows a 
weak negative correlation. 
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Discussion 
 
The use of IDEAL imaging, with ROI analysis, proved to be a rapid and reliable 
method for determination of vertebral FF. This method enables a large series of 
vertebral bodies to be measured following a single rapid acquisition achieved in 
under seven minutes. This contrasts with spectroscopy, which normally evaluates a 
single vertebra per acquisition, with significant post processing time required to 
obtain the relevant data. There was minimal inter- and intra-observer variation for 
these measurements for independent observers following our set protocol.  As such, 
it should be possible to extract relevant data from only one ROI per vertebral body, 
which will make post-processing FF calculation relatively simple.  The most striking 
observation was that the more inferior the vertebral location, the more likely the FF 
would steadily increase.  This FF gradient appears to be largely independent of an 
isolated measure of FF using MRS at a single vertebral body level.  This result has 
not been reported using the IDEAL approach, but is in agreement with reports in the 
literature using MRS to estimated FF 2, 3.  
 
An early report touches on the possibility of a marrow gradient noting a trend toward 
increasing FF for more inferior vertebral bodies measured with MRS 3. In this study 
the mean FF value at L1 was 40.5%, and at L5 it was 51.3%, albeit with wide ranges 
due partially to only ten patients being examined in this manner.  This trend was not 
consistent, and may have been overwhelmed by the stronger relationships noted 
with both age and gender 4.  Even with these caveats, it is worth noting that the 
corresponding figures from our series were broadly similar at 37.7% and 46.7%.   
 
Another previous report again using MRS to quantify FF focussed on post-
menopausal women, which would be expected to reduce the impact of age and 
gender on the results 2.  Vertebral levels from L1 to L4 were all measured individually 
for 40 women, some of whom were known to have low BMD.  The FF gradient 
increased by an average of 2.2%/vertebra moving inferiorly in the patients with low 
BMD, although no strong evidence of a gradient was seen in the healthy controls.  
The average figure in our series was 2.7%/vertebra, although only one of our five 
patients had a low BMD reading.   A subsequent report from the same group looking 
at diabetic women, also noted a trend towards reducing FF from L1 to L3 12. 
 93 
 
 
It would appear that our results using the IDEAL approach are consistent with some 
earlier observations reported using MRS suggesting a gradient in FF moving 
caudally down the lumbar spine.  While the two approaches correlate well with each 
other, the latter sequence has the advantage of been able to examine more vertebral 
bodies simultaneously in a shorter time 3, 9.  Given the observed gradient in FF, it 
would seem that future investigators will either need to examine multiple vertebral 
bodies with MRS, or use an alternative approach such as IDEAL.   
 
There have been several reports suggesting a correlation between FF measured at a 
single vertebral body level and BMD measured by DEXA imaging 3, 5, 7.  However, 
there is extensive overlap between normal, osteopaenic and osteoporotic individuals.  
Part of the reason for this may be anatomical variations such as osteophytes which 
can interfere with DEXA readings 13, 14.  Although this might be circumvented with the 
use of qualitative CT, the increased radiation dose and lack of widely validated 
population data for this modality may curtail its widespread use 15.  Our hypothesis is 
that the complex functional anatomy, physiology and biology of bone is poorly 
captured using a single parameter such as Fat Fraction at a single vertebral level 16-
18.  Additional factors such as the FF gradient may be helpful in separated people 
into distinct BMD categories, and as such this is an area that we are continuing to 
investigate. 
 
A second finding from our study was that there is a consistent reduction in FF 
moving from L5 to S1.  This contrasts with a result published using FLT-PET, 
although that study did not resolve to the same degree of anatomical precision as in 
the current report6. This may be due to other subtle degenerative pathology at this 
level such as spondylosis relating to the unique mechanics of the L5-S1 joint 
compared with the more superior thoracic and lumbar articulations.  Further work will 
be required to clarify both the consistency of the reduction, as well as trying to gain a 
greater understanding of the underlying causes. If the FF does not change 
consistently and at an equal rate along the spine, individual measures by 
spectroscopy may miss changes.  
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Loss of BMD is a common problem for men managed with ADT for prostate cancer 
19. This results in a higher rate of fractures for these men 20.  Previously, ADT was 
only used for men being managed palliatively for metastatic disease and hence with 
relatively low life expectancy.  Two key developments now make the long term 
toxicity of ADT more pertinent.  One is the evidence of efficacy of adjuvant ADT in 
the curative setting, meaning many men expecting to be cured of their prostate 
cancer will survive long enough to potentially experience the chronic effects of ADT 
exposure 21, 22.  The second is the increasing number of effective systemic therapies, 
extending the life of men in the metastatic setting 23.  Abiraterone Acetate in 
particular requires long term exposure to not only ADT, but also low dose 
prednisone, which would be expected to further accelerate loss of BMD 24. 
 
Although our small study is in a relatively homogeneous patient population, we have 
demonstrated the potential to measure large regions of the spine revealing some 
consistent findings.  Following from the results from this study, we have initiated a 
larger prospective trial to investigate the capacity of lumbar spine MRI to predict 
which men are at higher risk of accelerated loss of BMD while on ADT as treatment 
for their prostate cancer.  Several randomized studies have shown improvements in 
BMD for unselected men on ADT treated with bisphosphonates, RANKL inhibition or 
selective oestrogen reuptake modulators 25.  Although there are numerous guidelines 
recommending pharmacological intervention for such men mainly on the basis of 
their T-score on DEXA imaging, given potential toxicities like osteonecrosis of the 
jaw as well as the expense of such agents there is scope to further target therapy to 
men most likely to benefit 25-27.   
 
Our current study focuses on men with prostate cancer being managed with curative 
intent with an 18 month course of ADT and pelvic radiotherapy.  Due to improved 
signal to noise ratio and shorter image acquisition time to reduce motion artefact, we 
will use a 3 Tesla system for this successor study 12.  We aim to investigate whether 
multiparametric MRI of the lumbar spine at baseline including In:Out phase, pure 
fat/water as well as diffusion weighted imaging might contribute to a model combined 
with clinical and DEXA findings to identify a subgroup of patients at risk of 
accelerated loss of BMD 28.   
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Conclusions 
 
Rapid acquisition of a large range of vertebral bodies with accurate determination of 
FF with ROI was demonstrated.  We have observed the existence of a gradient in 
Fat Fraction from T10 to S2.  There is also a consistent dip in Fat Fraction between 
L5 and S1, which may be due to the different anatomy and degenerative changes at 
this level.  These findings will be explored in a larger prospective study attempting to 
use such extra information available on MRI to determine which men are at risk of 
more rapid loss of BMD while on ADT. 
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Chapter 5 – Serial Spinal MRI and DEXA changes while on ADT: A potential 
toxicity biomarker. 
 
Changes over time in bone mineral density are variable for men with prostate cancer 
being managed with androgen deprivation therapy.  Expanding on the foundations 
set in the previous chapter, we explored in a larger cohort whether changes in serial 
multiparametric MRI of the spine correlated with later changes in DEXA measured 
bone mineral density.   If a reliable early imaging biomarker of later loss of bone 
mineral density could be identified, further research would be justified in exploring a 
risk adapted approach to bone health incorporating these findings. 
 
Several observations were forthcoming.  An increase in fat fraction (FF) was 
observed from T11 to S2.  There was a positive correlation between baseline MR 
spectroscopy (MRS) FF and Dixon FF as well as a negative correlation between 
MRS FF and the apparent diffusion coefficient (ADC).  Over six months, MRS FF 
increased by a median of 25% in relative values, Dixon FF increased and ADC 
values decreased.  Men with >5% loss in bone mineral density after one year had 
triple the percentage increase in MRS FF at six months.  Although these 
observations are of interest, given the complexity associated with obtaining them, 
they are unlikely to be of significant clinical utility in the short term. 
 
 
Published as ‘Martin J, Arm J, Smart J, et al. Spinal Multiparametric MRI and DEXA 
changes over time in men with prostate cancer treated with Androgen Deprivation 
Therapy: A potential imaging biomarker of treatment toxicity.’  European Radiology 
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Abstract 
 
Objectives 
 
To explore changes in Bone Mineral Density (BMD) measured by DEXA and MRS 
Fat Fraction (FF), Dixon FF and ADC in lower spinal vertebral bodies in men with 
prostate cancer treated with Androgen Deprivation Therapy (ADT). 
 
Methods 
 
28 men were enrolled onto a clinical trial.  All received ADT.  DEXA imaging was 
performed at baseline and 12 months.  L-spine MRI done at baseline and six 
months.   
 
Results 
 
The number of patients who underwent DEXA, Dixon, ADC and MRS at 
baseline/follow-up were 28/27, 28/26, 28/26 and 22/20.  An increase in FF was 
observed from T11 to S2 (average 1%/vertebra).  There was a positive correlation 
between baseline MRS FF and Dixon FF (r=0.85, p<0.0001) and a negative 
correlation between MRS FF and ADC (r= -0.56, p= 0.036).  Over six months, MRS 
FF increased by a median of 25% in relative values (p=0.0003), Dixon FF increased 
(p<0.0001) and ADC values decreased (p=0.0014).  Men with >5% BMD loss after 
one year had triple the percentage increase in MRS FF at six months (61.1% v 
20.9%, p=0.19).   
 
Conclusions 
 
Changes are observed on L-spine MRI after six months of ADT. Further investigation 
is warranted of MRS change as a potential predictive biomarker for later BMD loss. 
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Key points: 
 
 Spinal marrow fat fraction increases after 6 months of Androgen Deprivation 
Therapy. 
 More inferior vertebral bodies tend to have higher fat fractions 
 MRS Fat Fraction changes were associated with later changes in DEXA BMD. 
 
 
Acronyms 
 
ADT = Androgen Deprivation Therapy 
BMD = Bone Mineral Density 
DEXA = Dual-Energy X-Ray Absorptiometry 
DWI = Diffusion Weighted Imaging 
FF = Fat Fraction 
HRPC = High Risk Prostate Cancer 
PRESS = Point Resolved Spectroscopy 
PROCITT = PROstate Cancer Imaging, Treatment and Toxicity  
SVS = Single voxel spectroscopic 
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Introduction 
 
Some men with apparently non-metastatic prostate cancer at diagnosis have a high 
probability of developing widespread disease following local therapy.1 This entity of 
high risk prostate cancer (HRPC) has been extensively studied, and multimodality 
treatment with pelvic radiotherapy and androgen deprivation therapy (ADT) has been 
shown in multiple randomized controlled trials to have a survival advantage 
compared to either treatment alone.2,3 
 
ADT reduces testosterone levels and leads to lower amounts of peripherally 
converted estrogens, which has a direct effect on bone mineral density (BMD). 
Numerous studies have demonstrated that this leads not only to changes on DEXA 
imaging, but also osteoporotic fracture rates and even overall survival.4-6 Current 
consensus guidelines recommend annual DEXA monitoring of BMD for men on ADT 
and intervention with anti-resorptive agents for those found to have osteopaenia or 
osteoporosis.7  Population based data suggests that less than 20% of men on ADT 
have a DEXA performed, suggesting a low awareness of the importance of 
managing bone health for such patients.8 
 
There is a wide variety in the rate of BMD change for men on ADT, quoted between 
0 and 8% in the first year of treatment.6,9  It is therefore plausible that a risk adapted 
approach is better targeted not only to men with osteopaenia or osteoporosis at 
baseline, but also the subgroup with more rapid loss in BMD.  Concurrently,  
literature has begun to emerge suggesting MRI Fat Fraction (FF) has a correlation 
with DEXA measured BMD.10  There is a biological rationale for this given the 
common stem cell progenitors for both bone forming osteoblasts and fat containing 
adipocytes and the effect of estrogen on driving the relative proportions of cellular 
differentiation.11  MRI also has the advantages of being a fully 3-dimensional 
approach better suited to understanding changes within a multifunctioning organ 
such as bone which is not susceptible to artefacts which can confound the 
interpretation of DEXA imaging.12  
 
We hypothesize that early changes on serial MRI of the spine may correlate with the 
rate of change in DEXA measured BMD for men on ADT.  If this is the case, further 
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investigation of early selective intervention with anti-resorptive therapy for such 
higher risk men would be warranted. 
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Materials and Methods 
 
Patient Recruitment 
 
A prospective clinical trial (PROCITT: PROstate Cancer Imaging, Treatment and 
Toxicity) was offered to men with HRPC between January 2013 and July 2014.  
Eligible men needed to have non-metastatic HRPC features (any one of: PSA>20, 
Gleason score of 8-10 or Stage of T3-T4 or N1), and be appropriate for an 18 month 
course of ADT and definitive prostate radiotherapy.  The Hunter New England 
Human Research Ethics committee provided ethical approval (12/08/15/4.02).  The 
project was funded by an unrestricted investigator initiated study grant by Abbvie 
Pharmaceuticals.  28 men with high risk prostate cancer were recruited to the study 
over an 18 month period.  The median age was 70 years (range 54-78), median PSA 
was 12.4, and 23 of the men had Gleason score 8 or 9 disease.   
 
Management 
 
After providing informed consent, all men had baseline imaging including a MRI, 
plain films of the thoracic-lumbar spine and DEXA imaging. They then commenced 
an 18 month course of ADT.  As per national bone health consensus guidelines, they 
were all recommended to commence oral Vitamin D and Calcium supplementation 
as well as moderate physical activity.7  At the six month time point, men had a repeat 
MRI just prior to commencing a course of prostate+/-pelvic radiotherapy, the 
technical details of which have been reported.13  Men continued to be followed after 
radiotherapy including receiving annual DEXA imaging for three years.  An MRI at 6 
months was selected as a compromise between sufficient time to assess any 
changes whilst still providing an opportunity for possible bone health interventions, 
while a DEXA at 12 months complies with consensus guidelines as well as the 
period of most rapid loss in BMD.7, 14 
 
Imaging Protocols 
 
MRI Dixon Method 
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All patients underwent morphological imaging of the lumbar spine in supine and feet 
first orientation on a 3 Tesla whole body scanner (Magnetom Skyra, Siemens AG, 
Erlangen, Germany) with the combination of a dedicated 18 Channel body matrix 
and 32 channel phase array spine receiver coils. After localiser scans, a 3-point 
Dixon Turbo Spin Echo T1 weighted scan was performed in sagittal plane to assess 
fat fraction. Four series of images (in/opposed phases, fat/water only) generated by 
the system were used for FF analysis. The sequence parameters were 
TR/TE=600/9.5ms, Slice thickness/gap=3mm/10%, FOV=340mm, Matrix=384x384 
with 0.9x0.9 in-plane resolution, iPAT=2, Number of slices=28 and Average=1.  
 
Regions of interest (ROIs) were manually applied in 2-dimensions on the mid-sagittal 
slice for all vertebral bodies within the field of view.  Each ROI would typically require 
a polygon with 6-10 points of at least 3 cm2, with the same ROI copied onto the 
corresponding Fat and Water images.  Mean readings from the Fat and Water Dixon 
images were recorded, and Dixon FF calculated for individual vertebral bodies as 
Mean Fat/(Mean Fat+Mean Water).   
 
Diffusion Weighted Imaging (DWI) 
 
After six patients had been accrued, a protocol amendment was made to allow more 
routine acquisition of DWI and MR Spectroscopy.  Following T1 weighted scan, Echo 
planar spin echo based (Single shot EPI) DWI sequences with a pair of rectangular 
motion probing gradient pulses along three orthogonal directions (phase, frequency 
and slice) were obtained with b-values equal to 0, 250, 500 and 750 s/mm2.15 Six 
sagittal slices were acquired. The sequence parameters include TR/TE=1400/87ms, 
Slice thickness/Gap=10mm/10%, FOV=260mm, Matrix=156x156mm with 
1.7mmx1.7mm in-plane resolution, iPAT=2.  
The quantitative analysis of diffusion was performed by calculating the Apparent 
Diffusion Coefficient (ADC) values. The ADC value was derived from the equation 
ADC = -1/b ln (S(b)/S(0)) where Sb and S0 are signal intensities from each voxel 
with and without diffusion gradients and b is the sensitizing parameter. The three 
directional diffusion images were used to generate an average ADC map using 
Syngo (Siemens Healthcare, Erlangen, Germany). The ADC values were measured 
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for each patient at all four b-values from 0 to 750 s/mm2 by drawing a ROI similar to 
the Dixon ROI within each vertebral body from T12 to S1 on all the DWI images.  
 
1H-Magnetic Resonance Spectroscopy (MRS) 
 
Single voxel spectroscopic (SVS) technique was employed in the transverse plane to 
generate non-water suppressed 1H spectra, and the voxel was placed within the 
marrow of the L3 vertebral body seen on T1 weighted images. The spectroscopic 
data was acquired using a double echo, slice selective technique based on Point 
Resolved Spectroscopy (PRESS) with an echo time of 30ms, TR of 2000ms, 64 
signal averages, 1024 complex data points, and bandwidth of 2000Hz and automatic 
image based shimming.  A voxel size of 8cm3 was used.  
Spectra were reconstructed using Syngo which involved water referencing for 
frequency shift correction, a Gaussian filter of 125ms was applied to the time domain 
data.  Following the fourier 
Transform, phase correction and 
baseline correction was applied to 
the spectrum. A series of peaks, 
including water at 4.7 ppm and five 
fat peaks at 1.1, 1.39, 1.9, 2.5 and 
5.36 ppm was used to model the 
spectrum using the Syngo curve 
fitting routine (see Figure 5.1).  The 
lipid peak area (LPA) was the sum 
of the dominant fat peaks at 1.1  
(-CH3) and 1.39 (-CH2) ppm and 
quantified relative to the sum of the 
water peak area (WPA) to give a 
MRS FF using LPA/(LPA+WPA).  
 
Figure 5.1: Example of curve fitting for a L3 MRS showing the water (left) and fat 
(right) peaks along with the area under the curve for each of the six respective 
positions. 
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One male subject not managed with ADT was scanned twice within one week to 
assess reproducibility.  This showed an average coefficient of variation of 3.5% for 
Dixon FF, 4.0% for ADC and a 3% variation in MRS FF. 
DEXA 
 
A DEXA scan was performed on all subjects within one week of their baseline MRI.  
Readings of BMD in g/cm2 were obtained individually for L1-L4 vertebral bodies as 
well as both necks of femurs (NOFs).  These were translated into age and gender 
matched T-Scores as per WHO recommendations.  Serial imaging was performed 
12 months later on the same DEXA scanner that the baseline imaging occurred on. 
 
Statistical Analysis 
 
DEXA Lumbar spine T-score scan values were averaged across L1-L4.  For Dixon 
and ADC, all fully visualized vertebrae were used, usually from T10 or T11 down to 
S1 or S2.  Due to evidence of a statistical interaction both over time and between 
vertebral body level and various scan parameters, it was not appropriate for all data 
to be pooled together for analysis, and hence the various analyses are presented 
separately. 
 
Correlations between scans/parameters were examined using Pearson correlation.  
Changes between baseline and follow-up scan values for each vertebra were 
examined using linear mixed modelling with robust standard errors.  Mean changes 
with 95% confidence intervals from baseline and p-value are presented.  All 
statistical analyses were performed using SAS v9.4 (SAS Institute, Cary, North 
Carolina, USA). 
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Results 
 
Baseline DEXA Results 
All men had baseline DEXA imaging.  Baseline DEXA T-Scores averaged from L1-
L4 spanned a range of -2.63 to 4.05, with a mean of 0.07.  Baseline DEXA showed a 
correlation between raw BMD measured at the NOF and L-Spine averaged from L1-
L4 (r= 0.62, p=0.0004).  An inverse correlation was noted between increasing age 
and raw BMD at the NOF (r= -0.41, p=0.03 – see Figure 5.2), with a weaker 
correlation between age and raw BMD at the L-Spine (r= 0.26, p=0.19).  The latter 
may be due to some confounding from degenerative changes in the L-Spine on 
DEXA imaging.12 
 
Figure 5.2: Association between age and DEXA BMD at the neck of femur (r= -0.41, 
p=0.03, 95% CI limits shown). 
 
Two men, aged 76 and 77, had a new diagnosis of osteoporosis on their baseline 
DEXA imaging with NOF T-scores of -2.8 and -2.7 respectively.  As per national 
consensus guidelines, they were commenced on oral bisphosphonate therapy.7  All 
28 men had no insufficiency fractures on thoraco-lumber spinal plain film imaging.  
No metastases were observed, but two men had evidence of haemangiomas of the 
vertebral bodies which were excluded from ROI delineation. 
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Baseline MRI Results 
The number of patients who underwent DEXA, Dixon, ADC and MRS at 
baseline/follow-up were 28/27, 28/26, 28/26 and 22/20, respectively.  Examining 
individual Dixon FF measures from T11 to S2, there was evidence of increasing 
values with more inferior vertebral bodies by 1%/vertebral body on average (Figure 
5.3).  The only exception was the L5-S1 vertebral bodies where a slight decrease 
was noted, 
possibly due to 
the different 
mechanical 
stress at this 
level.  For ADC, 
no strong trend 
was noted 
between the 
individual 
vertebral 
measurements 
from T11 to S2.   
 
Figure 5.3:  Trend for Dixon FF to increase by approximately 0.01/vertebral body 
moving inferiorly.  Note that most of the results are clustered around the fitted lines 
and that the slopes for the individual lines are generally similar to the fitted lines, 
both suggesting relatively small variations between individuals in this population. 
 
MRI Correlations 
There was evidence of a correlation between baseline MRS FF and Dixon FF 
(r=0.85, p<0.0001).  For the 14 men who had both an MRS FF and ADC at L3 
performed at baseline, there was a negative correlation between these parameters 
(r= -0.56, p= 0.036). 
 
Some correlation was noted between Age and increased MRS FF (r=0.37, p=0.09).  
Exploring a relationship between age and individual vertebral body Dixon FF and 
ADC values showed only weak positive correlations without any strong evidence of 
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statistical association.  There was no evidence of a relationship between baseline 
MRS FF, Dixon FF or ADC values per vertebral body verses baseline DEXA BMD at 
the L-spine or NOF.   
 
DEXA and MRI Changes over time 
 
On serial DEXA 12 months apart, similar relative median changes in raw BMD were 
observed both for the L-Spine (-3.2%, IQR -1.7 – -5.7, p<0.0001) and NOF (-3.4%, 
IQR -0.4 – -6.4, p=0.0003).  Due to our series focussing on the L-spine changes on 
MRI, and the potential for spurious relationships if excessive correlations were 
attempted, further analysis of BMD focussed on the L-Spine rather than NOF.  Out of 
the 26 patients who had 2 DEXAs performed, four had an increase in L-Spine DEXA 
raw BMD ranging from 0.1% to 7.4%, and ten had large decreases of greater than 
5% ranging from -5.2% to -11.7%.   
 
Men managed with ADT had MRS FF increase by an absolute median value of 
0.092 over six months.  This corresponded to a median 25% relative increase (IQR 
17% - 89%, p=0.0003).  Dixon FF also showed median increases over six months 
from a minimum of 6.3% at S2 to a maximum of 10.4% at T11 (p<0.0001 – table 5.1 
and figure 5.4).  Conversely, ADC values tended to decrease over six months 
(p=0.0014 – table 5.2). 
Figure 5.4: Line 
graph showing Dixon 
FF at baseline and 
six months per 
vertebral body.  Note 
again the trend for 
higher FF with more 
inferior vertebral body 
and the consistent 
increase in mean FF 
for every vertebral 
body over time. 
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Vertebral 
Level 
Dixon change p-value 
Percentage 
(95% CI) 
Absolute 
(95% CI) 
Overall <0.001 
T11 
10.40 
(3.8, 14.6) 
0.045 
(0.027, 0.062) 
<.0001 
T12 
7.25 
(2.6, 15.0) 
0.048 
(0.031, 0.064) 
<.0001 
L1 
9.50 
(1.8, 15.7) 
0.049 
(0.035, 0.064) 
<.0001 
L2 
8.80 
(0.8, 14.4) 
0.046 
(0.030, 0.061) 
<.0001 
L3 
8.80 
(2.7, 16.3) 
0.046 
(0.028, 0.063) 
<.0001 
L4 
7.95 
(1.7, 13.7) 
0.044 
(0.027, 0.060) 
<.0001 
L5 
6.82 
(1.2, 11.6) 
0.040 
(0.022, 0.058) 
<.0001 
S1 
8.61 
(-0.1, 13.5) 
0.051 
(0.029, 0.073) 
<.0001 
S2 
6.33 
(3.8, 9.8) 
0.035 
(0.015, 0.054) 
0.0005 
 
Table 5.1: Change in MRI Dixon Fat Fraction between baseline and after six months 
of ADT.  P-values are adjusted for bisphosphonate use and age at baseline. 
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Vertebral 
Level 
ADC Change p-value 
Percentage  
(95% CI) 
Absolute (95% CI) 
Overall 
0.0014 
T12 
-50.42 
(-63.6, -33.3) 
-0.00012 
(-0.00019, -
0.00005) 
0.0012 
L1 
-29.63 
(-46.9, 19.2) 
-0.00007 
(-0.00012, -
0.00001) 
0.0120 
L2 
-58.57 
(-78.2, -18.5) 
-0.00011 
(-0.00017, -
0.00005) 
0.0002 
L3 
-17.09 
(-61.5, 65.0) 
-0.00004 
(-0.00009, 0.00001 
) 
0.0952 
L4 
-28.41 (-62.5, 
14.3) 
-0.00005 
(-0.00010, -
0.00001) 
0.0284 
L5 
23.05 
(-34.5, 90.9) 
-0.00003 
(-0.00009, 0.00004 
) 
0.4436 
S1 
-50.00 
(-73.1, 4.5) 
-0.00011 
(-0.00018, -
0.00004) 
0.0026 
 
Table 5.2: Change in MRI ADC between baseline and after six months of ADT.  P-
values are adjusted for bisphosphonate use and age at baseline. 
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Predictors of DEXA Changes 
 
We wished to investigate whether there were any parameters at baseline or within 
the first six months of treatment which predicted for larger changes in BMD at one 
year.  We defined a larger change in DEXA L-spine raw score as a loss of BMD of at 
least 5% over 12 months, which is double the mean change in this parameter 
reported in the literature for men with prostate cancer on ADT.16  The univariate 
analysis of potential predictive factors is presented in table 5.3.  Note that the 
patients with >5% loss in BMD at one year had nearly triple the percentage increase 
in their MRS FF at L3 (61.1% v 20.9%).  Exploring DEXA BMD change and MRS FF 
change as continuous variables amongst the 17 patients who had all four relevant 
scans performed show that only three patients had a reduction in MRS FF, and 
these were the only three to exhibit an eventual increase in DEXA BMD of between 
3.2 and 7.4%.  The correlation between these variables is negative (r= -0.44, 
p=0.076), and is shown in figure 5.5). 
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Large decrease (>5%) of DEXA raw score 
No 
(n=18) 
Yes 
(n=10) 
p-value 
Age at baseline [mean (SD)] 69 (8) 69 (6) 0.84 
Bisphosphonate Use No 16 (62%) 10 (38%) 
0.27 
Yes 2 (100%) 0 
DEXA T-score at Baseline 
[mean (SD)] 
1.216  
(0.197) 
1.260  
(0.158) 
0.55 
MRS FF percent  change 
[median (IQR)] 
20.89  
(-3.5, 39.01) 
61.10  
(22.48, 92.51) 
0.19 
Dixon FF percent change 
[median (IQR)] 
8.12  
(1.41, 15.11) 
9.22  
(1.39, 12.23) 
0.90 
ADC percent change 
[median (IQR)] 
-24.21  
(-50.8, 10) 
-58.89  
(-62.65, 5.57) 
0.44 
Average Dixon FF vertebra change 
[median (IQR)] 
0.01  
(0.007, 0.012) 
0.009  
(0.005, 0.012) 
0.41 
Table 5.3: Univariate associations between various factors and DEXA percent 
decrease >5%.  Age, bisphosphonate use and DEXA T-Score are all from baseline, 
the MRS FF, Dixon FF and ADC percentage changes were all between baseline and 
the six month scans, and the average Dixon FF vertebra change looked at the 
gradient in FF across vertebral bodies at baseline. 
Figure 5.5: Percentage change 
in MRS FF over six months 
plotted against percentage 
change in DEXA L-Spine raw 
score over 12 months.  Note 
the small number of men 
exhibiting a positive change in 
both factors, and the moderate 
inverse relationship between 
the two variables (r= -0.44, 
p=0.076).  
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Discussion 
 
Our work shows correlations between various baseline MRI sequences, changes in 
FF between adjacent vertebral bodies and over time, and a correlation between 
changes in MRI FF at six months verses DEXA BMD changes after 12 months.  
Some of these replicate earlier work, particularly the correlations between MRS FF 
with both Dixon FF and ADC17 as well as changes in FF between adjacent vertebral 
bodies on MRS and using In-Out Phase techniques.18  The increased FF is plausible 
given the known effects of ADT on lipogenesis, with the increased adipocyte volume 
also potentially causing restricted diffusion.  The changes in MRI sequences over 
time under the influence of various oncological interventions and their correlation 
with DEXA BMD changes is a more emergent area which our work helps lay a 
stronger foundation for. 
 
Previous studies looking at changes in serial MRI FF have tended to be small and 
have heterogeneous interventions.  One series used a 9 patient cohort with 
gynaecological cancers managed with either chemotherapy or various pelvic 
radiotherapy regimens and showed over 6 months increases in In-Out Phase FF in 
L4 by an absolute average of 16.1%.19  A second series used a 19 patient cohort 
with a range of pelvic malignancies managed with several chemotherapy regimens in 
concert with various types and doses of pelvic radiotherapy.20  They observed using 
an In-Out FF measure that increases were more marked in the L4-S2 region than at 
other spinal levels, and also influenced by the myelotoxicity of the chemotherapy 
regimen.  Given the treatment variations, it can be challenging to be confident of the 
specific effect of the dose-volume response effect of either radiotherapy or a 
particular chemotherapy agent in this setting, as well as their interaction.  Our work 
shows that in the face of a standardised intervention, there is approximately a 25% 
relative increase in MRI FF over six months of ADT, but with a wide range, and there 
are some patients demonstrating much larger changes of 50% or more.  As this 
appears to have some correlation with later DEXA BMD changes, such patients may 
represent a subgroup where more aggressive early intervention with antiresorptive 
agents such as denosumab or bisphosphonates might be investigated. 
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There is now a growing body of work showing a correlation between MRI FF 
measured using either MRS or In-Out Phase, as well as ADC with DEXA BMD in 
various populations.10  This is not a relationship which we were able to confirm in our 
cohort.  Possible reasons for this include that some of the positive series were 
relatively small and included both men and women with a wide age range.  An early 
report examined 16 volunteers with an age range of 8-57, of whom only 2 males and 
4 females had both a DEXA and MRI performed.21  This series showed an inverse 
correlation between the two scans with a p-value of 0.076, but considered each 
vertebral body as a separate entity despite evidence of a strong within patient 
relationship across adjacent vertebrae.  Despite this, these initial findings have been 
largely confirmed in several subsequent series, including a 560 subject cohort 
spanning a wide age range and including both males and females.22 As outlined in 
the Introduction, here is also a biological rationale for this.11 We hypothesize that our 
inability to detect such a relationship in our cohort was a function of the relatively low 
number of patients, who were all male with a limited range of largely normal baseline 
BMDs. 
 
Several small studies have reported on the use of serial multiparametric MRI and 
changes in various imaging parameters as correlating with treatment response in 
several malignancies including rectal, prostate and head and neck cancers.23-25  
Many studies are ongoing exploring multiparametric MRI and other functional 
imaging such as PET as an early biomarker of later tumour response.26 Such 
concepts have the appeal of potentially allowing treatment adaptation, either 
intensification or de-escalation, while it is still being delivered.  Care is needed in the 
interpretation of such studies however, given the often large number of parameters 
explored in multiple physical locations over serial scans increasing the chance of a 
type I statistical error ie finding a statistical relationship when no real relationship 
exists. 
 
To our knowledge, the use of MRI as an early biomarker of treatment toxicity is a 
much less investigated entity.  Given that ADT can cause mild anaemia and fatigue, 
both of which could plausibly be mediated via effects at the level of bone marrow, 
there is potential for imaging to predict a suite of ADT related toxicity.  The PROCITT 
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study prospectively collected serial data on fatigue and blood counts, and once these 
data collection is complete we intend to explore whether such relationships exist.   
 
Our series has the advantages of being prospective and hence relatively 
standardised in patient population, treatment delivered and imaging protocols.  There 
are clear limitations.  It is a relatively small series, although larger than others looking 
at serial imaging of patients undergoing cancer treatment.  Although a comparison 
between Dixon and DEXA changes were the main aim of the study, the ADC and 
MRS sequences were not uniformly applied for all patients, reducing our power to 
detect a meaningful impact from these sequences.  Given the highly targeted patient 
cohort, further work will be required to assess whether similar observations occur in 
the broader population.  Although gross lesions seen on MRI were excluded from 
ROIs, degenerative changes may have affected the DEXA outputs; the lack of any 
major disc loss on plain films and MRI make this less likely to be a major confounder.  
The use of manual techniques to define ROIs is common, but does introduce 
additional variability into assessments.  We also used several DEXA platforms in the 
community, although our concentration on relative changes over time would be 
considered to be platform independent. 
 
There are several other potential future directions.  The utilisation rates of DEXA 
imaging for men on ADT is suboptimal, and a multifaceted Implementation science 
approach is being explored to try to use patients and their local medical officer to try 
to correct this.  It is possible that the inclusion of additional clinical factors such as 
serum and urine markers of bone turnover, and anthropomorphic parameters such 
as height, weight and BMI may lead to greater predictive power regarding men at 
risk of more rapid loss in BMD.  Some very preliminary work in this area is 
promising.16  We have collected such data, and hope to analyse this as our BMD 
data matures with further serial DEXA imaging.   
 
  
 119 
 
Acknowledgements 
The authors wish to acknowledge the assistance of Katie Baker and Hannah 
Woodford who assisted in MRI data extraction.  Mary-Clare Hanlon assisted with 
manuscript submission.  Peter Stanwell assisted with MRI sequence programming.  
Abbvie pharmaceuticals provided an unrestricted investigator initiated grant which 
funded the scans, trial management and statistical analysis.  All analysis and 
manuscript preparation was performed without any input from Abbvie 
Pharmaceuticals.  
 120 
 
References 
 
1. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of 
prostate cancer-specific survival after radiation therapy for patients with clinically 
localized prostate cancer. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 2002;20:4567-73. 
2. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without 
long-term androgen suppression for prostate cancer with high metastatic risk: 10-
year results of an EORTC randomised study. The Lancet Oncology 2010;11:1066-
73. 
3. Mason MD, Parulekar WR, Sydes MR, et al. Final Report of the Intergroup 
Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy 
Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 2015;33:2143-50. 
4. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after 
androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64. 
5. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively 
correlate with overall survival in men with prostate cancer. The Journal of urology 
2002;168:1005-7. 
6. Higano CS. Androgen-deprivation-therapy-induced fractures in men with 
nonmetastatic prostate cancer: what do we really know? Nature clinical practice 
Urology 2008;5:24-34. 
7. Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD. Bone 
and metabolic health in patients with non-metastatic prostate cancer who are 
receiving androgen deprivation therapy. The Medical journal of Australia 
2011;194:301-6. 
8. Alibhai SM, Yun L, Cheung AM, Paszat L. Screening for osteoporosis in men 
receiving androgen deprivation therapy. Jama 2012;307:255-6. 
9. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss 
during androgen-deprivation therapy for prostate cancer. N Engl J Med 
2001;345:948-55. 
 121 
 
10. Paccou J, Hardouin P, Cotten A, Penel G, Cortet B. The Role of Bone Marrow 
Fat in Skeletal Health: Usefulness and Perspectives for Clinicians. The Journal of 
clinical endocrinology and metabolism 2015;100:3613-21. 
11. Rosen CJ, Bouxsein ML. Mechanisms of disease: is osteoporosis the obesity 
of bone? Nature clinical practice Rheumatology 2006;2:35-43. 
12. Blake GM, Fogelman I. An Update on Dual-Energy X-Ray Absorptiometry. 
Seminars in Nuclear Medicine 2010;40:62-73. 
13. Wu R, Woodford H, Capp A, et al. A prospective study of nomogram-based 
adaptation of prostate radiotherapy target volumes. Radiation Oncology 2015;10:1-9. 
14. Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, 
withdrawal, or delay of alendronate in men with prostate cancer undergoing 
androgen-deprivation therapy. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 2008;26:4426-34. 
15. Barentsz JO, Weinreb JC, Verma S, et al. Synopsis of the PI-RADS v2 
Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and 
Recommendations for Use. European urology 2016;69:41-9. 
16. Greenspan SL. Bone Loss after Initiation of Androgen Deprivation Therapy in 
Patients with Prostate Cancer. Journal of Clinical Endocrinology & Metabolism 
2005;90:6410-7. 
17. Ueda Y, Miyati T, Ohno N, et al. Apparent diffusion coefficient and fractional 
anisotropy in the vertebral bone marrow. Journal of magnetic resonance imaging : 
JMRI 2010;31:632-5. 
18. Martin J, Nicholson G, Cowin G, Ilente C, Wong W, Kennedy D. Rapid 
determination of vertebral fat fraction over a large range of vertebral bodies. Journal 
of medical imaging and radiation oncology 2014;58:155-63. 
19. Bolan PJ, Arentsen L, Sueblinvong T, et al. Water-fat MRI for assessing 
changes in bone marrow composition due to radiation and chemotherapy in 
gynecologic cancer patients. Journal of magnetic resonance imaging : JMRI 
2013;38:1578-84. 
20. Carmona R, Pritz J, Bydder M, et al. Fat composition changes in bone marrow 
during chemotherapy and radiation therapy. International journal of radiation 
oncology, biology, physics 2014;90:155-63. 
 122 
 
21. Liney GP, Bernard CP, Manton DJ, Turnbull LW, Langton CM. Age, gender, 
and skeletal variation in bone marrow composition: a preliminary study at 3.0 Tesla. 
Journal of magnetic resonance imaging : JMRI 2007;26:787-93. 
22. Shen W, Chen J, Gantz M, et al. MRI-measured pelvic bone marrow adipose 
tissue is inversely related to DXA-measured bone mineral in younger and older 
adults. European journal of clinical nutrition 2012;66:983-8. 
23. Hotker AM, Garcia-Aguilar J, Gollub MJ. Multiparametric MRI of rectal cancer 
in the assessment of response to therapy: a systematic review. Diseases of the 
colon and rectum 2014;57:790-9. 
24. Kim S, Loevner L, Quon H, et al. Diffusion-weighted magnetic resonance 
imaging for predicting and detecting early response to chemoradiation therapy of 
squamous cell carcinomas of the head and neck. Clinical cancer research : an 
official journal of the American Association for Cancer Research 2009;15:986-94. 
25. Hotker AM, Mazaheri Y, Zheng J, et al. Prostate Cancer: assessing the 
effects of androgen-deprivation therapy using quantitative diffusion-weighted and 
dynamic contrast-enhanced MRI. European radiology 2015;25:2665-72. 
26. Jones M, Hruby G, Stanwell P, et al. Multiparametric MRI as an outcome 
predictor for anal canal cancer managed with chemoradiotherapy. BMC cancer 
2015;15:281. 
 
  
 123 
 
Chapter 6 – Circulating Tumour Cell Detection in Non-Metastatic Prostate 
Cancer 
 
Over the last decade there has been rapid development of various platforms to 
assay for biomarkers of tumour activity in the blood.  These have evolved from 
proteins derived from cancer cells such as PSA through to the cancer cells 
themselves, so called Circulating Tumour Cells (CTCs).  Given the higher tumour 
burden, much of this work has occurred in the metastatic setting.  Since a moderate 
proportion of men with high risk prostate cancer are destined for metastatic failure, 
we were interested in the incidence of CTC positivity in such men.  This manuscript 
details our approach to this question, showing a CTC positivity rate of only 14%, 
which is not greatly different to what has previously been reported in a healthy 
control population.  Although only published in late 2014, by mid-2016 seventeen 
citations had already been made referencing this work, demonstrating the ongoing 
interest in this field.  With more mature follow-up in upcoming years, we also hope to 
correlate tumour control outcomes with CTC positivity. 
 
Loh J, Jovanovic L, Lehman M, et al. Circulating tumor cell detection in high-risk 
non-metastatic prostate cancer. Journal of cancer research and clinical oncology 
2014;140:2157-62. 
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Abstract  
 
Aim  
The detection of Circulating Tumor Cells (CTCs) provides important prognostic 
information in men with metastatic prostate cancer.  We aim to determine the rate of 
detection of CTCs in patients with high-risk non-metastatic prostate cancer using the 
CellSearch® method. 
Method  
Samples of peripheral blood (7.5mL) were drawn from 36 men with newly diagnosed 
high-risk non-metastatic prostate cancer, prior to any initiation of therapy and 
analyzed for CTCs using the CellSearch® method.  
Results 
The median age was 70 years, median PSA was 14.1, and the median Gleason 
score was 9. The median 5-year risk of progression of disease using a nomogram 
was 39%. Five out of 36 patients (14%; 95% CI 5%-30%) had CTCs detected in their 
circulation. Four patients had only 1 CTC per 7.5mL of blood detected. One patient 
had 3 CTCs per 7.5mL of blood detected, which included a CTC cluster, also termed 
circulating tumor microemboli. Both on univariate and multivariate analysis, there 
were no correlations found between CTC positivity and the classic prognostic factors 
including PSA, Gleason score, T-stage and age. 
Conclusion  
This study demonstrates a low CTC detection rate using the CellSearch® method in 
high-risk non-metastatic prostate cancer, which is consistent with the limited 
literature available for non-metastatic prostate cancer. Further follow-up will explore 
disease related outcomes for our patient population, with CTCs potentially helping to 
identify a very-high risk non-metastatic population based on early tumor behavior 
rather than solely on classic clinicopathological predictors. 
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Introduction 
 
Since the isolation of PSA from prostate tissue in 1979(Wang et al. 1979), there has 
been no other molecular marker widely accepted for clinical use in the diagnosis, 
staging, and monitoring of disease response for prostate cancer. Despite baseline 
PSA at diagnosis having demonstrated prognostic significance, its usefulness is 
limited by its imperfect prognostic accuracy and poor correlation to pathological 
stage.   Risk categorization tools and multivariate nomograms that combine pre-
treatment clinical and pathologic factors are improvements over PSA alone but none 
are able to accurately predict which individual patients may already harbor 
micrometastatic disease. 
 
A key event in haematogenous dissemination of carcinoma is intravasation of cancer 
cells into vasculature. Cancer cells in blood are called circulating tumor cells (CTCs) 
and are important markers of distant metastases.  In metastatic breast, prostate and 
colorectal carcinomas, CTC numbers as detected using the CellSearch® CTC test, 
are associated with overall survival (OS) and progression-free survival (PFS)(Cohen 
et al. 2008; Cristofanilli et al. 2004; Danila et al. 2007). CTC counts were also found 
to be superior to PSA in predicting OS in metastatic castrate resistant prostate 
cancer (de Bono et al. 2008). Based on clinical validation, the CellSearch® CTC 
testing has been approved by the Food and Drug Administration (FDA) for 
monitoring disease progression and treatment response in patients with metastatic 
breast, prostate and colorectal carcinoma. 
 
The clinical utility of CTCs in patients with high-risk prostate cancer which appears to 
be non-metastatic by conventional imaging remains uncertain, with limited research 
evidence published in this area. The potential applications for CTCs in this setting 
include their use to differentiate true localized disease from those with occult 
metastatic disease, for prognostication, and to identify patients that may benefit from 
more aggressive treatment strategies. 
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Methods and materials 
 
Patients with newly diagnosed high-risk, non-metastatic prostate cancer were eligible 
for this prospective study. Inclusion criteria include histological diagnosis of prostate 
cancer, and high risk disease defined by any one of: baseline PSA≥20; Gleason 
grade 8-10 disease; Clinical stage T3-T4 or N1. All patients had staging 
investigations negative for disease outside of the prostate with the exception of peri-
prostatic pelvic lymph nodes including a 99m Technetium (99m Tc) whole body bone 
scan and computed tomography (CT) of the abdomen and pelvis. Patients were 
excluded if they had previous pelvic radiotherapy. All patients were planned for 
definitive treatment with radical radiotherapy to the prostate and eighteen months 
duration of androgen deprivation therapy.  
 
This study received approval from a human research ethics committee (NSW HREC 
Reference no: HREC/12/HNE/268). The trial recruited patients from three Australian 
hospitals, with all CTC assays performed at the same centre.  The clinical trial is 
registered on clinicaltrials.gov [ClinicalTrials.gov Identifier: NCT01418040] 
The objective of this study was to examine the CTC detection rate in high-risk non-
metastatic prostate cancer patients using the CellSearch® method. 
 
CTC isolation and detection 
Blood was collected in CellSave® tubes and processed within 96h of collection. CTC 
capture and assessment was performed using the CellSearch® platform, in 
accordance with manufacturer’s protocols and as previously described in detail 
elsewhere(de Bono et al. 2008) . In brief, immunomagnetically captured EpCAM 
(epithelial cell adhesion molecule)-positive cells were immunofluorescently stained 
for cytokeratins 8, 18 and 19 and nuclear stain DAPI (4’-6-diamidino-2-phenylindole). 
Contaminating leukocytes were identified as allophycocyanin (APC)-labelled, CD45-
positive cells. CTCs were identified as ≥4µm in size, cytokeratin-positive, DAPI-
positive and CD45-negative events.  
 
Data Collection 
Baseline patient and tumor related factors were recorded including patient age, initial 
PSA, tumor stage and core biopsy Gleason score based on the 2005 ISUP 
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consensus.  Estimates of the 5-year risk of biochemical or metastatic failure for each 
individual patient were generated using the Memorial Sloan Kettering Cancer Centre 
(MSKCC) nomogram.  
 
Analysis 
A 95% exact (Clopper-Pearson) binominal confidence interval was constructed 
around the point estimate of CTC positivity. The distribution of categorical variables 
based on CTC positivity was compared using Fishers exact test, and continuous 
variables using the Mann-Whitney U-test.  Logistic regression was used to estimate 
the joint effects of all predictors and linear discriminant analysis was used to explore 
clusters of clinico-pathological factors which may predict for CTC positivity.  
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Results 
 
Thirty-six patients had their peripheral blood collected for CTC testing. Six patients 
had multiple samples tested for CTCs; five had consecutive samples tested, and one 
had three samples examined over a period of 10 months. Patient characteristics are 
summarized in Table 6.1. The median age was 70 years, median PSA was 14.1, and 
the median Gleason score was 9. Median 5-year risk of progression of disease was 
39%.  
Variable Categories 
Total 
(N=36) 
CTC negative 
(N=31) 
CTC positive 
(N=5) 
P 
Clinical Stage 
(T) 
T1 9 (25%) 9 0 0.19 
T2 14 (39%) 10 4  
T3 13 (36%) 12 1  
N stage 
N0 34 (94%) 30 4 0.26 
N1 2 (5.6%) 1 1  
PSA 
median (min, 
max) 
14.1 (5.9, 
52.7) 
14.1 (6.2, 
52.7) 
10.0 (5.9, 
33.3) 
0.59 
Gleason 
score 
7 7 (19.4%) 5 2  
8 7 (19.4%) 7 0  
9 19 (52.8%) 16 3  
10 3 (8.3%) 3 0  
median (min, 
max) 
9 (7, 10) 9 (7, 10) 9 (7, 9) 0.55 
Age 
median (min, 
max) 
70 (54, 78) 70 (54, 78) 74 (69, 78) 0.12 
5 year risk of 
progression 
(%) 
median (min, 
max) 
39 (19, 73) 40 (19, 73) 37 (21, 47) 0.67 
 
Table 6.1: Patient characteristics and summary of results. 
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Five of the 36 patients (14%, 95% CI 5%-30%) presented with CTCs. No CTCs were 
detected in any of the patients where multiple samples were tested.  Four patients 
had 1 CTC per 7.5mL of blood detected. A single patient presented with 3 CTC 
events, which included a CTC cluster (Figure 6.1a), or circulating tumor microemboli 
(CTM).  Table 6.2 shows the characteristics of the five patients with CTCs detected. 
Unexpectedly patients with very high risk disease had no CTCs, including all three 
patients with Gleason 10 tumors, and the patient with a positive lymph node. 
 
Figure 6.1. Three CTC events detected in Patient 9. Circulating tumor cluster (6.1a). 
Note four individual nuclei in the DAPI channel and overlapping intensive cytokeratin 
staining in the CK-PE channel. Individual CTCs presented with a single nucleus per 
cell (6.1b and 6.1c).  
No. of CTCs 
No. of 
patients 
Age PSA 
Gleason 
score 
Stage 
1 CTC 
detected 
4 
78 18.5 7 T2 
76 33.3 7 T2 
74 5.9 9 T3 
69 9.7 9 T2N1 
3 CTCs 
detected 
1 70 10 9 T2 
 
Table 6.2: Characteristics of the CTC positive patients 
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Analysis results 
Univariate analysis showed that there were no clinico-pathological factors strongly 
predicting for CTC positivity (Table 6.1). The 5-year risk of progression score based 
on a validated multivariate (MSKCC) nomogram also showed no statistically 
significant association.  Multivariate methods failed to identify an apparent pattern in 
the data points.  There was no difference between CTC-positive and CTC-negative 
patient groups when compared for PSA, Gleason score, T-stage and age. 
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Discussion 
 
Our results are consistent with, and add to the current literature that demonstrate low 
levels of CTCs detected using the CellSearch® assay in non-metastatic prostate 
cancer. Detection rate of 14% is within the range reported by three other studies 
investigating CTCs in non-metastatic prostate cancer ( 5 to 27%)(Davis et al. 2008; 
Resel Folkersma et al. 2012; Thalgott et al. 2013). The patient cohort examined in 
the MD Anderson study (Davis et al. 2008) consisted of mainly low to intermediate 
risk prostate cancers. Their slightly higher rate of CTC detection at 21% could be 
due to false positives, which is supported by their observed CTC positivity rate of 
20% in a group of prostate biopsy negative controls. In the study from Spain, again 
the majority of the patients were mainly intermediate risk prostate cancers. They had 
a CTC detection rate of 27% (7 of 26 men with the localised prostate cancer). Three 
of ten healthy volunteers (10%) were found to have CTC in their circulation. In 
comparison, the 20 patients included in the German series (Thalgott et al. 2013) 
represented a higher risk group, with a median PSA of 21 and Gleason score of 7.5. 
The majority also had clinical T3 disease. Only one patient (5%) had 1 CTC per 
7.5mL of blood detected. The healthy controls in that series had no CTCs detected, 
suggesting improved specificity of the CellSearch® assay since the earlier study was 
conducted.   
 
Our series is the first to our knowledge to include only patients with high risk disease 
who could potentially already have micrometastases not detectable by conventional 
imaging. Patients in our series had higher risk disease than in either of the previously 
published reports (median Gleason score 9, 39% 5-year risk of progression 
according to the MSKCC nomogram) which potentially explains the higher proportion 
of CTC positive patients (14% vs. 5%) when compared with the German cohort 
(median 5-year risk of progression of 10%).However the confidence interval in our 
series is 5 to 30%, and thus the results from the three series may well represent the 
true population estimate. Multivariate analysis did not identify a discernible pattern in 
the CTC positive patients according to PSA, Gleason score, T-stage or age. This 
could reflect the small sample size and small number of events in this study, but 
does agree with the MD Anderson series findings. However, some patients with very 
high risk disease were CTC negative, including all three patients with Gleason 10 
 132 
 
tumors, and one patient with a positive lymph node. This is in keeping with the 
literature showing that some patients with such high risk disease are successfully 
cured with local therapies.  This raises the possibility that CTC positivity may help 
discriminate disease with a tendency towards early metastasis, although further 
follow-up of clinical outcomes will be essential to explore this hypothesis more fully. 
 
None of the CTC positive patients in our study had > 3 CTCs detected. This is in 
keeping with the findings of the Spanish study which did not detect >3 CTCs in their 
cohort of localised prostate patients. In that study, they identified a cutoff point of ≥3 
CTCs/7.5mL that best distinguished between localised and metastatic prostate 
cancer.  None of the CTC positive localised prostate patients in that Spanish study 
developed biochemical progression following radical prostatectomy (RP), although 
the length of follow-up at a median of 42 months may be insufficient (Resel 
Folkersma et al. 2012).  Assessment of the long-term disease control outcomes of 
the five CTC-positive patients in our study would inform if a worse prognosis is 
associated with CTC detection pre-treatment. It remains unclear at this stage what is 
the true biological potential of CTCs detected in peripheral blood of patients with 
localised prostate cancer.  If prognostic significance emerges, more aggressive 
treatment strategies may potentially improve outcomes in patients positive for CTCs. 
Possible strategies include radiotherapy dose escalation and incorporation of 
systemic therapies including adjuvant chemotherapy, biologic agents and novel 
agents targeting the hormonal axis. CTCs may therefore offer the potential to 
biologically adapt initial treatment options, although further investigation of this issue 
is essential. 
 
Most guidelines still recommend the use of 99m Tc bone scans and CT as staging 
investigations to detect metastatic disease in newly diagnosed high risk prostate 
cancers.  These techniques have limitations with low specificity and sensitivity. 
Newer imaging techniques such as whole body Magnetic Resonance 
Imaging(Lecouvet et al. 2012),  and [18F]-Fluoride positron emission tomography-CT 
(Even-Sapir et al. 2006) have been demonstrated to outperform  conventional 
imaging in the detection of bone metastases in high-risk prostate cancer patients, but 
still suffer from needing a threshold of millions of cancer cells in one area to be 
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positive. The incorporation of biologic data such as from CTCs remains a promising 
area of interest in optimising baseline prognostic accuracy.  
 
In one patient we detected 3 CTCs, including a CTM (Figure 1a). CTMs have been 
reported in peripheral blood of patients with a number of malignancies (Hou et al. 
2012; Kats-Ugurlu et al. 2009; Molnar et al. 2001). Animal model studies observed 
that intravenously injected CTM are more likely to form metastases than single tumor 
cells(Liotta et al. 1976).  One study demonstrated an association of CTM with worse 
survival in small cell lung cancer patients (Hou et al. 2012). An absence of 
proliferating cells within a CTM has been observed, making them potentially resistant 
to chemotherapy(Frisch and Francis 1994). The exact significance of CTM is 
currently not known.  
 
The low levels of detectable CTCs using the CellSearch® system in high-risk non-
metastatic prostate cancer may not be an accurate reflection of the true CTC 
frequency in this patient population. The CellSearch® platform is the only platform 
with the FDA approval for detection of EpCAM- and cytokeratin-positive CTCs in 
metastatic malignancies; however, CTCs from tumors with down regulated or absent 
EpCAM and/or cytokeratins go undetected. Although the majority of prostate cancers 
show overexpression of EpCAM, about 11% of prostate adenocarcinomas show no 
or weak expression of EpCAM(Spizzo et al. 2011). Furthermore, CTCs that have 
undergone epithelial-mesenchymal transition (EMT) escape detection due to down-
regulation of epithelial markers EpCAM and cytokeratins. 
 
Other techniques for detection and isolation of CTC have been used to capture 
EpCAM-negative cells, however none has been approved for clinical use so far. The 
CTC-Chip is a microfluidic device that requires a much lower volume of blood (1-2 
mL), is very sensitive and maintains viability of the captured cells. In one study, 
CTCs were detected in 8 of 19 (42%) patients with localized prostate cancer (median 
95 CTCs per mL; range 38 to 222) using this method (Stott et al. 2010). Nucleic acid- 
based methods indirectly detects the presence of CTCs by identifying tumor-specific 
DNA or mRNA in peripheral blood. It is a highly sensitive method, but false positive 
results can occur due to detection of non-malignant cells that carry the same gene 
expression.  Each of these techniques has its advantages and limitations, and 
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comprehensive validations across the different techniques have yet to be performed 
in clinical settings.  As such, the CellSearch® platform remains the gold standard for 
CTC detection. 
 
Moving beyond the enumeration of CTCs, the molecular characterization of these 
cells could serve as a real-time “liquid biopsy” to guide therapeutic decisions 
informed by the biology of a patient’s cancer.  One study demonstrated a significant 
association between expression of the TMPRSS2-ERG gene fusion in CTCs and 
PSA response to Abiraterone(Attard et al. 2009). Another study suggests that the 
monitoring of androgen receptor nuclear localization in CTCs might predict clinical 
responses to taxane chemotherapy (Darshan et al. 2011).  However contamination 
with other normal blood cells remains a significant challenge for the molecular 
analyses of CTCs, and further technological improvements and optimization of 
isolation techniques are required. 
 
The pre-treatment presence of disseminated tumor cells (DTC) in bone marrow of 
non-metastatic prostate cancer patients have been shown to predict clinical 
outcomes (Lilleby et al. 2013). In a systematic review, there was a suggestion that 
CTCs may be better at predicting prognosis than DTCs (Ma et al. 2014). The 
invasive nature of this method renders it less user-friendly compared to a peripheral 
blood draw for CTC detection. Of the different forms of circulating nucleic acids, cell 
free circulating DNAs (cfDNA) and microRNAs (miRNAs) show promise as potential 
biomarkers for prostate cancer. Higher levels of serum cfDNA concentration were 
found to be associated with increased risk of PSA recurrence within 2 years of RP 
(Bastian et al. 2007) . Significant associations were also observed for a range of 
histopathological prognostic factors in relation to total serum cfDNA 
concentration(Bastian et al. 2007). A relationship between the occurrence of CTCs 
and circulating tumor-associated DNA in blood has also been reported, which may 
provide a new tool for the monitoring of disease progression(Schwarzenbach et al. 
2009). One study suggests that circulating miRNAs measured at the time of RP 
could predict for future disease progression in men with intermediate risk prostate 
cancers(Selth et al. 2013). 
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Conclusion 
 
This study demonstrates that patients with high-risk, non-metastatic prostate cancer 
present with small number of CTCs in peripheral blood. This finding is consistent 
with the limited literature available in this setting. Other CTC isolation and detection 
technologies with improved sensitivity and specificity may enable detection of CTCs 
with mesenchymal phenotypes, although none as yet have been validated for clinical 
use. Newer assays are emerging for detection of new putative biomarkers for 
prostate cancer.  Correlation of disease control outcomes with CTC detection will be 
important.   
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Section 4 – Future Directions 
 
Chapter 7 – Where to from here? 
 
Introduction 
 
This thesis has addressed several aspects of the management of men with high risk 
prostate cancer.  The main thrust has being the use of imaging1 and serum 
biomarkers2 as predictors of treatment toxicity and efficacy respectively.  In both 
cases, a promising approach has been explored, with further follow-up necessary to 
ascertain any longer term potential of the respective biomarkers.  Regarding the 
delivery of EBRT, a novel approach integrating nomograms for risk prediction and a 
hypofractionated regimen has been shown to be both feasible and tolerable.3  
Furthermore, a key element of an EBRT quality assurance program has been 
assessed, with a suggestion that the extra effort and cost is unlikely to always be 
justified.4  In the five years since this project was initiated, the field has continued to 
evolve.  This chapter attempts to add some context as to where the findings of this 
thesis sit in the wider and continually evolving prostate cancer management milieu, 
acknowledging that these areas still only represent a fraction of the wider field. 
 
Radiotherapy 
  
In the subsequent biomarkers section we will touch on some of the potential 
expanded roles of EBRT for men with oligometastatic disease, nodal metastases at 
diagnosis, and irradiation of the primary tumour in the presence of more widespread 
disease.  Relevant to this thesis are also are the continuing evolution in the areas of 
hypofractionation, quality assurance and integration of systemic therapies.   
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Hypofractionation 
   
This trial concentrated on moderate hypofractionation of prostate EBRT, where the 
fraction size varies between 2-3 Gy per day.  Phase 3 data are beginning to emerge 
from several large RCTs that this approach is likely to result in approximately 
equivalent disease controlled compared to a more conventionally fractionated cohort.  
After presenting the phase two data of the experimental arm, the author lead the 
Australian arm of a Canadian RCT in this field where a four week regimen of 60 Gy 
in 20 fractions was compared with a standard arm of 78 Gy in 39 fractions using 
modern IMRT and IGRT.5,6 Over 200 Australian men participated in this 1200 patient 
study, with the final analysis due in 2016.   
 
Beyond this, hypofractionation has embraced the principles of SABR to give very 
high doses of 7-8 Gy per fraction in as few as five fractions, so called stereotactic 
monotherapy.  Promising single institution and multi-institution data has been 
presented of large cohorts treated in this manner, although generally with relatively 
short follow-up.7-9  In Australia, the author is the clinical principal investigator on a 
multicentre collaborative phase 2 study via the Trans-Tasman Radiation Oncology 
group (TROG) using advanced technology to track prostate motion while treatment is 
being delivered in a five fraction stereotactic monotherapy regimen – the SPARK 
trial.10  The first patient on this study was recruited by the author in February 2016, 
with technical data likely to be presented from 2017 onwards, and efficacy as well as 
toxicity data due in 2020.  Quality assurance is clearly becoming more adaptive on 
trials such as SPARK, based at least partially on the evidence presented in this 
thesis. 
 
Integration of systemic therapy 
  
This study used an 18 month course of ADT, largely on the basis of modelling 
suggesting this gave the best compromise between maximising efficacy and 
reducing toxicity.11 Since then, two key studies have helped consolidate the evidence 
base in this regard.  TROG 03-04 was a RCT which compared a 6 and 18 month 
course of ADT for men with high risk prostate cancer, and found a small survival 
advantage for the longer treatment course.12 Conversely, a RCT from Quebec has 
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compared 18 months with 36 months, suggesting modest if any additional efficacy 
from the 3 year duration of ADT.  This later study has generated some controversy, 
because it was powered for superiority of the longer treatment course rather than 
having the largely number of patients needed to be convinced of the non-inferiority of 
the 18 month regimen.  Overall, the intermediate duration of ADT appears to be 
gaining favour, with the main current international collaborative RCT for men with 
high risk disease using a 24 month treatment course in both the standard and 
experimental arms.13 
 
The integration of agents other than ADT into the management of men with high risk 
prostate cancer treated with EBRT will continue to be an area of energetic research.  
This has not historically proven to be a fruitful area of inquiry, with one notable trial of 
chemotherapy using Paclitaxel, Estramustine and Etoposide adjuvantly following 
EBRT showing excessive thromboembolic events requiring it to be abandoned prior 
to reaching target accrual.14  However, there is renewed enthusiasm since the 
presentation of data showing the early use of Docetaxel in men with newly 
diagnosed metastatic disease confers a large survival advantage (see Figure 
7.1).15,16 A single conflicting French RCT has been reinterpreted as being consistent 
with these positive trials based on differing patient populations and excessive 
treatment toxicity.17  This approach has quickly become a standard treatment 
approach in Australia, and has renewed interest in bringing Docetaxel into the initial 
treatment setting.  One RTOG study has recently been presented in abstract form 
suggesting an overall survival advantage for adjuvant Docetaxel following EBRT.18 
The esteemed discussant at this meeting who pioneered this use of Docetaxel in 
prostate cancer criticised these findings on the grounds of the toxicity and one sided 
p-value testing deployed, meaning that any uptake will need to await full peer 
review.19 Newer agents such as Enzalutamide are also being integrated with 
standard hormo-radiotherapy in currently accruing RCTs.13 Informed by the results of 
such studies, there will be the potential for the standard management of such men to 
continue to evolve in the near future. 
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Figure 7.1: Overall Survival 
curves from the 
CHAARTED study showing 
13.6 month improvement in 
median survival for patients 
with castrate naïve 
metastatic disease treated 
with early docetaxel at the 
time of initiation of ADT. 
(Sweeney et al. N Engl J 
Med 2015;373:737-46.) 
 
Biomarkers 
 
Bone Health 
 
Given the widespread availability, population data and reproducibility of DEXA 
imaging, it is unlikely that this will be usurped as the gold standard in BMD 
assessment in the near future.  The failure of either ultrasound or qualitative CT in 
this regard suggest that although MRI provides useful information, DEXA will 
continue to reign supreme.  One aspect being currently explored in collaboration with 
the CSIRO in Brisbane is the potential for automatic segmentation of spinal MRI data 
rather than manually defining regions of interest.20,21  This offers the likelihood of 
much faster and more reproducible data extraction from the myriad sequences and 
regions examined.  Although further work will incorporate serum and urine markers 
of bone turnover with anthropomorphic data to try to improve the predictive accuracy 
of MRI, even if such an approach provides useful information, it is unlikely to be 
simple enough to lead to widespread adoption.  In light of this, rather than exerting 
significant additional energy into finding a better test, the main effort in this area 
should be how best to increase the awareness of bone health amongst clinicians 
caring for men with prostate cancer on ADT.  There are several avenues which can 
be explored in this regard. 
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A bone health initiative was developed in conjunction with a pharmaceutical 
company which has Australia’s largest share of the ADT market.  Astra Zeneca 
convened an Advisory Board where I presented the data relating to the effects of 
ADT on bone health.  From this sprung a patient support program to allowed 
expanded access to bisphosphonate therapy for patients who fell between eligibility 
for these medications on the pharmaceutical benefits scheme and national 
consensus guidelines (see figure 7.2).  Although some degree of promotion 
accompanied this initiative, uptake has been low.  This would suggest interaction 
with clinicians caring for prostate cancer patients needs to occur at a more 
fundamental level. 
 
Figure 7.2: Front page 
of Astra Zeneca booklet 
on the management of 
bone health for men on 
ADT. 
 
 
 
 
A South Australian medical oncologist embarked on a TRIPP fellowship in early 
2014 focussing on bone health of women with breast cancer managed with 
endocrine manipulation.  I joined her management committee, and introduced men 
with prostate cancer treated with ADT into the conversation.  Rather than targeting 
radiation oncologists and urologists, this intervention targets the patients, asking 
them to engage with their general practitioners with a specific suite of bone health 
initiatives.  This work is ongoing, and there is optimism that mobilising the patients 
and their primary health carers will prove a more fruitful avenue in improving bone 
health.22 
 
Efficacy  
 
Much of the effort with efficacy biomarkers falls into two distinct areas.  These are 
the identification of subgroups with different prognoses, as well as the attempting to 
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predict subpopulations likely to respond to different treatments.  Most of this work is 
occurring in patients with more advanced, metastatic disease, but any positive 
findings will be worth exploring in the high risk non-metastatic population. 
 
Regarding circulating biomarkers, a wide plethora of options have emerged.  Trying 
to adapt systemic therapy according to CTC response has been trialled without 
success in breast cancer patients, but has yet to be reported on in a prostate cancer 
population.23  In addition to CTCs, cell free circulating DNA (cfDNA) and micro-RNA 
(miRNA) have also gained favour, largely due to their greater sensitivity and 
quantification abilities.24,25  Perhaps more exciting, is rather than pure enumeration of 
circulating tumour markers, it is now also possible to derive their function.  This work 
is most advanced in the case of the Androgen Receptor splice variants, in particular 
ARv7.26  This entity has the binding site for ligand excised yet retains constitutional 
activity (see figure 7.3).  As such, agents such as Abiraterone and Enzalutamide 
appear to have minimal efficacy in such patients, perhaps suggesting a greater role 
of cytotoxics like Cabazitaxel or Docetaxel.27  This is being prospectively explored,28 
although the large number of splice variants, their low individual frequency and the 
dynamic nature of phenotype selection through the use of therapeutics make this an 
enormously challenging area. 
 
Figure 7.3: Diagram showing the lack of a ligand binding region on the androgen 
receptor slice variants (AR-V), and how this constitutionally active pathway comes to 
dominant the cell response independent of the presence of ligands such as 
testosterone or enzalutamide. (From Nelson N Eng J Med 2014; 371: 1067-69.) 
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The use of more advanced imaging at the time of diagnosis for men with apparently 
localized disease is also a rapid emerging area.  Pelvic MRI including diffusion 
weighted imaging (DWI) has become relatively routine at the time of initial diagnosis 
both to assist in targeting of biopsies, definition of local extent of disease and hence 
operability, as well as affording more accurate staging of pelvic lymph nodes than 
achieved through the use of CT imaging. 29-31 Simultaneously, whole body MRI 
including DWI has gained some enthusiasm for better defining the presence of low 
volume metastatic disease, particularly in the axial skeleton.32,33  Although this 
technology has being available for a decade, it has failed to enter widespread use, 
partly due to the specialised coils need for whole body imaging, the time required for 
such studies, and the difficulty in interpreting them given the huge volume of data to 
be analysed.  There has been some work on using serial mpmMRI of the prostate as 
a patient progresses through a course of ADT to gauge early indications of later 
disease control.34  One of my PhD students is currently exploring the use of serial 
mpmMRI for patients with anal canal squamous cell carcinoma with the aim of 
defining subgroups for whom either treatment intensification or de-escalation may be 
appropriate, with similar work occurring in a wide range of mucosal tumours.35,36 
 
PSMA PET imaging has recently become available, with early data suggesting 
superiority to other imaging modalities in the sensitivity and specificity of detecting 
low volume nodal or metastatic prostate cancer (see figure 7.4).37,38  The relative 
ease of image interpretation and widespread access have led to the rapid uptake of 
this modality in Australia ahead of a firm evidence base emerging on the longer term 
impacts on disease control outcomes.39,40  The recent availability of combined PET-
MRI machines offers the potential to harness the advantages already outlined from 
both platforms in a single scanning session.  In conjunction with the Prostate Cancer 
Foundation of Australia, grant applications are currently underway both in the initial 
staging scenario as well as the metachronous recurrence setting (ie following 
efinitive therapy to the prostate) to try to rectify this.  
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Figure 7.4: CT and PSMA PET imaging of a man with high risk prostate cancer.  CT 
imaging showed a lymph node in the left common iliac chain which was borderline by 
size criteria.  PSMA shows obvious avidity in this lesion, as well as two much smaller 
lymph nodes in close proximity.  PSMA PET also showed much more widespread 
nodal disease throughout the pelvis, abdomen and chest, all of which appeared 
normal on CT imaging. 
 
Oligometastatic State 
 
In conjunction with the above imaging findings, a greater awareness has emerged of 
the continuum between organ confined disease and widespread metastatic disease.  
The entity of oligometastatic disease where a relatively small number of established 
metastatic lesions are present has relatively recently emerged in the oncology 
literature.41-45  In particular, the threshold between high risk apparently non-
metastatic prostate cancer and synchronous oligometastatic disease (ie low volume 
metastases detected at the time of initial diagnosis) has been recognized as a 
function not only of the disease, but also the increasing sensitivity of the imaging 
modalities utilised.  Evidence is beginning to emerge regarding the disease control 
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benefit of EBRT for men with nodal metastases at diagnosis, a group previously 
through to be beyond the benefit of local treatment.46  Irradiation of the primary 
tumour in the presence of widespread metastases is also the subject of an ongoing 
RCT,47 largely based on evidence from the renal cell carcinoma of the survival 
benefit of a cytoreductive nephrectomy for selected patients with established 
metastatic disease.48 
 
Simultaneously, therapeutics for oligometastatic prostate cancer have evolved both 
in the form of surgical intervention for pelvic nodal deposits as well as stereotactic 
ablative radiotherapy (SABR – see figure 7.5).  It is an open question whether the 
greater sensitivity of PSMA PET imaging is truly a step forward as the more 
aggressive therapeutics available raise the potential for greater toxicity without any 
evidence of long term efficacy.49  Grant applications and clinical trials are currently 
underway exploring both the utility of PSMA PET but also whether any meaningful 
disease free survival advantage is afforded by aggressively managing 
oligometastases.50-52  SABR, delivered in 1-5 sessions non-invasively, achieves local 
tumour control in approximately 90% of patients with <1% risk of medium term 
significant toxicity (see figure 7.6).53  There will clearly be a great need for clinical 
trials to validate this approach and ongoing rapid evolution in this space in the near 
future. 
Figure 7.5: Radiotherapy 
dose distribution from a 
SABR treatment of 
oligometastatic lymph 
nodes in the pelvis.  Note 
the intense dose in 
Orange to the PSMA PET 
avid lymph nodes, and 
much lower dose in blue to 
the uninvolved nodes. 
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 Figure 7.6: Serial T2 axial MRI showing oligometastatic disease to the posterior 
aspect of the T12 vertebral body pre-SABR (left) and 3 months post SABR (right).  
Note the normalisation of the spinal canal, and absence of persistent disease in the 
vertebral body, which correlated with a complete metabolic response on FDG-PET. 
 
Summary 
 
The management of men with high risk prostate cancer will continue to be a 
challenge for clinicians.  Even though this work has touched on several aspects of 
the treatment of such men, many other areas present additional complexities.  
Surgery is now often offered as a treatment option for high risk prostate cancer, 
driven largely by the widespread uptake of robotic radical prostatectomies and 
increasing aggression of urologists favouring surgical management of locally 
advanced and even metastatic disease.  Hormono-radiotherapy offers a very 
different toxicity profile and unknown differences in efficacy compared with surgery 
for such patients, making the initial decision about which treatment course to pursue 
largely uninformed by high level evidence.  Survivorship is another key area, as 
toxicities as broad as loss of sexual function to cognitive impairment can all lead to 
impaired quality of life, making the minimisation and management of these an area 
of need.  Numerous more focussed aspects of the technical delivery of EBRT 
including optimal planning approaches, treatment verification, radiation dose and 
incorporation of brachytherapy are all active areas of research.  At times, it can 
appear that far more is unknown than known about how best to guide patients 
through this ever more complex journey. 
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There are some certainties, generally applicable throughout medicine and science 
rather than being specific to the management of prostate cancer.  The trend towards 
greater subspecialisation will continue.  Despite this, clinicians who build bridges with 
other clinicians, imaging specialists, technical experts and consumer groups will be 
better placed to guide patients through their journey than clinicians who function in a 
more isolated fashion.  The volume of evidence and number of options will continue 
to increase, probably at a faster rate.  Skills on how to diffuse innovation 
appropriately will gain ever more importance.  Newer tools such as social media are 
likely to have an expanded role.54  In short, a resilience to change informed by a 
constantly evolving evidence base and in cooperation with professionals both within 
and outside their field of subspecialisation will be the most valuable tools a clinician 
can offer their patients. 
 
  
 150 
 
References 
 
1. Martin J, Nicholson G, Cowin G, Ilente C, Wong W, Kennedy D. Rapid 
determination of vertebral fat fraction over a large range of vertebral bodies. J Med 
Imaging Radiat Oncol 2014;58:155-63. 
2. Loh J, Jovanovic L, Lehman M, et al. Circulating tumor cell detection in high-
risk non-metastatic prostate cancer. Journal of cancer research and clinical oncology 
2014;140:2157-62. 
3. Wu R, Woodford H, Capp A, et al. A prospective study of nomogram-based 
adaptation of prostate radiotherapy target volumes. Radiat Oncol 2015;10:243. 
4. Martin J, Frantzis J, Chung P, et al. Prostate radiotherapy clinical trial quality 
assurance: How real should real time review be? (A TROG-OCOG Intergroup 
Project). Radiother Oncol 2013. 
5. Martin JM, Rosewall T, Bayley A, et al. Phase II trial of hypofractionated 
image-guided intensity-modulated radiotherapy for localized prostate 
adenocarcinoma. Int J Radiat Oncol Biol Phys 2007;69:1084-9. 
6. PROFIT Clinical Trial. (Accessed 12 January 2016, at 
https://clinicaltrials.gov/ct2/show/NCT00304759.) 
7. King CR, Freeman D, Kaplan I, et al. Stereotactic body radiotherapy for 
localized prostate cancer: pooled analysis from a multi-institutional consortium of 
prospective phase II trials. Radiother Oncol 2013;109:217-21. 
8. King CR, Collins S, Fuller D, et al. Health-related quality of life after 
stereotactic body radiation therapy for localized prostate cancer: results from a multi-
institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys 
2013;87:939-45. 
9. Tang CI, Loblaw DA, Cheung P, et al. Phase I/II study of a five-fraction 
hypofractionated accelerated radiotherapy treatment for low-risk localised prostate 
cancer: early results of pHART3. Clin Oncol (R Coll Radiol) 2008;20:729-37. 
10. SPARK Clinical Trial. (Accessed 12 January 2016, at 
https://clinicaltrials.gov/ct2/show/NCT02397317.) 
11. Williams S, Buyyounouski M, Kestin L, Duchesne G, Pickles T. Predictors of 
Androgen Deprivation Therapy Efficacy Combined With Prostatic Irradiation: The 
Central Role of Tumor Stage and Radiation Dose. International Journal of Radiation 
OncologyBiologyPhysics 2011;79:724-31. 
 151 
 
12. Denham JW, Steigler A, Joseph D, et al. Radiation dose escalation or longer 
androgen suppression for locally advanced prostate cancer? Data from the TROG 
03.04 RADAR trial. Radiother Oncol 2015. 
13. ENZARAD Clinical Trial. (Accessed 12 January 2016, at 
https://clinicaltrials.gov/ct2/show/NCT02446444.) 
14. Rosenthal SA, Hunt D, Sartor AO, et al. A Phase 3 Trial of 2 Years of 
Androgen Suppression and Radiation Therapy With or Without Adjuvant 
Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy 
Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902. Int J 
Radiat Oncol Biol Phys 2015;93:294-302. 
15. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in 
Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015;373:737-46. 
16. James ND, Sydes MR, Clarke NW, et al. Addition of docetaxel, zoledronic 
acid, or both to first-line long-term hormone therapy in prostate cancer 
(STAMPEDE): survival results from an adaptive, multiarm, multistage, platform 
randomised controlled trial. Lancet 2015. 
17. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with 
docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a 
randomised, open-label, phase 3 trial. The Lancet Oncology 2013;14:149-58. 
18. Sandler H, Chen HC, Rosenthal SA, et al. A phase III protocol of androgen 
suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by 
chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate 
cancer (RTOG 0521). J Clin Oncol 2015;33:LBA5002. 
19. Tannock IF, De Wit R, Berry WR, et al. Docetaxel plus prednisone or 
mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of 
Medicine 2004;351:1502-12. 
20. Neubert A, Fripp J, Engstrom C, et al. Automated detection, 3D segmentation 
and analysis of high resolution spine MR images using statistical shape models. 
Physics in medicine and biology 2012;57:8357-76. 
21. Neubert A, Fripp J, Engstrom C, Gal Y, Crozier S, Kingsley MI. Validity and 
reliability of computerized measurement of lumbar intervertebral disc height and 
volume from magnetic resonance images. The spine journal : official journal of the 
North American Spine Society 2014;14:2773-81. 
 152 
 
22. Boaz A, Baeza J, Fraser A, European Implementation Score Collaborative G. 
Effective implementation of research into practice: an overview of systematic reviews 
of the health literature. BMC research notes 2011;4:212. 
23. Smerage JB, Barlow WE, Hortobagyi GN, et al. Circulating tumor cells and 
response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 
2014;32:3483-9. 
24. Sapre N, Selth LA. Circulating MicroRNAs as Biomarkers of Prostate Cancer: 
The State of Play. Prostate cancer 2013;2013:539680. 
25. Kienel A, Porres D, Heidenreich A, Pfister D. cfDNA as a Prognostic Marker of 
Response to Taxane Based Chemotherapy in Patients with Prostate Cancer. The 
Journal of urology 2015;194:966-71. 
26. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide 
and abiraterone in prostate cancer. N Engl J Med 2014;371:1028-38. 
27. Antonarakis ES, Lu C, Luber B, et al. Androgen Receptor Splice Variant 7 and 
Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant 
Prostate Cancer. JAMA Oncol 2015;1:582-91. 
28. ARMOR3-SV Clinical Trial. (Accessed 12 January 2016, at 
https://clinicaltrials.gov/ct2/show/NCT02438007.) 
29. Hamoen EH, de Rooij M, Witjes JA, Barentsz JO, Rovers MM. Use of the 
Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer 
Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-
analysis. European urology 2015;67:1112-21. 
30. Barentsz JO, Weinreb JC, Verma S, et al. Synopsis of the PI-RADS v2 
Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and 
Recommendations for Use. European urology 2016;69:41-9. 
31. Crawford ED, Stone NN, Yu EY, et al. Challenges and Recommendations for 
Early Identification of Metastatic Disease in Prostate Cancer. Urology 2014;83:664-9. 
32. Lecouvet FE, Simon M, Tombal B, Jamart J, Vande Berg BC, Simoni P. 
Whole-body MRI (WB-MRI) versus axial skeleton MRI (AS-MRI) to detect and 
measure bone metastases in prostate cancer (PCa). Eur Radiol 2010;20:2973-82. 
33. Venkitaraman R, Cook GJ, Dearnaley DP, et al. Whole-body magnetic 
resonance imaging in the detection of skeletal metastases in patients with prostate 
cancer. J Med Imaging Radiat Oncol 2009;53:241-7. 
 153 
 
34. Hotker AM, Mazaheri Y, Zheng J, et al. Prostate Cancer: assessing the 
effects of androgen-deprivation therapy using quantitative diffusion-weighted and 
dynamic contrast-enhanced MRI. Eur Radiol 2015;25:2665-72. 
35. Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The Role of FDG-PET 
in the Initial Staging and Response Assessment of Anal Cancer: A Systematic 
Review and Meta-analysis. Annals of surgical oncology 2015. 
36. Jones M, Hruby G, Stanwell P, et al. Multiparametric MRI as an outcome 
predictor for anal canal cancer managed with chemoradiotherapy. BMC cancer 
2015;15:281. 
37. Maurer T, Weirich G, Schottelius M, et al. Prostate-specific membrane 
antigen-radioguided surgery for metastatic lymph nodes in prostate cancer. 
European urology 2015;68:530-4. 
38. Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic Efficacy of Gallium-
PSMA-PET compared to Conventional Imaging in Lymph Node Staging of of 130 
consecutive Patients with Intermediate to High-Risk Prostate Cancer. The Journal of 
urology 2015. 
39. van Leeuwen PJ, Stricker P, Hruby G, et al. 68Ga-PSMA has high detection 
rate of prostate cancer recurrence outside the prostatic fossa in patients being 
considered for salvage radiation treatment. BJU international 2015. 
40. Morigi JJ, Stricker PD, van Leeuwen PJ, et al. Prospective Comparison of 
18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients 
Who Have Rising PSA After Curative Treatment and Are Being Considered for 
Targeted Therapy. Journal of nuclear medicine : official publication, Society of 
Nuclear Medicine 2015;56:1185-90. 
41. Loh J, Davis ID, Martin JM, Siva S. Extracranial oligometastatic renal cell 
carcinoma: current management and future directions. Future oncology 
2014;10:761-74. 
42. Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J 
Clin Oncol 2014;32:2902-12. 
43. Tree AC, Khoo VS, Eeles RA, et al. Stereotactic body radiotherapy for 
oligometastases. The Lancet Oncology 2013;14:e28-e37. 
44. Salama JK, Hasselle MD, Chmura SJ, et al. Stereotactic body radiotherapy 
for multisite extracranial oligometastases: final report of a dose escalation trial in 
patients with 1 to 5 sites of metastatic disease. Cancer 2012;118:2962-70. 
 154 
 
45. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with 
stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat 
Oncol Biol Phys 2012;83:878-86. 
46. James ND, Spears MR, Clarke NW, et al. Failure-Free Survival and 
Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: 
Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA Oncol 2015:1-
10. 
47. STAMPEDE clinical trial. (Accessed 12 January 2016, at 
https://clinicaltrials.gov/ct2/show/NCT00268476).) 
48. Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell 
Carcinoma Database Consortium model as a prognostic tool in patients with 
metastatic renal cell carcinoma previously treated with first-line targeted therapy: a 
population-based study. The Lancet Oncology 2015;16:293-300. 
49. Palma DA, Salama JK, Lo SS, et al. The oligometastatic state - separating 
truth from wishful thinking. Nature reviews Clinical oncology 2014;11:549-57. 
50. Palma DA, Haasbeek CJ, Rodrigues GB, et al. Stereotactic ablative 
radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-
COMET): study protocol for a randomized phase II trial. BMC cancer 2012;12:305. 
51. Decaestecker K, De Meerleer G, Ameye F, et al. Surveillance or metastasis-
directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study 
protocol for a randomized phase II trial. BMC cancer 2014;14:671. 
52. Supiot S, Rio E, Pacteau V, Mauboussin MH, Campion L, Pein F. 
OLIGOPELVIS - GETUG P07: a multicentre phase II trial of combined salvage 
radiotherapy and hormone therapy in oligometastatic pelvic node relapses of 
prostate cancer. BMC cancer 2015;15:646. 
53. Ost P, Bossi A, Decaestecker K, et al. Metastasis-directed therapy of regional 
and distant recurrences after curative treatment of prostate cancer: a systematic 
review of the literature. European urology 2015;67:852-63. 
54. Katz MS. Social media and medical professionalism: the need for guidance. 
European urology 2014;66:633-4. 
 
  
 155 
 
Appendix: PROCITT Clinical Trial Protocol 
 
The following is the clinical trial protocol used as a structure for the accrual, 
investigation and analysis of the men involved in the study which lead to the 
manuscripts in chapters 3 through 6.  
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CLINICAL RESEARCH PROTOCOL  
 
 
 
 
 
  
A Phase 2 Clinical Trial Exploring 3-Dimensional Imaging of Androgen 
Deprivation Induced Osteoporosis, Radiotherapy Hypofractionation and the 
Prognostic Significance of Micrometastatic disease in men with Prostate 
Cancer. 
 
Short Title: PROstate Cancer Imaging, Treatment and Toxicity (PROCITT) 
 
Funding Sponsor: Abbott Australasia Ltd 
ABN 95 000 180 389 
Sir Joseph Banks Corporate Park 
32-34 Lord St 
Botany NSW 2019 
(+612) 9384 9800 
Protocol Number: IIS MET-10-0030 
Current version: Version 2: July 2012 (Newcastle study) 
Previous version: Version 1-3: June 2011 (Toowoomba pilot study) 
 
This document is confidential and the property of the Department of Radiation 
Oncology, Calvary Mater Hospital, Newcastle.  No part of it may be transmitted, 
reproduced, published, or used without prior written authorization from the institution. 
 
This document is a protocol for a clinical research study. The study will be conducted 
in compliance with all stipulations of this protocol, the conditions of the ethics 
committee approval, the NHMRC National Statement on Ethical Conduct in Human 
Research (2007) and the Note for Guidance on Good Clinical Practice (CPMP/ICH-
135/95).   
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Trial Management Committee 
 
Principle Investigator:      Dr Jarad Martin (Calvary Mater Hospital, Newcastle 
[CMN])  
 
Medical Imaging: Dr Gary Cowin  (Centre for Advanced Imaging, University 
of Queensland [UQ]) 
 
 Dr Peter Stanwell (University of Newcastle) 
 
 Mr Jameen Arm (CMN) 
 
Endocrinology: Prof Geoff Nicholson (School of Medicine, UQ) 
 
Osteoporosis Imaging: Prof Christian Langton (Queensland University of 
Technology [QUT]) 
 
Urology:   Dr Peter Chong (Hunter New England Health) 
 
Radiation Oncology: Prof Jim Denham (CMN) 
  
Dr Colin Tang (CMN) 
 
Dr Anne Capp (CMN) 
 
Dr Chris Wratten (CMN) 
 
Dr Scott Williams (University of Melbourne) 
 
Radiation Therapy:  Ms Leisa Newton (CMN) 
 
Medical Physics:  Dr Trish Ostwald (CMN) 
  
    Dr Peter Greer (CMN) 
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Molecular Biology:  Prof Colleen Nelson (QUT) 
 
    Dr Lidija Jovanovic (QUT) 
 
Statistics: Dr Ashley Plank (Toowoomba Cancer Research Centre) 
 
Trial Coordinator: Ms Sarah Gallagher (CMN)   
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List of Abbreviations 
 
Abbreviation Term 
AE Adverse Event 
ALP Alkaline phosphatase 
BM Bone Marrow 
BMD Bone Mineral Density 
BMF Bone Marrow Fat 
bNED Biochemical No Evidence of Disease 
bsALP Bone Specific ALP 
CRF Case Report Form 
CT Computerised Tomogram 
CTC Circulating Tumour Cells 
CTV Clinical Target Volume 
CTX C-telopeptide of type I collagen 
DEXA Dual Energy X-Ray Absorptiometry 
Dpd Deoxypuridinoline 
DRE Digital Rectal Examination 
EPI Electronic Portal Image  
FBC Full Blood Count 
FWR Fat-to-water peak ratio 
HAT Hepatic Adipose Tissue 
Hb Haemoglobin 
HREC Human Research Ethics Committee 
HypoRT Hypofractionated Radiotherapy 
IDEAL T2-weighted iterative decomposition of water and fat 
with echo asymmetric and least squares estimation. 
IGRT Image Guided Radiotherapy 
IMRT Intensity modulated Radiotherapy 
MDCT Multidetector CT 
MRI Magnetic Resonance Imaging 
NHMRC National Health and Medical Research Council 
NHT Neoadjuvant Hormonal Therapy 
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NTX N-telopeptide 
P1NP N-Terminal Pro-peptide of Type 1 Procollagen  
PC Prostate Cancer 
PCSS Prostate Cancer Specific Survival  
pHR-QCT Peripheral High Resolution Quantitative CT 
PI Principal Investigator 
PICF Patient Informed Consent Form 
PROCITT PROstate Cancer Imaging, Treatment and Toxicity 
PSA Prostate Specific Antigen 
PTV Planning Target Volume 
QCT Quantitative CT 
RCT Randomized Controlled Trial 
RT Radiotherapy 
SAE Serious Adverse Event 
SAT Subcutaneous Adipose Tissue 
SB PRV Small Bowel Planning Target at Risk Volume 
SHBG Sex Hormone Binding Globulin  
SUSAR Suspected, unexpected, serious adverse reaction 
TRUS Transrectal Ultrasound 
VAT Visceral Adipose Tissue 
WBBS Whole Body Bone Scan 
WPRT Whole Pelvic Radiotherapy 
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Study Summary 
Title 
A Phase 2 Trial Exploring Magnetic Resonance Imaging of Androgen 
Deprivation Induced Osteopaenia, Radiotherapy Hypofractionation 
and the Prognostic Significance of Micrometastatic disease. 
Short Title PROstate Cancer Imaging, Treatment and Toxicity (PROCITT) 
Protocol Number IIS MET-10-0030 
Phase Phase 2  
Methodology Prospective observational non-interventional study 
Study Duration 5 years (2 years accrual, 3 years minimum follow-up) 
Study Center(s) Single-centre– Calvary Mater Hospital, Newcastle. 
Objectives 
Primary Objective: That baseline MR imaging of lumbar spine fat 
fraction combined with clinical factors predicts which men are at 
greater risk of accelerated Androgen Deprivation Therapy (ADT) 
induced bone mineral density loss than baseline DEXA scanning 
alone. 
 
Secondary Objectives 
 Feasibility, toxicity (acute and late) and efficacy (3 year bNED by 
Phoenix definition) of multimodality therapy with hypofractionated 
radiotherapy 
 To correlate marrow changes on MR with changes in blood counts 
and patient reported fatigue 
 Prognostic value of circulating tumour cells 
 Describe changes in marrow fat distribution under the influence of 
ADT. 
Number of 
Subjects 
100 
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Diagnosis and 
Main Inclusion 
Criteria 
Men with histological confirmed prostate cancer 
High risk disease (any one of PSA≥20, Gleason 8-10, Stage T3-4) 
CT abdomen and pelvis and Whole body bone scan not positive for 
metastatic disease. 
Planned for 18 months of Androgen Deprivation Therapy 
Informed Consent 
Statistical 
Methodology 
 Construction of a model predicting annual rate of bone loss based 
on baseline imaging, clinical and biochemical characteristics.   
 Correlation of changes in bone marrow with changes in blood 
counts and patient reported fatigue. 
 Incidence of Circulating Tumour Cells (CTC)  
 Final report of efficacy measured by PSA control using Phoenix 
definition compared with novel parameters including CTC count 
and haemoglobin drop. 
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Introduction 
 
 This document is a protocol for a clinical research study. The study will be 
conducted in compliance with all stipulations of this protocol, the conditions of the 
ethics committee approval, the NHMRC National Statement on Ethical Conduct in 
Human Research (2007) and the Note for Guidance on Good Clinical Practice 
(CPMP/ICH-135/95).  
Investigators and Facilities 
 
1. Study Location 
 
Calvary Mater Hospital 
Edith St 
Waratah, Newcastle  
New South Wales 2298 
Australia 
 
2. Study Management 
 
The study will be coordinated by a research team consisting of the Principal 
Investigator and a study coordinator. Informed consent discussions and clinical 
assessments will be conducted by the principal investigator. The study coordinator 
will be delegated responsibility for subject’s imaging appointments, follow-up visits, 
data collection and maintenance of study documentation.   Dr Jarad Martin is the 
Principle Investigator and sponsor for this study.  This study is investigator initiated, 
and funded through a competitive grant from Abbott pharmaceuticals.   
Background 
 
1. ADT induced Osteoporosis 
 
Prostate cancer is a common malignancy in Australian men.  In men with localized 
disease at the time of diagnosis, baseline PSA level, tumour stage and Gleason 
grade can be used to help stratify into risk categories.  Men with high risk disease 
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are defined by an absence of metastatic disease using conventional imaging, and 
any one of the following: a presenting PSA of >20, Gleason grade 8-10 disease on 
histology, or stage T3-4 disease.[1]  Such men are often treated with a combination of 
radiotherapy to the prostate and pelvic lymph nodes, in conjunction with a course of 
adjuvant androgen deprivation therapy (ADT) of between 18-36 months.[2]  Recent 
literature suggests that the greatest benefit from adjuvant ADT comes from the first 
4-6 months of treatment, and although there is measurable benefit from prolonging 
the course of ADT, it follows the law of diminishing returns with progressively smaller 
benefit per unit of increased treatment time.[3]  This is important, in that if cumulative 
toxicities are being inflicted by prolonging the treatment, there is likely to be a 
duration where the harm of further treatment will start to outweigh the diminishing 
disease control benefits. 
 
With greater clinical experience of the use of adjuvant ADT, there has become a 
better awareness of the toxicities associated with this treatment.  Accelerated loss of 
bone mineral density has long been recognized as a complication of being 
hypogonadal.  There is now good evidence that this leads to an approximately 7% 
higher risk of fractures for men with prostate cancer managed with ADT.[4]  
Osteoporotic fractures are associated with increased morbidity and mortality, and a 
high proportion of patients who suffer them never fully regain their pre-fracture level 
of functioning. 
 
There are Australian guidelines for the management of osteopaenia / osteoporosis 
for men managed with ADT.[5, 6]  They recommend monitoring of bone mineral 
density (BMD) using annual DEXA scanning, supplementary Vitamin D with Calcium, 
and the use of bisphosphanate therapy for men with prevalent minimal trauma 
fracture or baseline BMD T-Score <-2.0.  One point high-lighted is that there is a 
wide spectrum in the rate of bone mineral loss between patients and techniques of 
measurement, with figures as high as 8% per year reported.  This is far in excess of 
a normal rate of bone loss amongst males of 0.5% per year.[7]   
 
Although validated nomograms exist for the general population combining DEXA 
findings with clinical parameters to predict long term fracture risks, no such tool 
exists for men rendered hypogonadal with the use of ADT.[8]  Guidelines for men on 
ADT are empirical, and largely copy risk factors from the general population.[9]   
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Beyond baseline BMD, the only clinical factor shown to have any accuracy in 
predicting bone loss for men on ADT is the change in serum P1NP (N-Terminal Pro-
peptide of Type 1 Procollagen, a marker of bone formation).[10] One study showed 
that men in the highest tertile for P1NP after 6 months of ADT had the greatest loss 
in BMD at 12 months.  This finding has not been verified, and there remains a need 
to investigate the utility of other clinical parameters either at baseline or early in ADT 
therapy to find accurate predictors of which patients are at highest risk for 
accelerated BMD loss. 
 
 Osteoporosis Imaging 
 
Currently, the main method to reliably determine which men are more rapid bone 
losers is to perform serial DEXA imaging.  Thus, by the time that rapid bone loss 
occurs, it is too late to take measures to prevent it by interventions such as curtailing 
the duration of adjuvant ADT.  Furthermore, we have level 2 evidence from a 
randomized clinical trial, that intervention with a bisphosphonate needs to be 
instigated at the commencement of ADT and continued throughout the duration of 
ADT to maximize bone density.[10]  This study will aim to define a predictive tool 
combining baseline imaging and clinical characteristics to help determine which 
patients are at higher risk of accelerated bone loss prior to the initiation of ADT. 
 
Osteoporosis is a complex condition characterized by loss of both cortical and 
trabecular bone.[11]  The structural basis of bone loss is poorly quantified by DEXA 
scanning which combines cortical and trabecular bone density in its measurement.[12]  
However, they can be separately and non-invasively quantified with the use of 
ultrasound (US), computerized tomography (CT), peripheral high resolution 
quantitative CT (pHR-QCT) or magnetic resonance imaging (MRI).[13]  The last of 
these methods has the advantages of not being operator dependent, not requiring 
exposure to ionizing radiation and wide availability.  A disadvantage is the relatively 
poor characterization of cortical and trabecular bone at a field strength of 1.5 T. 
 
There has been some work using CT imaging to separately quantify both cortical and 
trabecular BMD, as well as other parameters of trabecular bone quality.  Much of this 
work has used pHR-QCT, which has revealed detailed changes in the porosity of 
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cortical bone for men on ADT which is likely to weaken the bone, and as been 
termed ‘trabecularization’.[14]  Recent studies have compared this technique which 
has relatively limited accessibility, with more widely available technologies such as 
Quantitative CT (QCT) and Multidetector CT (MDCT).[15, 16] A very accurate 
correlation for Trabecular BMD was found between all 3 CT modalities.  This raises 
the possibility that BMD can be estimated from the staging MDCT performed on all 
prostate cancer patients, without needing to expose them to the extra radiation dose 
required to perform a QCT. 
 
An advantage of MRI is that it also allows the collection of additional information 
regarding bone marrow (BM) including fat fraction and perfusion.  These measures 
have previously shown some correlation with BMD measured by DEXA imaging, 
however the correlation is relatively poor, with a wide degree of unexplained 
variation.[17-19]  BM has intimate proximity with trabecular bone, and paracrine factors 
such as the RANK-Ligand secreted from the BM plays a key role in recruiting bone 
resorbing osteoclasts.[20]  It might therefore be that some of the variation in BMD 
measured with DEXA is due to baseline variation in BM composition.  There are also 
possible correlations between BM fat (BMF), and subcutaneous adipose tissue 
(SAT), visceral adipose tissue (VAT) and hepatic adipose tissue (HAT), all of which 
can be separately quantified by MRI.[21] This, is turn, may be linked with the 
deranged insulin levels and response linked with ADT administration, and may be 
posited as a cause of increased cardiovascular morbidity.[22] 
 
Other evidence shows that ADT induces a drop of haemoglobin from an average 
baseline value of 151 g/L down to 135 within 18 months of starting treatment.[23]  No 
haemolytic process is evident, and the circumstantial evidence points to bone 
marrow suppression as being the mechanism for this.  Such mild anaemia may also 
contribute to the insidious fatigue often seen in men treated with ADT.  There is also 
some evidence from reanalysis of randomized trial data, that men who have the 
greatest drop in haemoglobin in the 3 months following initiation of ADT have a 
poorer overall survival in the setting of metastatic disease.[24]  As such, measuring 
BM at baseline may help in predicting which patients are at risk of both losing bone 
faster, becoming anaemic, and suffering fatigue.  It is therefore plausible that 
measurement of BM will add an important dimension to our knowledge of the bone 
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as a functional unit as well as better explaining some of the toxicities associated with 
ADT. 
 
2. Circulating Tumour Cells 
 
For a cancer to metastasize from the primary site of origin to other parts of the body, 
malignant cells must undergo a series of changes.  One crucial step involves being 
able to use blood vessels to transport tumour cells around the body.  Assays are 
now commercially available to measure these Circulating Tumour Cells (CTCs), 
including one which has FDA approval with the brand-name ‘CellSearch’.[25, 26] This 
has superceded older approaches using reverse transcriptase polymerase chain 
reaction to detect CTC in men with prostate cancer.[27] 
 
Work over the last decade in patients with metastatic cancer has shown that the 
presence of CTCs in men with PC are a bad prognostic factor, with higher levels of 
CTCs correlating with poorer overall survival.[28]  On the other side of the spectrum of 
tumour burden, work looking at patients undergoing a radical prostatectomy has 
shown only a very low incidence of CTCs (~20%) prior to surgery, which was no 
different to that measured in a cohort of healthy controls.[29]  One issue with this 
study is that <5% of the patients involved would be predicted to eventually suffer 
metastatic failure, hence the chance of finding CTCs was likely to be very low based 
on the mainly low to intermediate risk patient cohort examined. 
 
Men with high risk PC have a much higher chance of eventual metastatic failure, of 
the order of 20-30%, or higher depending on their initial risk factors (PSA level, 
tumour stage and Gleason grade).  At the time of diagnosis these men may therefore 
exhibit CTC levels intermediate between the metastatic and surgical cohorts 
previously considered.  It may be that high risk PC patients with CTCs detected 
represent a very high risk group, and apart from providing important prognostic 
information for men, it could therefore warrant treatment intensification with 
increased duration of adjuvant ADT, or entry into clinical trials. 
 
3. Prostate Radiotherapy Hypofractionation 
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Radiotherapy (RT) has been shown to independently improve overall survival for 
men with high risk PC managed with ADT.[30]  As such, standard of care for these 
men remains bimodality treatment with both RT and ADT.[1] 
 
RT has traditionally been given at doses of 1.8-2 Gy per day due to concerns about 
the potential for larger fraction sizes to cause late toxicity.  Over the last 10 years 
multiple randomized controlled trials (RCTs) have shown that higher doses of RT (of 
the order of 74-80 Gy) lead to better rates of no biochemical evidence of disease 
(bNED).[31, 32]  Due to the long natural history of PC, bNED is a validated surrogate 
endpoint looking at PSA control,[33] however the trial with the longest follow-up is now 
also beginning to show an improvement in Prostate Cancer Specific Survival 
(PCSS).[31]  The use of such regimens leads to treatment durations of 8-10 weeks, 
which can be inconvenient for patients, consume a large proportion of the capacity of 
a RT department, and consequently be a significant factor in the existence of waiting 
lists for radiotherapy. 
 
There is growing data for PC suggesting that hypofractionation (that is, daily fraction 
sizes of >2 Gy) is particularly effective at maximizing tumour effect.  Newer 
technologies such as image guided RT (IGRT) which ensures more accurate 
delivery of the RT, and intensity modulated RT (IMRT) which reduces unwanted 
radiation dose to adjacent normal structures are now in clinical use in Australia.  
They both have been used in phase 2 trials of Hypofractionated RT (HypoRT), with 
results for efficacy and late toxicity comparable to those reported in the literature for 
conventionally fractionated cohorts.[34, 35]  There have been two small RCTs recently 
reported comparing HypoRT and conventionally fractionated populations, both 
showing no increased toxicity with the HypoRT, and better bNED.[36, 37]  One of these 
focused mainly on high-risk men and included ADT, similar to the patient population 
eligible for PROCITT.[36] 
 
4. Radiotherapy Volume 
 
When defining the RT treatment volume for a man with PC, traditional thinking has 
been to treat the prostate alone.  However, for a local treatment modality such as RT 
or surgery, it is important to appreciate the natural patterns of spread of the disease.  
For instance, there are good consensus guidelines for patients with head and neck 
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cancer to help radiation oncologists to know who are most likely to benefit from 
elective treatment of their cervical neck lymph nodes.  This is because, despite the 
neck being negative at the time of diagnosis, surgical  neck dissection series have 
helped to inform decision aids regarding the chance of a clinically normal neck 
harbouring sub-clinical disease. 
 
Nomograms have been constructed from large surgical PC cohorts to help define the 
risk of extracapsular extension, seminal vesicle involvement and lymph node 
involvement based on initial clinical parameters.  Trying to treat all patients with the 
progressively larger treatment volumes required to include these areas would 
potentially increase toxicity without a high chance of improving efficacy.  However, if 
a threshold risk level of 15-25% were required prior to including each elective target 
volume, we would aim to apply such treatments to patients most likely to benefit.  
Such concepts are already beginning to enter into consensus guidelines,[1, 38] and 
represent a promising avenue of investigation.   
 
Of all of these expanded treatment volumes, only Whole Pelvic Radiotherapy 
(WPRT) has been investigated in men with PC in RCT.[39]  Neither of the 
contemporary RCTs found a significant benefit for the use of WPRT.  However, 
many practice changing RCTs have used WPRT on all patients.[2, 40-42]  One of the 
reasons for this discrepancy is likely to be that entry criteria for the largest WPRT 
RCT estimated a 15% risk of pelvic lymph node involvement.[39]  Later work has 
shown that this only corresponded to a 2% pathological risk of nodal involvement.  
This emphasizes the need to use validated decision tools to select appropriate 
treatments. 
 
5. Duration of neoadjuvant ADT 
 
Often adjuvant ADT is given prior to commencing RT.  This is known as neoadjuvant 
hormonal therapy (NHT).  There is no clear guidance on what duration to give this 
for, although 3-6 months is a common approach.  Results from an Australian 
randomized trial have shown 6 months of NAT to result in superior survival than 3 
months.[43]  Intuitively, it would seem that some patients would benefit from a shorter 
duration of NHT than others depending on their tumour response.  There has been 
some preliminary work looking at an adaptive approach for this, where RT is started 
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once a maximal PSA response has been achieved.[44]  Given the Australian data, 
this study will apply a 6 month period of NHT for all patients. 
Study Objectives 
 
Primary Hypothesis 
That baseline MR imaging of lumbar spine bone marrow and fat fraction combined 
with clinical factors predicts which men are at greater risk of accelerated Androgen 
Deprivation Therapy (ADT) induced bone loss than baseline DEXA scanning alone. 
 
Secondary Hypotheses 
 Determine feasibility, toxicity (acute and late) and efficacy (3 year bNED by 
Phoenix definition) of multimodality therapy with hypofractionated radiotherapy 
 Correlate marrow changes on MR with changes in blood counts and patient 
reported fatigue 
 Determine prevalence of CTCs in men with high risk prostate cancer and the 
prognostic significance of CTCs 
 Implementation of a nomogram based radiotherapy target delineation algorithm. 
Study Design 
General Design 
A Phase 2 Clinical Trial Exploring Advanced Imaging of Androgen Deprivation 
Induced Osteoporosis, Prognostic Significance of Circulating Tumour Cells and 
Hypofractionated Radiotherapy in men with Prostate Cancer.  
Primary Study Endpoint 
Construction of a predictive model based on pre-treatment imaging and clinical 
parameters with rate of bone loss measured on serial DEXA scans. 
Secondary Study Endpoints 
 
 Feasibility, toxicity (acute and late) and efficacy (3 year bNED by Phoenix 
definition) of multimodality therapy with hypofractionated radiotherapy 
 Correlation of marrow changes on MR with changes in blood counts and patient 
reported fatigue 
 Incidence of CTCs in men with high risk prostate cancer 
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 Correlation of CTC with efficacy outcomes 
 Feasibility of nomogram based radiotherapy target delineation 
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Study Design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient Eligible 
Informed Consent 
Baseline Bloods, 
Imaging, Urine 
Start RT after  
6 months  
of NHT 
Repeat MRI. 
Use nomogram to 
define target volumes: 
ECE, SVI, PLN 
Continue ADT for 18 
months in total 
Repeat DEXA annually 
Ongoing follow-up for 
3 years 
Enrol on ManPlan (if 
available) 
Commence Calcium 
and Vitamin D 
Commence ADT (Leuprorelin IM) 
Include 4 weeks of antiandrogen 
to prevent flare 
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Subject Selection and Withdrawal 
Inclusion Criteria 
1. Patient capable of giving informed consent 
2. Histological diagnosis of prostate cancer 
3. High risk disease defined by any one of: 
a. Baseline PSA≥20 
b. Gleason grade 8-10 disease 
c. Clinical stage T3-T4 
4. Negative conventional staging in the form of a: 
a. T99m whole body bone scan 
b. CT of the abdomen and pelvis 
5. No previous pelvic radiotherapy 
Exclusion Criteria 
 
1. History of prior malignancy within the last 5 years with the exception of non-
melanomatous skin cancers. 
2. ECOG performance status >1 
3. Inability to have intraprostatic fiducials inserted. 
4. Inability to have a MRI due to: 
a. Implanted magnetic metal eg intraocular metal 
b. Pacemaker / Implantable defibrillator 
c. Extreme claustrophobia 
Subject Recruitment and Screening 
Patients from the Calvary Mater Newcastle Hospital outpatient Radiation Oncology 
clinics will be offered recruitment into the study by Radiation Oncologists.  
Information about the study will be discussed with prospective participants, who will 
be allowed time to consider the Patient Informed Consent Form (PICF).  This 
information will then be reviewed again with patients interested in study participation 
to ensure they have fully comprehended the information provided.  Patients will be 
aware that declining to take part in the study will not affect the standard treatment 
which they will receive.  Any agreement will be voluntary, and free from coercion.  
Consent will be obtained either by a Radiation Oncologist, or a research assistant 
approved in the investigator log by the Principle Investigator (PI). 
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Early Withdrawal of Subjects 
Reasons for withdrawal 
The investigator may withdraw a patient from the study treatment and follow-up 
procedures if the patient:  
 Is in violation of the protocol;  
 Experiences a serious or intolerable adverse event  
 Develops, during the course of the study, symptoms or conditions listed in the 
exclusion criteria  
 Requests or requires early discontinuation for any reason 
 Metastatic disease confirmed prior to commencing pelvic radiotherapy.  For such 
patients, the pelvic radiotherapy component of the study will be suspended. 
 
The investigator will also withdraw all subjects from the study if the study is 
terminated. Subjects are free to withdraw from the study at any time upon their 
request or the request of their legally acceptable representative. 
Data Collection and Follow-up for Withdrawn Subjects 
When a patient withdraws from the study, the reasons for withdrawal shall be 
recorded by the investigator on the relevant page of the CRF. Whenever possible, all 
subjects who withdraw from the study prematurely will undergo scheduled visits for 
study assessments (follow-up). Subjects who fail to return for study assessments will 
be contacted by the research team in an attempt to have them comply with the 
protocol via two documented phone calls and one registered letter.  
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Study Procedures 
Study Period Baseline Enrolme
nt 
Prior to RT Radiotherapyb Post-RT 18 Months Follow-Up Study End 
Visit Number Visit 0 Visit 1 Visit 2a Visit 3a-3f Visit 4 Visit 5a, 5b Visit 6a, 
6b… 
Visit 7 
Week -2 – 0 0-4 17  RT wk0-6 RT week 
14 
Every 6 
months until 
end of ADT 
Every 12 
months 
3 years from 
beginning of study 
Informed Consent a X        
Eligibility Check X        
Demographic 
Information 
X        
Medical History X        
Physical Examination  X  X  X X X X 
Whole Body Bone Scan X        
CT Abdomen & Pelvis X        
Blood collection  X X  X X X X 
Bone Markers  X X      
MRI Lumbar Spine f  X  X     
Fatigue Questionnaire f  X    X   
DEXA scan e  X    X X  
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Thoracic Spine plain 
films 
 X       
Circulating Tumour 
Cells 
 X      X d 
RTOG Radiotherapy 
Toxicity Assessment c 
 X  X X X X X 
 
a See Appendix 9 
b See Appendices 7 and 8  
c See Appendix 5 
d Only for men with an initially positive CTC assay 
e To be performed annually while on study 
f To be performed at baseline and after 18 months 
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Definitions of events: 
 
Informed consent: Patient reads, understands and signs informed consent. 
Eligibility check: Inclusion and exclusion criteria reviewed to ensure patient 
eligibility to be included in the study. 
Demographic information: Date of birth, age at enrollment 
Medical History: Prostate cancer related parameters (PSA results, prostate 
biopsy results including overall Gleason grade), Medical comorbidities, 
medications (including bisphosphonates), ECOG performance status 
(appendix 1). 
Physical Examination: Must include a digital rectal examination (DRE).  Also 
height at baseline, and annual weight. 
Whole Body Bone Scan: To be performed by a diagnostic imaging facility 
able to interpret initial and delayed images of the skeleton for the presence of 
any areas of increased uptake following the administration of Technetium 
99m.  Any areas suspicious for metastatic disease need further imaging such 
as plain films, CT or MRI to exclude metastases. 
CT Abdomen/Pelvis: Any lymph nodes greater than 15 mm in size in the 
pelvis require further imaging or biopsy to exclude metastases to allow 
eligibility.  In the absence of pelvic disease, lymph nodes in the abdomen 
need to be at least 20 mm in the short axis to be treated as positive. 
Blood collection: 
– At baseline: 
o PSA 
o Total testosterone, Sex Hormone Binding Globulin (SHBG), 
calculated free testosterone 
o -oestradiol 
o Follicle Stimulating Hormone, Luteinizing Hormone, Prolactin 
o Full Blood count (FBC) 
o Urea and electrolytes 
o Liver function tests including alkaline phosphatase (ALP), 
Lactate Dehydrogenase 
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o 25-Hydroxy Vitamin D 
o Calcium/Phosphate 
o Circulating Tumour Cells 
– All other visits requiring blood collection 
o PSA 
o Testosterone (until back in normal range) 
o -oestradiol (until testosterone normal) 
o FBC  
Bone Markers: Serum and urine markers to be collected at baseline, and 
every 3 months for the first 6 months on ADT: 
– Serum: Bone specific ALP (bsALP), osteocalcin, Procollagen Type 1 
N-Terminal Pro-peptide (P1NP), C-telopeptide of type I collagen 
(CTX) 
– Urine: N-telopeptide (NTX)/creatinine,  
Quality of Life: Collected via the PROMIS fatigue questionnaire (Appendix 
4).  Perform annually until end of year 3. 
MRI Lumbar Spine: As outlined in appendix 3.  Performed at baseline and 
then again only if the patient is having a MRI for prostate radiotherapy 
planning. 
DEXA Scan: Performed as outlined in appendix 3 at baseline, after 1 year, 
and after 2 years. 
Thoracic spine plain films: Performed at baseline to assess for insufficiency 
fractures. 
RTOG Radiotherapy Toxicity assessment: Acute genitourinary (GU) and 
gastrointestinal (GI) toxicity to be recorded weekly while proceeding through 
radiotherapy, and then again at visit 4.  Late GU and GI toxicity to be recorded 
at all subsequent visits.  See appendix 5. 
Statistical Plan 
Sample Size Determination 
The primary endpoint is the construction of a prognositc model based on early 
treatment imaging and clinical parameters with rate of bone loss measured on 
serial DEXA scans.  There is no comprehensive data regarding even the 
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variability of fat fraction on MRI in elderly males, let alone the likely impact this 
will have on the rate of bone loss (if any).  This makes any power calculations 
very difficult, although clearly a larger number of patients will give greater 
confidence of being able to detect a relationship, if one exists.  As a 
compromise, the study will remain accruing for 2 years or a maximum of 100 
patients.  Data from these patients will be used to construct a model to predict 
the rate at which patients lose BMD based on data obtained from only 
baseline data and information available within 6 months of commencing ADT.   
Statistical Methods 
 
1. BMD Loss 
 
For the primary endpoint, the response variable is the rate of bone loss 
measured between at least two DEXA scans of the neck of femur performed 
at least 12 months apart with units grams/cm2/year.  The model will be 
constructed following the final patient who receives their second analyzable 
DEXA scan using a discriminant analysis.  Potential explanatory variables will 
include: 
 
Patient (From 
WHO Fracture 
Risk 
Assessment 
Tool) 
Age (Years) 
Weight (kg) 
Height (cm) 
Smoking status (Current, No) 
Bisphosphonate therapy (Yes/No) 
Previous fracture (Yes/No) 
Parent Hip fracture (Yes/No) 
Steroids (Yes/No) 
Rheumatoid arthritis (Yes/No) 
Alcohol ≥30g/day (Yes/No) 
Laboratory Changes after 3 months in: 
Haemoglobin 
Bone specific alkaline phosphatase  
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Osteocalcin 
Procollagen Type 1 N-Terminal Pro-peptide 
Urine N-telopeptide/Creatinine 
Oestradiol 
Testosterone 
Imaging Baseline DEXA BMD Neck of femur (g/cm2) 
Bone Marrow fat fraction from MRI (%) 
 
Any variable which achieves a significance level of less than 0.1 will be 
incorporated into the predictive model. 
 
2. Correlation of CTC with efficacy  
 
Patients will be dichotomized from baseline CTC results into those with 
negative readings (<1 CTC/7.5 mL blood sample) and those with positive 
readings (≥1 CTC/7.5 mL blood sample).  The response variable of interest 
will be bNED by the Phoenix definition (nadir + 2).  The timing to any events 
or censoring will be measured from the date the first dose of ADT is delivered.  
A Kaplan-Meier survival function will be constructed to determine if a positive 
CTC assay has any prognostic significance, and the magnitude of that effect 
on bNED.  For men who had an initially non-zero CTC count, a repeat assay 
will be performed at the completion of the study to assess any change 
following treatment. 
 
3. Correlation of changes in Haemoglobin with MRI measured marrow 
fraction and fatigue 
 
For this component, there are three main endpoints: 
 Change in Haemoglobin: This will be the difference between the 
baseline Hb and the lowest level subsequently measured while the 
patient has a castrate level of testosterone.  Patients with an incurrent 
illness responsible for the drop in HB (eg gastrointestinal bleed) will be 
excluded. 
 181 
 
 MRI measured marrow fraction: As assessed prior to commencing ADT 
using the MRS and other imaging sequences on the lumbar spine.   
 Fatigue: As recorded by the validated PROMIS short fatigue 
questionnaire v1.  A total score of between 7 to 35 is possible, with a 
higher score representing greater fatigue.  We are interested in the 
change in this score between baseline, and the 18 month repeat 
questionnaire. 
Scatterplots and correlation coefficients will be performed to see if there is any 
inter-relationship between these 3 variables. 
 
4. Hypofractionated radiotherapy 
 
Aim is to report the efficacy and toxicity associated with the radiotherapy 
regimen delivered.  Efficacy to be measured by bNED via the Phoenix 
definition as for CTC, with exploratory analyses based on baseline PSA, 
Gleason grade (6-8 v 9-10), tumour stage (T1-2 v T3-4), marrow fraction, 
change in Hb, delivery of whole pelvic radiotherapy and duration of 
testosterone suppression.  The latter quantity is defined as the period of time 
where the testosterone level is <0.5, presumed to commence 2 weeks after 
the first ADT dose is delivered. 
 
Late GI and GU toxicity recorded.  Maximal late GI and GU toxicity recorded 
for each patient as well as the timing of this event and the late GI and GU 
toxicity at last follow-up. 
 
5. Feasibility Outcomes 
 
 Nomogram based radiotherapy target delineation: The main interest with 
this endpoint is the ability for clinicians to adhere with a novel, but 
potentially complex means of contour delineation.  All CTVs as defined in 
appendix 7 will be scored by a radiation therapist who was not involved in 
generating those contours.  For each patient they will assess the following 
criteria: 
 182 
 
o CTVece  Required    (Yes / No) 
o CTVece  Generated as per protocol (Yes / No / NA) 
o CTVsv  Required    (Yes / No) 
o CTVsv  Generated as per protocol (Yes / No / NA) 
o CTVln  Required    (Yes / No) 
o CTVln  Generated as per protocol (Yes / No / NA) 
For any areas where a potential violation is observed, this will be 
reviewed by a Radiation Oncologist prior to being recorded as such.  The 
aim is to observe a protocol compliance rate of ≥90%. 
Subject Population for Analysis 
 
All patients with data available for the relevant analyses will be included.  For 
example, only patients who receive radiotherapy will be included for the 
hypofractionated radiotherapy and nomogram based radiotherapy target 
delineation analyses.  For the BMD analysis, as a minimum patients require 
two DEXA scans at least 12 months apart, as well as a baseline MRI.  For the 
CTC analysis, only patients who had a baseline CTC blood test taken will be 
included.  For the change in Hb analysis, at least 2 Hb levels (including a 
baseline measure) 3 months apart, and a baseline Lumbar spine MRI are 
necessary as a minimum. 
Safety and Adverse Events 
Definitions 
Adverse Event (AE):  
 
Any untoward medical occurrence in a patient enrolled into this study 
regardless of its causal relationship to study treatment (see appendix 10). 
 
An adverse event (AE) is any symptom, sign, illness or experience that 
develops or worsens in severity during the course of the study.  Intercurrent 
illnesses or injuries should be regarded as adverse events.  Abnormal results 
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of diagnostic procedures are considered to be adverse events if the 
abnormality: 
 results in study withdrawal 
 is associated with a serious adverse event 
 is associated with clinical signs or symptoms 
 leads to additional treatment or to further diagnostic tests 
 is considered by the investigator to be of clinical significance 
 
Serious Adverse Event (SAE):  
Adverse events are classified as serious or non-serious.  
An SAE is defined as any event that:  
• results in death; or  
• is immediately life threatening; or  
• requires inpatient hospitalisation; or  
• requires prolongation of existing hospitalisation; or  
• results in persistent or significant disability/incapacity; or  
• is a congenital anomaly/birth defect.  
 
Important medical events may be considered an SAE when, based upon 
appropriate medical judgement, they may jeopardize the patient and may 
require medical or surgical intervention to prevent one of the outcomes listed 
in this definition.  
 
Suspected Unexpected Serious Adverse Reaction (SUSAR): 
A SUSAR is any SAE that is both suspected to be related to the study and is 
unexpected (i.e. not consistent with applicable product information).  
Eliciting Adverse Event Information 
 
Adverse events will be recorded from the time the patient signs the Informed 
Consent Form until 30 days after the last visit. At every study visit subjects will 
be asked “How have you felt since your last visit?” in order to elicit any 
medically related changes in their well-being. They will also be asked if they 
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have been hospitalised, had any accidents, used any new medication or 
changed concomitant medication regimens. In addition, AEs will be 
documented from physical examinations findings, clinically significant lab 
results or other documents (including patient diaries and correspondence from 
their primary care physician) that are relevant to patient safety. 
 
Adverse Event Reporting Period 
The study period during which adverse events must be reported is normally 
defined as the period from the initiation of any study procedures to the end of 
the study treatment follow-up.  For this study, the study treatment follow-up is 
defined as 3 months following the last day of radiotherapy.  
 
Preexisting Condition 
A preexisting condition is one that is present at the start of the study.  A 
preexisting condition should be recorded as an adverse event if the 
frequency, intensity, or the character of the condition worsens during the 
study period. 
 
General Physical Examination Findings 
At screening, any clinically significant abnormality should be recorded as a 
preexisting condition.  At the end of the study, any new clinically significant 
findings/abnormalities that meet the definition of an adverse event must also 
be recorded and documented as an adverse event.  
 
Post-study Adverse Event 
All unresolved adverse events should be followed by the investigator until the 
events are resolved, the subject is lost to follow-up, or the adverse event is 
otherwise explained.  At the last scheduled visit, the investigator should 
instruct each subject to report any subsequent event(s) that the subject, or the 
subject’s personal physician, believes might reasonably be related to 
participation in this study.  The investigator should notify the study sponsor of 
any death or adverse event occurring at any time after a subject has 
discontinued or terminated study participation that may reasonably be related 
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to this study.  The sponsor should also be notified if the investigator should 
become aware of the development of cancer or of a congenital anomaly in a 
subsequently conceived offspring of a subject that has participated in this 
study.  
 
Abnormal Laboratory Values 
A clinical laboratory abnormality should be documented as an adverse event if 
any one of the following conditions is met:  
 The laboratory abnormality is not otherwise refuted by a repeat test to 
confirm the abnormality 
 The abnormality suggests a disease and/or organ toxicity 
 The abnormality is of a degree that requires active management; e.g. 
change of dose, discontinuation of the drug, more frequent follow-up 
assessments, further diagnostic investigation, etc. 
 
Hospitalization, Prolonged Hospitalization or Surgery 
Any adverse event that results in hospitalization or prolonged hospitalization 
should be documented and reported as a serious adverse event unless 
specifically instructed otherwise in this protocol.  Any condition responsible for 
surgery should be documented as an adverse event if the condition meets the 
criteria for and adverse event.  
 
Neither the condition, hospitalization, prolonged hospitalization, nor surgery 
are reported as an adverse event in the following circumstances: 
 Hospitalization or prolonged hospitalization for diagnostic or elective 
surgical procedures for a preexisting condition.  Surgery should not be 
reported as an outcome of an adverse event if the purpose of the 
surgery was elective or diagnostic and the outcome was uneventful. 
 Hospitalization or prolonged hospitalization required to allow efficacy 
measurement for the study. 
 Hospitalization or prolonged hospitalization for therapy of the target 
disease of the study, unless it is a worsening or increase in frequency of 
hospital admissions as judged by the clinical investigator. 
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Assessment and documentation of Adverse Events 
 
At each contact with the subject, the investigator must seek information on 
adverse events by specific questioning and, as appropriate, by examination.  
Information on all adverse events should be recorded immediately in the 
source document, and also in the appropriate adverse event module of the 
case report form (CRF).  All clearly related signs, symptoms, and abnormal 
diagnostic procedures results should recorded in the source document, 
though should be grouped under one diagnosis. 
 
All adverse events occurring during the study period must be recorded.  The 
clinical course of each event should be followed until resolution, stabilization, 
or until it has been determined that the study treatment or participation is not 
the cause.  Serious adverse events that are still ongoing at the end of the 
study period must be followed up to determine the final outcome.  Any serious 
adverse event that occurs after the study period and is considered to be 
possibly related to the study treatment or study participation should be 
recorded and reported immediately. 
 
For the purposes of this study the investigator is responsible for recording all 
Adverse Events, regardless of their relationship with the exposure, with the 
following exceptions:  
• Conditions that are present at screening and do not deteriorate will not be 
considered adverse events.  
• Abnormal laboratory values will not be considered adverse events unless 
deemed clinically significant by the investigator and documented as such.  
 
The description of each AE on the CRF will include:  
 A description of the AE;  
 The onset date, duration, date of resolution;  
 Severity (mild, moderate or severe);  
 Seriousness (i.e. is it a Serious AE?)  
 Any action taken (eg treatment, follow-up tests);  
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 The outcome (eg recovery, death, continuing, worsening);  
 The likelihood of the relationship of the AE to the treatment being 
investigated (e.g. Unrelated, Possible, Probable, Definite).  
 
Changes in the severity of an AE will be reported (eg worsening headache). 
AEs characterized as intermittent will be document for each episode. All AEs 
will be followed to adequate resolution. 
Reporting of Serious Adverse Events 
 
Any SAE occurring in a study participant will be reported to the local HREC 
within 24-72 hours of occurrence, in accordance with the safety reporting 
policy of the HREC. The HREC safety reporting form will be completed, 
signed and submitted by the investigator  
 
Investigators and the protocol sponsor must conform to the adverse event 
reporting timelines, formats and requirements of the various entities to which 
they are responsible, but at a minimum those events that must be reported 
are those that are: 
 related to study participation, 
 unexpected, and  
 serious or involve risks to subjects or others  
The minimum necessary information to be provided at the time of the initial 
report includes: 
 Study identifier 
 Study Center 
 Subject number 
 A description of the 
event 
 Date of onset 
 Current status 
 Whether study treatment was 
discontinued 
 The reason why the event is classified as 
serious 
 Investigator assessment of the 
association between the event and study 
treatment 
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SUSARs 
 
All SUSARs occurring in a study participant will be reported to the local HREC 
in an expedited fashion (i.e. within 15 calendar days of first knowledge), or for 
fatal or life threatening events, an initial or full report within 7 calendar days 
and a follow-up report if necessary within the 15 calendar day timeframe. An 
investigator will complete, sign and submit the SUSAR report. 
Data Handling and Record Keeping 
Confidentiality 
Subject confidentiality is strictly held in trust by the participating investigators, 
research staff, and the sponsoring institution and their agents. This 
confidentiality is extended to cover testing of biological samples in addition to 
the clinical information relating to participating subjects. The study protocol, 
documentation, data and all other information generated will be held in strict 
confidence. No information concerning the study or the data will be released 
to any unauthorized third party, without prior written approval of the principal 
investigator. All laboratory specimens, evaluation forms, reports and other 
records that leave the site will be identified only by the Subject Identification 
Number (SIA) to maintain subject confidentiality. Clinical information will not 
be released without written permission of the subject, except as necessary for 
monitoring by HREC or regulatory agencies. 
Case Report Forms 
The study case report form (CRF) is the primary data collection instrument for 
the study.  All data requested on the CRF must be recorded.  All missing data 
must be explained.  If a space on the CRF is left blank because the procedure 
was not done or the question was not asked, write “N/D”.  If the item is not 
applicable to the individual case, write “N/A”.  All entries should be printed 
legibly in black ink.  If any entry error has been made, to correct such an error, 
draw a single straight line through the incorrect entry and enter the correct 
data above it.  All such changes must be initialed and dated.  DO NOT 
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ERASE OR WHITE OUT ERRORS.  For clarification of illegible or uncertain 
entries, print the clarification above the item, then initial and date it. 
Records Retention 
 
It is the investigator’s responsibility to retain study essential documents for at 
least 15 years after the completion of this clinical trial.  All information will be 
stored in the Radiation Oncology research office of the Calvary Mater 
Newcastle, either on a password protected computer or in files kept in a 
locked room.  Access to this information will be limited to the principal 
investigator, research assistants and statistician as authorized by the 
delegation log.   
Ethical Considerations 
 
This protocol and the informed consent document and any subsequent 
modifications will be reviewed and approved by the HREC. A letter of protocol 
approval by HREC will be obtained prior to the commencement of the study, 
as well as approval for other study documents subject to HREC review.  
 
This study will be conducted in compliance with the current version of the 
protocol. Any change to the protocol document or Informed consent Form that 
affects the scientific intent, study design, patient safety, or may affect a 
participant’s willingness to continue participation in the study, is considered an 
amendment, and therefore will be written and filed as an amendment to this 
protocol and/or Informed Consent Form. All such amendments will be 
submitted to the HREC for approval prior to becoming effective. 
 
All protocol deviations must be recorded in the patient record (source 
document) and on the CRF and must be reported to the PI. Protocol 
deviations will be assessed for significance by the PI. Those deviations 
deemed to have a potential impact on the integrity of the study results, 
subjects safety or the ethical acceptability of the study will be reported to the 
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HREC within 30 days.  Where deviations to the protocol identify issues for 
protocol review, the protocol will be amended as per this section.   
Study Finances 
 
This study is financed through an unrestricted research grant provided by 
Abbott pharmaceuticals.  Abbott was not involved in the development of this 
protocol, and will not be involved in analyzing or reporting the results.  Full 
disclosure of the funding source will be provided in any publications and 
presentations relating to this work.   
Publication Plan 
 
Primary responsibility for the publication of the study results rests with the 
principal investigator.  Information cannot be passed onto any other party 
without permission of the principal investigator.  Abbott pharmaceuticals will 
be acknowledged as the funding source in all publications, and will have the 
opportunity to review all manuscripts prior to submission for publication.   
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Appendix 1: Clinical Prostate Cancer Staging (TNM 7th edition 
2010) 
 
Stage Interpretation 
TX Primary tumor cannot be assessed. 
T0 No evidence of primary tumor. 
T1 Clinically inapparent tumor neither palpable nor visible by 
imaging. 
T1a Tumor incidental histologic finding in ≤5% of tissue resected. 
T1b Tumor incidental histologic finding in >5% of tissue resected. 
T1c Tumor identified by needle biopsy (e.g., because of elevated 
PSA).a 
T2 Tumor identified by needle biopsy (e.g., because of elevated 
PSA). 
T2a Tumor involves ≤one-half of one lobe. 
T2b Tumor involves >one-half of one lobe but not both lobes. 
T2c Tumor involves both lobes. 
T3 Tumor extends through the prostate capsule.b 
T3a Extracapsular extension (unilateral or bilateral). 
T3b Tumor invades seminal vesicle(s). 
T4 Tumor is fixed or invades adjacent structures other than seminal  
vesicles such as external sphincter, rectum, bladder, levator muscles,  
and/or pelvic wall. 
 
 
aTumor found in one or both lobes by needle biopsy, but not palpable or 
reliably visible by imaging, is classified as T1c. 
bInvasion into the prostatic apex or into (but not beyond) the prostatic capsule 
is classified not as T3 but as T2. 
 
Prostate Cancer Risk Group Stratification (NCCN): 
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Low Risk: All of PSA<10, Gleason Grade 6 AND Stage T1 or T2a 
Intermediate Risk: One of PSA 10-20, Gleason Grade 7 OR Stage T2b-c 
High Risk: Any one of PSA>20, Gleason Grade 8-10 OR Stage T3-4 
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Appendix 2: ECOG/Zubrod Performance Status 
 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedentary nature, e.g., light house work, 
office work 
2 Ambulatory and capable of all self-care but unable to carry out any 
work activities. Up and about more than 50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 
50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined 
to bed or chair 
5 Dead 
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Appendix 3: Imaging Specifications 
 
DEXA Scan 
 
Ensure that calibration procedures have been performed as per published 
guidelines.[12, 45]  DEXA scans to be performed on the hip and lumbar spine 
with individual vertebrae L1-L5 measured independently.  BMD Data to be 
recorded from all of these sites individually. 
 
MRI Lumbar Spine 
 
3 Tesla MRI 
Position with knee rest to reduce lumbar lordosis. 
Use lumbar phased-array coil and abdominal flex coils. 
Standard clinical magnetic resonance imaging sequences will be used for this 
study including T1, T2, and Diffusion Weighted Imaging will be performed to 
allow calculation of an Apparent Diffusion Coefficient. 
 
Lumbar spine fat content  
 
Imaging: Standard in-phase/out phase imaging will used to generate pure fat 
images and water images of the lumbar vertebrae. Sagittal images will be 
positioned along the spine. This will allow determination of the fat content for 
each vertebra contained within the imaging field-of-view.  
 
Total time the patient is required to be in the MRI system is less than 40 min. 
One initial patient will be request to repeat measurements 2 times to ensure 
reproducibility of the imaging.  Standard phantom calibration will also be 
recorded. 
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Appendix 4: PROMIS Fatigue Questionnaire 
 
Please see attached PROMIS Fatigue – Short Form 1 
This is summarized below: 
 
Please respond to each question by marking one box per row. 
 
In the past 7 days: 
 
 Never Rarely Sometimes Often Always 
How often did you feel tired?      
How often did you experience 
extreme exhaustion? 
     
How often did you run out of 
energy? 
     
How often did your fatigue limit 
you at work (include work at 
home)? 
     
How often were you too tired to 
think clearly? 
     
How often were you too tired to 
take a bath or shower? 
     
How often did you have enough 
energy to exercise strenuously? 
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Appendix 5: RTOG toxicity scales 
 
Acute Genitourinary 
 
Grade 0 1 2 3 4 5 
No 
change 
Frequency 
of urination 
or nocturia 
twice pre-
treatment 
habit: 
dysuria, 
urgency, 
not 
requiring 
medication 
Frequency 
of urination 
or nocturia 
less 
frequent 
than every 
hour: 
urgency, 
bladder 
spasm 
requiring 
local 
anaesthetic 
eg Ural 
Frequency with 
urgency and 
nocturia hourly or 
more frequently.  
Dysuria, pelvic pain 
or bladder spasm 
requiring regular, 
frequent narcotic.  
Gross haemturia 
with or without 
passage of clot 
Haematuria 
requiring 
transfusion.  
Acute 
bladder 
obstruction 
not due to 
clot passage.  
Ulceration or 
necrosis. 
Death 
 
Acute Gastrointestinal 
 
Grade 
0 
1 2 3 4 5 
No 
change 
Increased 
frequency 
or change 
in quality of 
bowel 
habits not 
requiring 
Diarrhoea 
requiring 
parasympatolytic 
drugs.  Mucous 
discharge not 
requiring 
sanitary pads.  
Diarrhoea 
requiring 
parenteral 
support.  
Severe 
mucous or 
blood 
Acute or 
subacute 
obstruction, 
fistula or 
perforation.  Gi 
bleeding 
requiring 
Death 
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medication.  
Rectal 
discomfort 
not 
requiring 
medication. 
Rectal or 
abdominal pain 
requiring 
analgesics. 
discharge 
requiring 
sanitary pads.  
Abdominal 
distension 
with 
distended 
bowel loops 
on plain X-
ray. 
transfusion, 
abdominal pain 
or tenesmus 
requiring 
decompression 
or bowel 
diversion. 
 
Late Gastrointestinal 
 
Grade 0 1 2 3 4 5 
None Mild 
diarrhea.  
Mild 
cramping.  
Bowel 
movement 
up to 5 
times daily.  
Slight rectal 
discharge 
or bleeding. 
Moderate 
diarrhea 
and colic.  
Bowel 
movement 
>5 times 
daily.  
Excessive 
rectal 
mucous or 
intermittent 
bleeding. 
Obstruction or 
bleeding requiring 
surgery. 
Necrosis / 
Perforation.  
Fistula. 
Dead 
 
Late Genitourinary 
 
Grade 
0 
1 2 3 4 5 
None Slight Moderate Severe Necrosis / Dead 
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epithelial 
atrophy.  
Minor 
telangiectasia 
(microscopic 
haematuria). 
frequency.  
Generalized 
telangiectasia.  
Macroscopic 
haematuria. 
frequency and 
dysuria.  Severe 
generalized 
telangiectasia 
(often with 
petechiae).  
Frequent 
haematuria.  
Reduction in 
bladder capacity 
(<150 cc). 
Contracted 
bladder 
(capacity 
<100 cc).  
Severe 
haemorrhagic 
cystitis. 
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Appendix 6: Radiotherapy Contouring Guide 
 
Clinical Target Volumes (CTV) 
 
Prostate:  The prostate is defined using CT and/or MRI imaging.  Additional 
information such as the position of the most inferior gold fiducial marker from 
the apex of the prostate, any extraprostatic disease detected on pre-ADT MRI 
or clinically and the volume of the prostate as recorded during Trans-rectal 
Ultrasound (TRUS) should be incorporated into delineation of the prostate 
CTV.  This volume is labeled CTVp 
 
Extracapsular extension (ECE): If the predicted risk of ECE is greater than 
15% via the online Sloan Kettering nomogram, a 3 mm margin is added in all 
directions around the prostate CTV.  Any overlap of this volume with the 
rectum is removed.  The remaining volume is labeled CTVece. 
 
Seminal Vesicle Invasion (SVI): If the predicted risk of SVI is greater than 
15% via the online Sloan Kettering nomogram, the proximal 20 mm of the 
seminal vesicles (SV) are contoured as a separate CTV measured along the 
length axis of the SV.  The 20 mm is measured obliquely along the axis of the 
SV, not in the longitudinal axis.  Note that the SV often commences inferior to 
the most superior visualized prostate, and it is therefore not always necessary 
to contour the SV for 20 mm above the prostate.  If less than 20 mm of SV are 
visible, contour only what SV can be identified.  If the SV are identified as 
harbouring disease, the whole SV will need to be contoured.  The resulting 
volume is labeled CTVsv. 
 
Pelvic Lymph Nodes (PLN): If the predicted risk of PLN involvement is greater 
than 15%, they are contoured according to guidelines from the RTOG.  Use 
the Roach formula to calculate this (2/3 x PSA + (Gleason – 6) x 10).  This 
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volume is not attempted for men with bilateral total hip joint replacements due 
to difficulty in safely delivering treatment to such a large treatment volume.  
The CTV extends 7 mm around relevant vascular structures bilaterally, not 
including vessels, muscle, bladder or bone.  Some summary points working 
from the inferior aspect of the volume: 
 Superior to the upper limit of the pubic symphsis, the obturator lymph 
nodes are included. 
 Superior to the top of the femoral heads, both internal and external iliac 
lymph nodes are included. 
 Superior to the upper limit of the rectum, the presacral region is 
included in addition to the internal and external iliac lymph nodes  
 Cease contouring 10 mm inferior to the anterior-superior aspect of the 
S1 vertebral body (the sacral promontory) 
The resulting CTV is labeled CTVln. 
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Planning Target Volume 
 
PTV70 Gy =  
 CTVp + 5 mm in all directions 
 
PTV61.6 Gy =  
 For patients with a CTVece but no CTVsv: CTVece + 5 mm in all 
directions  
 For patients with both CTVece and CTVsvi: CTVece + 5 mm in all 
directions and CTVsvi + 5 mm in superior, inferior, left and right 
directions, and 7 mm in anterior and posterior directions. 
 This volume is not required for patients with no CTVece or CTVsv. 
 
PTV50.4 Gy = CTVln + 5 mm in all directions 
 
Critical Structure Contouring 
 
Bladder = Whole bladder (solid organ) 
Rectum = From ano-rectal junction (usually around bottom of ischial 
tuberosities) to recto-sigmoid flexure (solid organ) 
Small Bowel = Contour any visible small bowel as well as peritoneal contents 
within 8 mm of the superior aspect of the PTV and label as small bowel.  This 
is because small bowel can occupy any space within the peritoneal cavity.  
Extend this volume by 3 mm in all directions to create the Small Bowel 
Planning Target at Risk volume (SB PRV). 
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Appendix 7: Radiotherapy Details 
 
Preparation:  
 Empty rectum and comfortably full Bladder prior to planning and each 
day of treatment 
 2-3 Gold fiducial markers placed in prostate region 
 
Position: Supine 
 
Immobilisation: Vac-lock bag or similar custom device 
 
Scanning: 
 CT: <3 mm axial slice thickness commencing above L4 vertebra, and 
extending inferiorly to >3 cm below perineum 
 MRI: Prostate MRI is optional to assist with contouring.  2 mm slices 
with T2 weighting are performed.  Fusion to the planning CT is based 
on the location of the gold fiducial markers. 
 
Planning: Intensity Modulated radiotherapy (IMRT) technique using either 
static fields or arc therapy (volumetric modulated arc therapy [VMAT]).  
Planning objectives and field arrangement optimized to achieve best 
dosimetry. 
 
Treatment: Pre-treatment electronic portal image (EPI) taken using kilovoltage 
imaging.  Any deviation of the gold seed centre of mass from that observed in 
the planning scan is corrected for in the transverse, sagittal and coronal 
planes prior to treatment each day ie 0 mm action threshold. 
 
Radiotherapy Dose Constraints 
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Guidelines taken from ICRU 83 (dose reporting for IMRT)[48], RTOG protocol 
04-15 (hypofractionated prostate radiotherapy)[49], and QUANTEC[50].  For all 
PTV and CTV volumes, doses below that prescribed would be a protocol 
variation. 
 
PTV70 Gy: Dose prescription - D98 = 70 Gy 
PTV70 Gy: Maximum to 1 cc – Major variation if >77 Gy.  Minor variation if 
74.9-77 Gy. 
CTVp, CTVece, CTVsvi:   D99 = 70 Gy 
PTV61.6 Gy: Dose prescription - D98 = 61.6 Gy 
PTV50.4 Gy: Dose prescription - D98 = 50.4 Gy 
CTVln: D99 = 50.4 Gy 
Rectum (Mandatory): D15% < 74 Gy.  D25% < 69 Gy, D35% < 64 Gy, D50% 
< 59 Gy.  
Rectum (Ideal): D15% < 74 Gy.  D25% < 60 Gy, D35% < 50 Gy, D50% < 40 
Gy. 
Small Bowel PRV: D99% < 52 Gy 
Neck of Femur: D5% < 44 Gy 
Bladder (Mandatory): D15% < 79 Gy.  D25% < 74 Gy, D35% < 69 Gy, D50% 
< 64 Gy. 
Bladder (Ideal): D15% < 74 Gy.  D25% < 60 Gy, D35% < 50 Gy, D50% < 40 
Gy. 
Penile Bulb: Mean dose < 51 Gy (Not mandatory if PTV coverage needs to be 
compromised to achieve). 
 
If the mandatory rectal or small bowel dose constraints cannot be met, the 
patient can be treated with an alternative radiotherapy regimen giving 74-78 
Gy at 2 Gy per day.  Scale PTV and CTV objectives accordingly eg if 
prescribed dose is 76 Gy: 
 
Rename PTV: PTV70 Gy  PTV76 Gy 
PTV76 Gy: D98 = 76 Gy 
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PTV76 Gy: Maximum 81.3 Gy.  81.31 – 83.6 Gy = Minor violation.  >83.6 Gy 
= Major violation. 
CTVp, CTVece, CTVsvi:   D99 = 76 Gy 
Rectum (Mandatory): V75 Gy < 15%, V70 Gy < 20%, V65 Gy < 25%, V60 Gy 
< 35%, V50 Gy < 50%. 
Small Bowel PRV: D99% < 52 Gy 
Neck of Femur: D5% < 53 Gy 
Bladder (Mandatory): V80 Gy < 15%, V75 Gy < 25%, V70 Gy < 35%, V55 Gy 
< 50%. 
Penile Bulb: Mean dose < 51 Gy (Not mandatory if PTV coverage needs to be 
compromised to achieve). 
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Appendix 8: Patient Information Sheet 
 
A Phase 2 Clinical Trial Exploring 3-Dimensional Imaging of Androgen 
Deprivation Induced Osteopaenia, Radiotherapy Hypofractionation and 
the Prognostic Significance of Micrometastatic disease in men with 
Prostate Cancer. 
 
Short Title: PROstate Cancer Imaging, Treatment and Toxicity (PROCITT) 
 
This document is designed to complement information given to you verbally 
by your doctor. 
 
You are being invited to take part in a clinical research study for men with 
Prostate Cancer (PC).  The doctors at this hospital are trying to develop better 
methods of treatment for this disease. They are also trying to better 
understand what causes some of the side effects of treatments.  This is called 
clinical research. In order for you to decide whether you should agree to be 
part of this study, you should understand enough about its aims, risks and 
benefits to make an informed decision. This process is known as informed 
consent. 
 
This Participant Information Sheet contains information about the research 
trial. Its purpose is to explain to you as openly and clearly as possible all the 
procedures involved in this project before you decide whether or not to take 
part in it. 
 
Please read this Participant Information Sheet carefully. Feel free to ask 
questions about any information in the Information Sheet. Before deciding 
whether or not to take part, you may wish to discuss the trial with friends or 
relatives or your local health worker. 
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Should you decide not to participate in this trial, your doctor will discuss 
details of your treatment options with you. Your decision not to participate will 
not affect any other aspect your treatment. 
 
‘What is the main purpose of this trial?’ 
 
Your doctor has explained that you require radiotherapy for your PC.  You 
also need a type of hormonal therapy known as Androgen Deprivation 
Therapy (ADT).  Although ADT improves the chance of cure, it can also have 
side effects.  One of these is thinning of the bones.  When this is advanced, it 
is called osteoporosis.  Men with osteoporosis have a higher chance of getting 
fractures of bones such as the hip and spine.  To help stop this from 
happening, your Doctor will recommend you start taking Calcium and Vitamin 
D tablets every day. 
 
We do not know exactly how ADT speeds up thinning of the bones.  We also 
cannot pick which men have fast or slow bone thinning while on ADT.  If we 
could find the men likely to have faster bone thinning before starting 
treatment, we might be able to add other treatments to help strengthen the 
bone, or change the time they remain on ADT. 
 
Currently, the best way to measure for osteoporosis is to do a bone mineral 
density scan using a DEXA scanner.  This technology is widely available, and 
has a lot of experience about how best to use it.  It also has limitations in that 
it cannot see the different parts of the bone or the bone marrow within the 
bone.  All of these interact to keep bones strong.  Doing special scans to look 
at these different parts of bone more accurately may help us understand 
better how ADT speeds up bone thinning. 
 
The main purpose of this study is to see if doing extra tests on the bone can 
help figure out how ADT speeds up bone loss as well as which men loss bone 
faster.  These tests include a type of scan called a Magnetic Resonance 
Imager (MRI), as well as urine and blood tests.  You would not need to have 
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any more blood samples taken than is normally the case for men receiving 
this type of treatment, but each time you have blood taken more tests would 
be done on that blood sample.  
 
‘Does the trial have any other purposes?’ 
 
Sometimes cancer can travel to other parts of the body.  Although scans can 
be normal before you start treatment, very small amounts of cancer can be 
impossible to find using current scans such as a CT and bone scan.  To get to 
other parts of the body, small parts of the original cancer need to use blood 
vessels.   
 
There is a blood test which can sometimes detect cancer cells in the blood.  
This blood test may help show which men with metastatic prostate cancer will 
do better with a particular treatment.  However, it has not been well looked at 
for men without metastatic disease.  We aim to see if this blood test for 
circulating tumour cells is useful for men without metastatic prostate cancer. 
 
‘How is the radiotherapy in this trial different?’ 
 
Radiation Oncologists try to predict where the cancer is most likely to be, and 
to target the radiotherapy to those areas.  There is no standard way to do this, 
so different Radiation Oncologist will use different methods.  This trial aims to 
use a decision making tool called a nomogram to help tailor the area to treat 
in a more structured way. 
 
Radiotherapy for prostate cancer can take up to 8 weeks of treatment, 4-5 
times per week.  In recent year several other studies have shown that by 
giving a larger dose of radiotherapy every day, treatment can be completed in 
a shorter time.  The largest trial reported so far used a 28 day schedule given 
in 5 and a half weeks, and reported cure rates and side effects equal to what 
would be expected from an 8 week program.  Although used overseas, this 5 
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½ regimen has not been used widely in Australia, and we would like to see if 
we gain similar results here as have been reported from the US. 
 
‘Why have I been invited to participate in this trial?’ 
 
You have been invited to participate in this trial because your doctor has 
recommended radiotherapy and ADT for your prostate cancer. 
 
‘What if I don’t want to take part in this trial or withdraw later?’ 
 
Participation in this trial is voluntary. It is completely up to you whether you 
participate. If you decide not to participate, it will not affect the treatment you 
receive now or in the future. Whatever your decision, it will not affect your 
relationship with the staff caring for you. Your doctor will discuss other 
treatment options that may be available if you do not wish to take part in the 
trial. Discuss all these options with your doctor before deciding whether to 
take part in this research trial.  If you feel that you are only able to participate 
in the part of the study looking at the shorter radiotherapy approach, or the 
aspect of the trial about bone health, this is also possible. 
 
New information about the treatment being studied may become available 
during the course of the trial. You will be kept informed of any significant new 
findings that may affect your willingness to continue in the trial. 
 
If you wish to withdraw from the trial once you have started, you can do so at 
any time without having to give a reason. However, data or samples which 
have been made anonymous may not be withdrawn. If you join the trial and 
then decide to withdraw your consent, please notify a member of the research 
team immediately. This is important so that you can be informed if there are 
any health risks or special requirements that you need to know. 
 
Your doctor may decide you should stop treatments if they consider it in your 
best interest, but this does not mean that you have to withdraw from the trial. 
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Your doctor will advise you if alternative treatment is available or appropriate if 
you stop the trial treatment or withdraw from the trial. 
 
It is important that you tell your doctor about any treatments or medications 
you may be taking including non-prescription medications, vitamins or herbal 
remedies, or other alternative procedures. You should also tell your doctor 
about any changes to these during your participation in the trial. 
 
‘What does this trial involve - What will happen if I take part?’ 
 
Trial Procedures: 
If you agree to participate in this trial, you will be asked to sign this Participant 
Consent Form. The timing of the start of your treatment is usually between 2 
to 4 weeks following your first meeting with the radiation oncologist. 
 
Prior to starting treatment: 
 
Routine Procedures: 
There are some routine assessments that will be done before you start any 
treatment that would have been completed whether you decide to participate 
in this study or not. These assessments will be performed to evaluate the 
extent of your disease. Some of these assessments include blood tests and 
scans. 
 
CT Scan of the Abdomen and Pelvis: 
A CT is a computerised scan that provides a picture of your body using a 
highly sensitive x-ray beam. Some patients may require an injection of 
contrast (dye) to improve the quality of their scans. There is a possibility of an 
allergic reaction (anaphylaxis) to the contrast used in scans which, although 
rare, can be life threatening. 
 
Bone Scan: 
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A whole body bone scan is necessary to look specifically at the bones for any 
signs of cancer which may have spread there.  This involves the injection of a 
weakly radioactive dye and two sets of scans. 
 
DEXA Scan and Bone X-Rays: 
A DEXA scanner looks specifically at bone mineral density.  Specific x-rays 
may also be needed to see if there is any sign of bone weakness. 
 
Blood Tests: 
Standard blood tests include PSA, testosterone, blood counts, and Vitamin D 
levels. 
 
Other Tests: 
Other relevant tests may be performed at the discretion of your doctor(s), and 
may, to some extent, be made necessary by the results of other tests.  These 
tests, as well as determining the extent of your cancer, will assess how well 
your various organs are functioning. 
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Trial Specific Assessments: 
The following assessments will only be performed if you agree to participate in 
the trial: 
 
Blood Tests: 
Extra blood samples will be needed to test for the circulating tumour cells 
amongst other tests associated with cancer, osteoporosis, and anaemia.  
These will be performed at the same time as the routine blood testing, so that 
no extra trips to a pathology lab should be necessary. 
 
Fatigue (QOL) Questionnaire: 
Prior to starting treatment you will be asked to fill in a questionnaire about 
your energy levels. This is known as a Quality of Life Questionnaire. It will 
usually take less than 5 minutes to complete. You will be asked to fill it out 
again 18 months after starting the study. 
 
MRI Scan Lumbar Spine 
An MRI helps look specifically at the bone marrow in the spine.  It is 
important you tell your doctor if you have a pacemaker, defibrillator, or 
have ever had metal in your eye.  An MRI tunnel is similar to a CT, except 
more narrow.  Tell your doctor if you have claustrophobia.  The total time for 
the scan is around 40 minutes. 
 
Urine Tests 
A special urine test is needed before starting ADT, and then again while on 
ADT, to measure the rate your bones are rebuilding. 
 
During treatment: 
 
Radiotherapy 
 
A normal course of radiotherapy extends over 8 weeks, with 39 actual days of 
treatment given daily, Monday to Friday.  For this study, the radiation 
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treatment will extend over a period of 5 ½ weeks, with 28 days of treatment. 
The area treated may include not only the prostate, but potentially areas 
surrounding the prostate such as the glands behind the prostate (the seminal 
vesicles) or the lymph nodes in your pelvis.  This shorter treatment schedule 
has been used for many years in some American hospitals, but has not being 
widely used in Australia. 
 
Treatment takes approximately 10-15 minutes each day.  The actual areas 
treated will depend on the type of prostate cancer you have, and your doctor 
will be able to discuss this with you prior to you starting the radiotherapy. 
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Post-Treatment Follow-up: 
Following the completion of your treatment you will have regular follow-up 
visits by your doctors, occurring every 6 months for a total of 5 years. You will 
have complete clinical examinations and will be monitored for the effect of the 
treatment.  A DEXA scan will be repeated 12 months, then again after 2 years 
to look at the health of your bones.   
 
‘Are there risks to me in taking part in the trial?’ 
All medical procedures involve some risk of injury. In addition, there may be 
risks associated with this trial that are presently unknown or unforeseeable. In 
spite of all reasonable precautions, you might develop medical complications 
from participating in this trial.  Blood tests, scans, radiotherapy and hormonal 
therapy are all part of the usual management of prostate cancer, and it is 
unlikely you will experience any different risks by taking part in the trial. 
 
This trial aims to further medical knowledge and may improve future treatment 
of Prostate Cancer; however it may not directly benefit you. Your doctor will 
discuss with you the benefits for your personal circumstances of the 
treatments recommended. 
 
Blood tests: 
You may experience some mild discomfort and minor bruising or swelling at 
the site where blood is collected. 
 
Hormonal Therapy: 
There are several side effects associated with Hormonal therapy: 
– Common (>20%) 
o Sweats and hot flashes 
o Poor sex drive 
o Poor erections 
– Occasional (10-20%): 
o Tiredness 
o Weight gain 
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– Uncommon (1-10%) 
o Low mood 
Many of these side effects will persist for several months after the completion 
of hormonal therapy, and sometimes they never fully go away. 
 
Radiotherapy: 
Side effects of radiotherapy are common, they usually occur within days or 
weeks of starting radiotherapy and most resolve within a month of its 
completion. These side effects may include: 
– A skin reaction like a mild sunburn, which may occur in the lower 
pelvis (creams can be prescribed by your doctor to help ease any 
discomfort),  
– You may feel tired during the treatment.  
– Bladder irritation which can usually be managed with medication, but 
in around 1 in a hundred men temporarily requires a catheter. 
– Bowel irritation such as diarrhoea is uncommon (1-10%), but if it 
does occur, can usually be treated by reducing the fibre in your diet 
or starting traveller’s diarrhoea type remedies. 
After all of the side effects from radiotherapy have gone away, other side 
effects may occur months, or even years after treatment finishes.  Less than 1 
in 50 men would be expected to have side effects severe enough to warrant 
medical intervention.  Around 1 in 10 may have a moderate side effect, but 
choose not to have any direct treatment for it. 
– Alternating constipation and diarrhoea needing changes to the diet 
– Bladder urgency, where you need to pass water with relatively little 
warning 
– Bleeding from the back passage.  In about 1 in 50 men, this needs 
to be treated, which involves a colonoscopy (camera in the back 
passage). 
– Permanent problems with erections 
Each individual is different and the occurrence and severity of these side 
effects will vary from participant to participant. Any toxicity will be carefully 
monitored and your treatment may be modified if necessary. 
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Radiation treatment does not make you radioactive. In other words, you will 
not expose anyone else to radiation and it is perfectly safe to be in close 
contact with family or friends including children. 
 
Other potential risks: 
There are no known short or long term side effects of a MRI scan.  
 
‘Are there benefits to me in taking part in the trial?’ 
It is not possible to predict if participating in this study will have any personal 
benefit for you. By Including MRI scanning and other ways of better looking at 
your bones, it is hoped to improve our understanding of why hormonal therapy 
causes some men’s bones to get weaker faster.  If we are able to answer this 
question, further research will be needed to confirm the results.  Your 
personal benefit cannot be guaranteed, however other patients may benefit in 
the future from knowledge gained in this trial. 
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‘What happens if I suffer injury or complications as a result of the trial?’ 
If you suffer any injuries or complications that may be as a result of your 
participation in this cancer research trial, you should immediately contact 
either your radiation oncologist, general practitioner or local hospital 
emergency department, who will assist you in arranging appropriate medical 
treatment.  In the unlikely event of an injury caused by your participation in 
this cancer research trial, compensation may be payable to you. The Principal 
Investigator of this trial, Dr Jarad Martin, maintains a clinical trials insurance 
policy to protect you in these circumstances. 
 
‘Will taking part in this trial cost me anything, and will I be paid?’ 
Participation in this trial will not cost you anything more than your usual 
treatment costs. You will not receive payment for taking part in this research 
trial. 
 
‘How will my confidentiality be protected and what happens with the 
results?’ 
All records including medical history, radiological imaging, laboratory tests 
and radiotherapy treatment records will be considered “source data” and 
retained for at least 15 years after the completion of the study. The 
information collected will be kept in the Calvary Mater Newcastle Research 
Centre under lock and key and computer password protection. Your medical 
records may be released in confidence to the regulatory authorities and 
Human Research Ethics Committee with the understanding that these records 
will be used only in connection with carrying out our obligations relating to this 
study.  
 
If you withdraw from the study, the study data collected prior to your 
withdrawal may still be processed along with other data collected as part of 
the clinical trial. Should you allow it, your medical information regarding your 
progress would still be collected. 
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When the results of the trial are presented at scientific meetings or published 
in a medical journal no individual participant will be recognisable from the data 
presented. In any publication, information will be provided in such a way so 
you cannot be identified. By signing the attached Consent Form, you 
authorise release of, or access to, this confidential information to the relevant 
trial personnel and regulatory authorities. 
 
It is desirable that your family doctor be advised of your decision to participate 
in this research trial.  By signing the Consent Form, you agree to your family 
doctor being notified of your decision to participate in this research trial. 
 
At all times, you have the right to access and to request correction of 
information held about you by the Calvary Mater Newcastle Research Centre.   
 
If you do not consent to the access to your information described above 
and how it will be used, you will not be able to join the research trial. 
 
‘What should I do if I want to discuss this trial further before I decide?’ 
When you have read this information, your doctor will discuss it with you and 
any queries you may have. If you would like to know more at any stage, 
please do not hesitate to contact your doctor on 02 4921 1211 or the Clinical 
Trial Coordinator on 02 4014 3947. 
 
‘Who should I contact if I have concerns about the conduct of this trial?’ 
This project will be carried out according to the National Statement on Ethical 
Conduct in Research Involving Humans (2007) produced by the National 
Health and Medical Research Council of Australia. This statement has been 
developed to protect the interests of people who agree to take part in 
research.  The ethical aspects of this research project have been approved by 
the Hunter Research Ethics Committee.   You may contact the Research 
Ethics Coordinator on 02 4921 4950 if you have concerns about the conduct 
of this trial. 
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‘What are my rights?’ 
a) You may ask questions regarding this trial and can expect clear and 
understandable answers in return. 
b) Participation in this trial is voluntary and you are not obligated to participate 
if you do not wish to. You may withdraw from this trial at any time you wish 
without jeopardising further treatment at this hospital. Your doctor may 
withdraw you from the trial if it is felt that continuing would involve a risk to 
you. 
c) Your medical records will be released in confidence to the trial 
coordinators, to the regulatory authorities and the Human Research Ethics 
Committee with the understanding that these records will be used only in 
connection with carrying out our obligations relating to this trial. You will not 
be identified as an individual in any of these reports or subsequent 
publications. 
d) If any complications of this disease or of the treatment occur, the oncology 
centre will provide appropriate treatment for these problems. 
e) If any new information becomes available that may influence your decision 
to continue in this trial, such information will be given to you. 
f) Your participation in this trial will not involve any additional costs. 
 
This study has been reviewed and approved by the Human Research Ethics 
Committee for the Calvary Mater Newcastle. Should you wish to discuss the 
study with someone not directly involved, in particular in relation to matters 
concerning policies, information about the conduct of the study or your rights 
as a participant, or should you wish to make an independent complaint, you 
can contact the coordinator of the Research Ethics Committee of the Calvary 
Mater Newcastle on 02 4921 4950 
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“Who do I ask if I have a question?’ 
 
Clinical Trial: 
The doctor you should contact should any problems arise is Dr Jarad Martin 
The contact telephone number is 02 4921 1211. 
If after hours, ask for the Radiation Oncologist on call. 
 
Urgent Medical Assistance:   
If at any time during your treatment you require urgent medical assistance 
after-hours, contact your nearest general practicioner or hospital emergency 
department.  You should tell the medical staff if you are participating in this 
clinical research study. 
 
Ethical Approval: 
This study has been reviewed by the Hunter Research Ethics Committee and 
has been duly approved. You may contact the Research Ethics Coordinator 
02 4921 4950 should you have any complaints about the conduct of the 
research or wish to raise any concerns. The Research Ethics Coordinator 
may contact specific member of the Research Ethics Committee at their 
discretion. 
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CONSENT FORM 
 
A Phase 2 Clinical Trial Exploring 3-Dimensional Imaging of Androgen 
Deprivation Induced Osteoporosis, Radiotherapy Hypofractionation and 
the Prognostic Significance of Micrometastatic disease in men with 
Prostate Cancer. 
 
Short Title: PROstate Cancer Imaging, Treatment and Toxicity (PROCITT) 
 
Dr ____________________________ has discussed this trial with me. 
I have: 
 Read, understood and kept a copy of the Patient Information Sheet; 
 Had the opportunity to ask questions about this trial and have had any 
questions or queries answered to my satisfaction; 
 Been informed of the possible risks or side effects of the tests or 
procedures being conducted; 
 Understood that the project is for the purpose of research and not for 
treatment; 
 Been informed that the confidentiality of the information will be 
maintained and safeguarded; 
 Given permission for access to my medical records, for the purpose of 
this research; 
 Given permission for medical practitioners, other health professionals, 
hospitals or laboratories outside this hospital, to release information 
concerning my disease and treatment, which is needed for this study 
and understand that such information will remain confidential. 
 Given permission for my pathology samples to be reviewed and further 
non genetic tests to be performed on this material to confirm diagnosis. 
 Given consent to the publishing of results from the study provided my 
identity is not revealed. 
 Been assured that I am free to withdraw at any time without comment 
or penalty; and 
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 Agreed to participate in the study.  Please tick boxes which apply: 
□ Shortened course of radiotherapy including tailoring of target 
volumes       
□ Spinal Bone Loss component, including MRI and extra blood 
and urine testing. 
 
PATIENT’S NAME: 
___________________________________________________________ 
Please Print 
 
PATIENT’S SIGNATURE:______________________________ DATE: 
___________________ 
 
 
I, the supervising physician, confirm that I have fully explained the nature, 
purpose and reasonably foreseeable risks to the patient taking part in the 
study. I confirm that he/she has read and kept a copy of the Patient 
Information Sheet and that he/she freely agrees to participate in the study. 
 
PHYSICIAN’S NAME: 
___________________________________________________________ 
Please Print 
 
PHYSICIAN’S SIGNATURE: ___________________________ DATE: 
___________________ 
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REVOCATION OF CONSENT FORM 
 
A Phase 2 Clinical Trial Exploring 3-Dimensional Imaging of Androgen 
Deprivation Induced Osteoporosis, Radiotherapy Hypofractionation and 
the Prognostic Significance of Micrometastatic disease in men with 
Prostate Cancer. 
 
Short Title: PROstate Cancer Imaging, Treatment and Toxicity (PROCITT) 
I hereby wish to; 
(Please initial one) 
 
Partially withdraw from the study above. 
I do not wish to receive any further treatment prescribed by the study named 
above however I consent for my information to continue to be collected for the 
purposes of this study. 
 
Totally withdraw my consent to participate in the study named above. 
I do not wish to receive any further treatment or attend study related follow up 
assessments. I understand that such withdrawal WILL NOT jeopardise the 
treatment that I receive now or in the future, my relationship with the staff 
caring for me or my relationship with Radiation Oncology Queensland. 
 
 
PATIENT’S NAME: 
___________________________________________________________ 
Please Print 
 
PATIENT’S SIGNATURE: _____________________________  
 
DATE:____________________ 
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Appendix 9: Causality and assessment of severity – Adverse 
Events  
 
The severity of an Adverse Event will be assessed as follows:  
 
Mild:  Events that require minimal or no treatment and do not 
interfere with the patient’s daily activities  
 
Moderate:  Events that cause sufficient discomfort to interfere with daily 
activity and/or require a simple dose of medication  
 
Severe:  Events that prevent usual daily activity or require complex 
treatment  
 
The relationship of the event to the study drug will be assessed as follows:  
 
Unrelated:  There is no association between the exposure and the reported 
event. AEs in this category do not have a reasonable temporal 
relationship to exposure, or can be explained by a commonly 
occurring alternative aetiology.  
 
Possible:  The event could have cause or contributed to the AE. AEs in 
this category follow a reasonable temporal sequence from the 
time of exposure and/or follow a known response pattern to the 
test article, but could also have been produced by other 
factors.  
 
Probable:  The association of the event with the exposure seems likely. 
AEs in this category follow a reasonable temporal sequence 
from the time of exposure and are consistent with the known 
action of the exposure, known or previously reported adverse 
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reactions to the exposure, or judgement based on the 
investigators clinical experience.  
 
Definite:  The AE is a consequence of exposure. AEs in the category 
cannot be explained by concurrent illness, progression of 
disease state or concurrent medication reaction. Such events 
may be widely documented as having an association with the 
exposure or that they occur after rechallenge. 
 
 232 
 
  
Appendix 10: Circulating Tumour Cell Assay 
 
Circulating Tumour Cells (CTC) enumeration using the CellSearch® 
System (Veridex, LLC, Johnson & Johnson).  
 
The CellSearch® System is cleared by US Food and Drug Administration as a 
diagnostic tool for the detection and enumeration of CTCs in metastatic 
breast, colorectal and prostate cancer. The CellSearch system can detect a 
single circulating tumour cell in 7.5 ml of blood. 
 
Description of technique for CTC enumeration 
CTC enumeration using the CellSearch® system is based on 
immunomagnetic capture and immunofluorescent profiling of the cells of 
epithelial origin from whole blood. The CellSearch® Epithelial Cell Kit used 
for CTC enumeration contains the ferrofluid reagent, which comprise anti-
EpCAM antibodies coated magnetic nanoparticles that specifically bind to 
EpCAM (epithelial cell adhesion molecule) on CTCs. Immunomagnetically 
captured cells in the sample are afterwards mixed with fluorescently labelled 
antibodies and DAPI (4’, 6-diamidino-2-phenylindole, dihydrochloride) nuclear 
stain. Phycoerythrin (PK) conjugated anti-CK 8, 18 and/or19 (intracellular 
cytokeratins 8, 18 and/or 19) antibodies are used to differentiate CTCs from 
leukocytes, which are specifically stained with allophycocyanin (APC) 
conjugated anti-CD45 antibodies. Following the staining, sample is transferred 
to a cartridge inserted into a Magnest® device, where under the influence of 
the magnetic field, nanoparticle-labelled and fluorescently stained cells are 
positioned for the scanning on the CellSearch® CellTracks Analyzer II®. 
Acquired images of differentially stained cells are presented in a gallery 
format for identification. The image analysis is done by certified users who 
have been trained by Johnson & Johnson, and whose proficiency is 
tested at three-monthly intervals. CTCs are identified based on cell 
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morphology and CK+, DAPI+, CD45- phenotype. Leukocytes are identified 
with CK-, DAPI+ and CD45+ phenotype. 
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Appendix 11: Patient Information regarding Calcium and Vitamin 
D supplementation 
 
GUIDELINES FOR THE PREVENTION OF OSTEOPOROSIS 
FOR MEN WITH PROSTATE CANCER ON HORMONE THERAPY  
 
Thinning of the bones is a common problem for men on hormonal therapy for 
prostate cancer.  Left untreated, bones can become weak enough to fracture.  
It is important to try to reduce the chance of this happening. 
 
The following guidelines are provided to reduce the risk of bone loss during 
hormonal therapy.   
 
Calcium & Vitamin D: 
Calcium and vitamin D are both essential for strong bones.  Men over the age 
of 50 years are recommended to consume 1500 mg of calcium and 800 IU 
of vitamin D daily from all sources, including the amount in the diet and from 
supplements.  
 
FOOD SOURCES OF CALCIUM:  
Food Source Portion size Calcium (mg) 
Cheese (Swiss) 50 g (2oz) 440 
Cheese (Cheddar, Mozzarella) 50 g (2 oz) 390 
Milk (skim, 1 or 2% MF or whole) 250 ml (1 cup) 300 
Buttermilk or Chocolate Milk 250 ml (1 cup) 300 
Yogurt, plain  175 ml (¾ cup) 300 
Milk powder, Dry 45 ml (3 Tbsp) 280 
Fortified beverages (soy, rice, orange 
juice)  
250 ml (1 cup) 300 
Blackstrap molasses 15 ml (1 Tbsp) 180 
Parmesan cheese 15 ml (1 Tbsp) 90 
 235 
 
Sardines, with edible bones 24 g 90 
Cottage cheese, 2% MF 125 ml (1/2 cup) 80 
Figs, dried, uncooked 3 80 
Orange, raw 1 medium 50 
Broccoli, frozen, boiled, drained 250 ml (1 cup) 50 
Calcium intake from all sources should not exceed 2500 mg per day. 
 
FOOD SOURCES OF VITAMIN D:  
Food Source Portion size Vitamin D (IU) 
Fish, herring 100 g (3 oz) 900  
Fish, mackerel or salmon 100 g (3 oz) 650  
Fish, sardines or tuna 100 g (3 oz) 250  
Milk or Soy Beverage, fortified 250 ml (1 cup) 90 
Margarine, fortified 5 ml (1 tsp) 55 
Egg 1 large 25 
Adapted from the Manual of Clinical Dietetics, 6th Edition (p. 746-747), by 
American Dietetic Association et al, 2000. 
Vitamin D from all sources should not exceed 2000 IU per day or 50 ug. 
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Vitamin and Mineral Supplements: 
If you can’t meet the recommended amounts with food alone, consider a 
supplement.  Some calcium supplements also include vitamin D.  A standard 
multivitamin and mineral supplement provides approximately 200 mg of calcium and 
200 IU of vitamin D and other nutrients.  It would be common to use 3 tablets 
containing these quantities every day.  It is important to check the label of the 
preparation you purchase – please review with your pharmacist or doctor if in doubt. 
 
Protein: 
Adequate protein is required to maintain bone health.  Include one of the following 
protein rich foods at each meal: meat, fish, poultry, beans, lentils, nuts, eggs, milk, 
yogurt and cheese.  
 
Caffeine and salt: 
Excess caffeine and salt can have a negative effect on bone.  Caffeine is found in 
coffee and also tea, chocolate (cocoa) and some soft drinks.  For optimal bone 
health limit coffee to less than 4 cups per day.   
 
Foods high in salt generally include processed foods such as canned soups, snack 
foods, crackers, packaged pastas and sauces. Check the nutrition label on 
processed foods and limit salt to less than 2100 mg per day. 
 
Physical Activity: 
Being physically active maintains optimal bone health and decreases the risk of a 
bone fracture by improving bone mass and increasing muscular strength, 
coordination and balance and thereby reducing falls.  Physical activity that is weight 
bearing is best, examples include walking, dancing, stair climbing, aerobics, skating 
and weight lifting.  
 
Smoking: 
Smoking is related to poor bone and general health.  If you smoke, ask your doctor 
for assistance to stop smoking. 
. 
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For more information visit the following web sites: 
 
Osteoporosis Australia: Booklets to download and other resources  
www.osteoporosis.org.au  
 
Find your 30: Information provided by the Queensland government to encourage 
physical activity. 
www.your30.qld.gov.au/  
 
